Functional characterisation of the T cell mediated anti-tumour response in a melanoma patient : identification of a HLA-DRβ1*10011 restricted unique antigen by Renkvist, Nicolina
Open Research Online
The Open University’s repository of research publications
and other research outputs
Functional characterisation of the T cell mediated
anti-tumour response in a melanoma patient :




Renkvist, Nicolina (2003). Functional characterisation of the T cell mediated anti-tumour response in a melanoma
patient : identification of a HLA-DR1*10011 restricted unique antigen. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2003 Nicolina Renkvist
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
FUNCTIONAL CHARACTERISATION OF THE T 
CELL MEDIATED ANTI-TUMOUR RESPONSE IN A 
MELANOMA PATIENT: IDENTIFICATION OF A 
HLA-DRpl^lOOll RESTRICTED UNIQUE ANTIGEN
b y
Nicolina Renkvist
Master of Science in Molecular Biology
A thesis submitted to the Open University for the degree of Doctor of Philosophy
18 December, 2002
The Unit of Immunotherapy of Human Tumours; Department of 
Experimental Oncology; Istituto Nazionale per lo Studio e la Cura dei 
Tumori; Via Venezian 1 ; 201 33 Milan; Italy ' ^ '
ProQuest Number: 27527229
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27527229
Published by ProQuest LLO (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346




LIST OF TABLES................................................................................................................ XII
ABSTRACT...........................................................................................................................XIV
QUOTATION....................................................................................................................... XVI
FORMAL DECLARATION..................................................................  XVII
COPYRIGTH WAIVER...............   XVII
ACKNOWLEDGEMENTS............................................................................................ XVIII
BIOGRAPHIC INFORMATION.....................................................................................XIX
LIST OF ABBREVIATIONS.............................................................................................. XX
OUTLINE OF THE THESIS................................................  XXII
In d e x
C H A P T E R  1: IN T R O D U C T IO N .........................................................................................................1
1.1 M e l a n o m a ..............................   2
1.1.1 What is a tumour?................................................................................................2
1.1.2 What is melanoma?..............................................................................................2
1.2 A n tig e n  p r o c e s s in g ....................  5
1.2.1 The HLA system....................................  5
1.2.2 The endogenous (cytosolic) pathway for antigen presentation....................... 6
1.2.3 The endocytic pathway............................................... 8
1.3 H u m a n  t u m o u r  a n t ig e n s ...........................................................................................  12
1.3.1 Tumour antigens as targets of T cells...............................................................12
1.3.L i History o f  Tcell defined tumour antigens.............................................. 12
1.3.1.a Spontaneously arising tumours...................................................  ...13
1.3.2 Classification of T cell defined tumour antigens......................................... 15
1.3.2. i The nature o f  tumour antigens................   15
1.3.2. a Group 1. Class I  HLA-restricted cancer/testis antigens........................16
1.3.2. Hi Group 2. Class I  HLA-restricted differentiation antigens.................... 18
1.3.2.iv Group 3. Class I  HLA-restricted widely expressed antigens................ 18
1.3.2.V Group 4. Class I  HLA-restricted, tumour-specific antigens................. 19
1.3.2. vi Class II HLA-restricted antigens.............................................................19
1.3.3 Melanoma antigens..............................   22
1.4 T h e  im po r t a n c e  of  id e n t ify in g  n e w  t u m o u r  a n t ig e n s .................................... 24
1.5 Fr o m  a n t ig e n  d isc o v e r y  to  im m u n o t h e r a py .........................................................25
1.5.1 The present concepts.......................................................................................... 25
1.6 M eth o d s  fo r  id en tific a tio n  o f  t u m o u r  a n t ig e n s .............................................. 27
1.6 .1 Genetic approach............................................................................................... 27
1.6.2 Biochemical approach: Elution from HLA molecules................................... 27
1.6.3 SEREX  ...................................................................................   29
1.6.4 Reverse immunology........................................................................................ 31
1.7 T CELL MEDIATED ANTI-TUMOUR IMMUNITY...................................................................32
1.7.1 Classification of T cells..................................................................................... 32
1.7. l .i CD8+ and CD4+ T cells.......................................................................... 32
1.7. l.ii T  cell effector killing mechanisms............................................................32
1.7. l.iii Thl and Th2 subpopulations: Polarised cytokine release..................... 33
In d e x
1.7.1. iv Tel and Tc2 cells....................................................................... 32
1.7.1.V T regulatory cells...................................................................................... 34
1.7.1.VÎ T regulatory cells and IL-10 .................................................................... 35
1.7.2 T cells recognition of cancer cells................................................................... 35
1.7.2.i Cancer cells as immunogenic targets......................................................35
1.7.2.U CD4+ cells in anti-tumour immunity.......................................................36
1.7.2. in Antibody mediated anti-tumour responses  ...................................... 39
1.8 IL-10 IN IMMUNOLOGY....................   40
1.8.1 Cytokines and chemokines...............................................................................40
1.8.2 Early findings.....................................................................................................40
1.8.3 The IL-10 gene...........................................................   41
1.8.4 The role of IL-10 in the immune system..................................................  41
1.8.5 IL-10 influence on macrophages and monocytes............................................43
1.8.6 IL-10 and B cells................................................................................................43
1.8.7 The influence of IL-10 on DCs and T cells.....................................................44
1.8.8 IL-10 in tumour immunity................................................................................45
C H A P T E R  2: M A T E R IA L S A N D  M E T H O D S .......................   47
2.1 T h e  m e la n o m a  patien t  15392 ...........................................................................................48
2.2 C ell u l a r  M e t h o d s ...............................................................................................................49
2.2.1 Statistics............................................................................................................. 49
2.2.2 General principles for eukaryotic cell culture..................................................49
2.2.3 Cell lines and clones..........................................................................................50
2.2.4 General procedures of cell culture....................................................................51
2.2.5 Cryopreservation of cells in liquid nitrogen.................................................... 53
2.2.6 Recovery of frozen cells................   53
2.2.7 Generation of tumor-specific T cell clones.....................  53
2.2.8 Restimulation of T cell clones..........................................................................54
2.2.9 FACS analysis................................................................   55
2.2.10 Transfection: the Lipofectamine method..................  55
2.2.11 Transformation: the DEAE-dextran/chloroquine method ........................ 57
2.2.12 Cytotoxic assay.................................................................................................. 57
2.2.13 Stimulation of T cells using 0K T3...................................................................58
2.2.14 Cytokine release assay.......................................................................................59
ill
In d e x
2.2.15 Peptide synthesis................................................................................................ 59
2.2.16 Peptide pulsing................................................................................................... 60
2.2.17 ELISA  .................................       60
2.3 M o l e c u l a r  M eth ods   ......................         62
2.3.1 General principles  ........................................................................................62
2.3.2 mRNA extraction............................................................................................... 62
2.3.3 cDNA synthesis  ...............  63
2.3.4 RT-PCR...........................................................................   64
2.3.5 Subcloning of HLA-DRpi*01021 and DRpi*10011.....................................6 6
2.3.6 Electrophoresis................................................................................................... 6 6
2.3.7 Purification of DNA bands from g e l................................................................67
2.3.8 Ligation of DNA insert to an expression vector.............................................. 6 8
2.3.9 Dephosphorylation of vector DNA prior to ligation................ ,..........  6 8
2.3.10 Precipitation of DNA......................................................................     6 8
2.3.11 Preparation of DNA for sequencing.................................................................69
2.3.12 Digestion.............................................................................  69
2.3.13 Preparation of antibiotic stocks......................................................................... 69
2.3.14 Glycerol storage of bacteria.............................................................................. 70
2.3.15 Plating of bacteria.................................................................................  70
2.3.16 Preparation of agar plates for bacterial growth................................................70
2.3.17 Small scale preparation of plasmid DNA: Mini-preparation........................... 70
2.3.18 Large scale plasmid preparation of plasmid DNA: Maxi-preparation 72
2.3.19 Spectrophotometric measurement of DNA concentration.............................. 73
2.3.20 Preparation of competent cells....................... . .................................................73
2.3.21 Transformation with competent cells...............................................................74
2.4 C o n stru ctio n  of th e  m ela n o m a  cD N A  l ib r a r y ...................................................75
2.4.1 Extraction of polyA-mRNA.................................................   75
2.4.2 cDNA synthesis................................................................................................. 76
2.4.3 First strand cDNA synthesis............................................................................. 76
2.4.4 Second strand cDNA synthesis  .................................................................77
2.4.5 BstXI adapter ligation........................................................................................78
2.4.6 Digestion with Xba 1..........................................................................................78
2.4.7 Column chromatography...................................................................................78
2.4.8 Library construction....................... .79
IV
In d e x
2.4.9 Digestion of the pEAK8 /Ii vector.................................................................... 79
2.4.10 Ligation of cDNA to the pEAK8 /Ii vector......................................................80
2.4.11 Electroporation.........................................   80
2.4.12 Evaluation of colonies by PCR.........................................................................81
2.4.13 Multi-screen Minipreparations.........................................................................81
2.5 Subcloning and sequencing of il-10 produced by melanoma specific
cd4+ t cell clones............................... 83
2.5.1 Subcloning of IL-10.......................................................................................... 83
2.5.2 Preparation of genomic DNA (for IL-10)....i...................................................84
2.5.3 Cytokine genotyping............................................................   85
2.5.4 Transwell experiments...................................................................................... 8 6
CHAPTER 3: HLA-CW8 RESTRICTED RECOGNITION OF A GPlOO EPITOPE 
BY CD8+ T LYMPHOCYTES....................................................     88
3.1 Introduction.....................       89
3.2 Aim of the chapter................................................................................................ 91
3.3 Results...................................................................................................................... 91
3.3.1 The selected CD8 + T cell clone TB6 8 6  recognises the autologous tumour in
the context of HLA-B or -C..............................................................   91
3.3.2 Identification of the gene encoding the TB6 8 6  epitope................................. 93
3.3.3 TB6 8 6  and TB254 recognise the same epitope ofgplOO.............................. 96
3.4 Discussion.........................................  98
CHAPTER 4: CHARACTERISATION OF THE CD4+ T CELL RESPONSE IN A  
LONG TERM SURVIVING MELANOMA PATIENT: IDENTIFICATION OF 
TUMOUR SPECIFIC CD4+ T CELLS WITH A THl-THO CYTOKINE 
PROFILE...........................................................     102
4.1 INTRODUCTION...................................................................................................103
4.2 Aim of the chapter.............................................................................................. 106
4.3 Results.................................................................................................................... 106
4.3.1 Characterisation of anti-melanoma CD4+ effector T cells...........................106
In d e x
4.3.1.1 Phenotypic evaluation o f  TAL and PBL derived from Pt15392 by
FACS..................................   106
4.3. l.ii Cytotoxic responses o f  the TAL and PBL populations......................... 107
4.3.l.iii The in vitro cultured T cells released IFN-y in response to tumour
stimulation.................................................................................................................109
4.3.1.iv Characterisation o f  the CD4 + T cell subset.......................................... I l l
4.3.1.V TCR expression o f  established CD4+ clones........................................ 112
4.3.1.vi Functional characterisation o f established CD4 + clones................... 114
4.4 Discussion............................................................................................................... 116
CHAPTER 5: ANTI-MELANOMA CD4+ T CELL CLONES RELEASING HIGH 
AMOUNTS OF NON-INHIBITORY IL-10.................................   120
5.1 Introduction..............................    121
5.1.1 Functions of IL-10..........................................   121
5.1.2 Polymorphism of the IL-10 gene promoter................................................... 124
5.2 Aims of the chapter.............................................................................................125
5.3 Results.....................................................................................................................125
5.3.1 Analyses of CD4+ T cells releasing high amounts of IL-10.........................125
5.3. l .i  IL-10 present in the cytokine cocktail did not result in T  cell inhibitory
activity..................................................................................................   125
5.4 Determination of the IL-10 secretion phenotype..................................... 129
5.4.1 Genotyping............................. .........................................................................129
5.4.2 Subcloning of IL-10.........................................................................................132
5.4.2.1 Subcloning o f  the IL-10 produced by the CD4+, class II  HLA restricted
anti-tumour T cell clones..........................................................................................132
5.5 Discussion................................................................................................................134
5.5.1 Functional role of the IL-10 released by CD4+ T cells................................ 135
5.5.2 Genotyping and subcloning.............................................................................136
5.5.3 Conclusions.......................................................................................................137
VI
In d e x _______________________________________________________________________________________________________
CHAPTER 6: CONSTRUCTION AND SCREENING OF AN H-CDNA FUSION 
LIBRARY: IDENTIFICATION OF A POSITIVE CONSTRUCT..............................140
6.1 Introduction.........................      141
6.2 Aims of the chapter.............................................................................................143
6.3 Results.....................................................................................................................144
6.3.1 Rationale for cDNA library construction and screening..............................144
6.3.l .i  Construction and qualitative evaluation o f  the li-cDNA fusion
library. .................................................................................................................148
6.3.l.ii Library construction: oriented expression ...................................... 149
6.3.l.iii Library construction: fractionation....................................................... 149
6.3. l.iv  Library construction: quantitative estimation...................................... 151
6.3.1.v Library construction: cDNA and vector ligation........................  153
6.3.1.vi Library construction: transformation...........................      154
6.3.1. vii Qualitative library evaluation...............................................................154
6.3.1.viii Library amplification............................................................................. 157
6.3.1.ix Preparation o f the recipient cells 293 suitable fo r  the library
screening.................................................................................................................... 158
6.3.1.x Screening o f  the li-cDNA fusion library and identification o f  a positive
pool conferring activation o f  a CD4+ T cell clone.................................................158
6.4 Discussion................................................................................................................162
CHAPTER 7: IDENTIFICATION OF THE PROTEIN AND DEFINITION OF THE 
EPITOPE OF THE UNIQUE ANTIGEN PTPR-k/M .......................   167
7.1 Introduction......................................................................................... ................168
7.2 Aims of the chapter.............................................................................................168
7.3 Results............................................................................................................... .....168
7.3.1 Construct/sequence identification...................................................................168
7.3. l .i  Molecular approaches fo r  sub-cloning the positive pool o f  the li-cDNA 
library.................................................................... ...................................................168
7.3.2 Database search and sequence identification................................................. 172
7.3.2. i Characterisation o f  the insert from Clone #11.....................................172
7.3.3 Database analysis of insert #11...................................................    172
Vll
In d e x
7.3.3J An internalATG codon directs the PTPR-K/m expression..................172
7.3.3.U A polyclonal CD4+ T cell response against the PTPR-K/m antigen. 175
7.3.3. in Identification o f  the immunogenic region ofPTPR- K/m......................178
7.3.3.iv Identification o f  the TB5I5 epitope derived from PTPR-K/m............. 178
7.4 Discussion...................... ........................................................................................ 184
7.4.1 Characteristics of the PTPR-K/m gene............................................................184
7.4.2 No need for the invariant chain....................................................................... 186
7.4.3 The definition of the epitope........................................................................... 189
7.4.4 Conclusions...........................................   190
CHAPTER 8: DISCUSSION AND FUTURE PERSPECTIVES.................................. 191
8.1 Discussion..................   192
8.1.1 Background............................................................................................. 192
8.1.2 Choice of patient....................................................................   193
8.1.3 Identification of a CD4+ T cell epitope..........................................................194
8.1.4 The role of the mutation in the transformation process................................ 195
8.1.5 CD4+ T cell defined antigen belong to the category of unique tumour
antigen............................................................................................................................. 195
8.1.6 PTPR-K/m: association with tumour suppression..........................................196
8.1.7 Immunogenicity of unique tumour-antigen................................................... 201
8.1.8 CD4+ T cell response in Ptl5392................................................................... 203
8.1.9 Conclusions.......................................................................................................205
8.2 Future PLANS ....................................................................................................... 206
8.2.1 Definition of the shortest epitope/binding motifs for the COOH end 206
8.2.2 Tissue expression of PTPR-K/m..................................................................... 206
8.2.3 Cloning of the full length PTPR-K/m gene.................................................... 207
8.2.4 Analysis of the in vivo expressed PTPR-k protein........................................207
8.2.5 Potential transformation activity..................................................................... 207
8.2.6 Systemic immune response directed against PTPR-K/m.............................. 207
BIBLIOGRAPHY.................................................................................   209
PUBLICATIONS................................................................................     247
vm
In d e x _______________________________________________________________________________________________________
LIST OF FIGURES
Chapter 1
Figure 1.1: The multi-step pathway to tumour development....................................................3
Figure 1.2: Class I HLA-dependent antigen processing........................................................... 7
Figure 1.3: A schematic view of the 3-dimensional structure of the invariant chain.............9
Figure 1.4: Class II HLA-dependent antigen processing: exogenous uptake........................11
Figure 1.5: The classification of tumour antigens................................................................... 17
Figure 1.6: Methods for antigen cloning (I).............................................................................28
Figure 1.7: Methods for antigen cloning (II)........................................................................... 30
Figure 1.8: Cross-priming......................................................................................................... 37
Figure 1.9: The pleiotropic activities of IL-10........................................................................ 42
Chapter 3
Figure 3.1: Cytotoxic activity against a HLA-B or -C  restricted antigen expressed on both 
the autologous tumour and allogenic melanoma cells sharing the class I HLA haplotype
withPtl5392.............................................................................................................................. 92
Figure 3.2: HLA-B or -C  restricted recognition of an antigen expressed on both the 
autologous tumour and allogenic melanoma cells sharing the class I HLA haplotype with
Ptl5392....................................................................................................................................... 94
Figure 3.3: HLA-Cw8  restricted recognition of the gplOO antigen....................................... 95
Figure 3.4: Reconstruction of SNDGPTLI as the immunogenic epitope of clone TB6 8 6 . . 97
Chapter 4
Figure 4.1 : TCR-dependent lysis of the autologous tumour by T cells derived firom TALs.
 108
Figure 4.2: NK-like activity of TALs and PBMCs................................................................110
Figure 4.3: Reactivity of T cell clones derived from a long time surviving melanoma 
patient (Pt15392)................................   113
IX
In d e x
Chapter 5
Figure 5.1 : Overview of the transwell setting........................................................................127
Figure 5.2: The supernatant of CD4+ T cell clones did not inhibit the induction of class I
HLA restricted melanoma specific T cells.............................................................................128
Figure 5.3: The supernatant of CD4 + T cells did not affect the generation of MART-127-
35 specific T cells.................................................................................................................... 130
Figure 5.4: Cytokine Genotyping: pattering of PCR amplification bands and their
association to the IL-10 genotype...........................................................................................131
Figure 5.5: The long time surviving melanoma patient Ptl5392 has an intermediate IL-10 
secreting phenotype.........................................  133
Chapter 6
Figure 6.1 : A schematic view of the construction and screening of an li-cDNA library.. 145 
Figure 6.2: The construction of an inavariant chain (li) -  cDNA fusion library by ligation
of the cDNA-adapter insert to the pEAK8 /Ii vector..............................................................146
Figure 6.3: Detailed view of the strategy for the transfection of the invariant chain (li) -
cDNA library from melanoma cells of Pt15392.................................................................... 147
Figure 6.4: A quantitative and qualitative evaluation of different fractions of the li-cDNA
library performed with PCR colonies..................................................................................... 155
Figure 6.5: Class II HLA expression on 293-EBNA cells stable transfected with CIITA.159
Figure 6 .6 : Reactivity of clone TB515 against the autologous tumour................................160
Figure 6.7: Cytotoxic activity of clone TB515 against the autologous tumour.................. 161
Figure 6 .8 : Characterisation of the class II HLA expression on Mel 5392 cells.................163
Figure 6.9: Recognition of a positive HLA-DRp 1*10011 restricted pool of the li-cDNA 
fusion library.............................................................................................................................164
Chapter 7
Figure 7.1: The molecular strategy to the single construct: the subcloning strategy of how 
to identify a single positive construct from pool #D2 of the li-cDNA library of Ptl5392.
...............................................................................   169
Figure 7.2: The subcloning procedure: subcloning of the positive pool #D2.....................171
Figure 7.3: The positive cDNA #11 encodes a 700 bp insert................................................173
X
In d e x
Figure 7.4: Clone #11 encodes a 674 bp insert that shows 99% homology with the tyrosine
phosphatase receptor kappa (PTPR-k) gene................................   174
Figure 7.5: The invariant chain is not needed for class II HLA processing and T cell
recognition................................................................................................................................ 176
Figure 7.6: A polyclonal CD4+ T cell response directed against the PTPR-K/m gene 177
Figure 7.7: Definition of the immunogenic region of the PTPR-K/m gene with the aid of
amplified minigenes.................................................................................................................179
Figure 7.8: Selection of an immunogenic region of PTPR-K/m minigenes suitable as a
replica sequence for the design of peptides............................................................................180
Figure 7.9: The definition of the immunogenic core region of the PTPR-K/m gene 182
Figure 7.10: Definition of the immunogenic PTPR-K/m peptide......................................... 183
Figure 7.11: Recognition of the mutated PTPR-K/m peptide by 2 additional CD4+ T cell 
clones........................................................................................................................................ 185
Chapter 8
Figure 8.1: A schematic view of homophilic binding through the extracellular regions of
the PTPR-k gene......................................................................   198
Figure 8.2: A schematic view summmarising the proposed functions of the PTPR-k gene 
as 1) a membrane receptor; 2) a signalling protein and 3) a tumour antigen...................... 200
XI
In d e x
LIST OF TABLES
Chapter 1
Table 1.1: Class II HLA restricted antigens............................................................................ 21
Chapter 2
Table 2.1 : Cell lines and clones used in this study.................................................................52
Table 2.2: The primers used to amplify p-actin, HLA-DRp 1*01021, HLA-DRp 1*10011
and the minigenes...................................................................................................................... 65
Table 2.3: The primer sequences used to amplify the full length sequence of the IL-10 
gene.......................................................................................    84
Chapter 3
Table 3.1: The TCR expression of clones TB254 and TB6 8 6 , which both recognise the 
gp 1 0 0 7 1 - 7 8  SNDGPTLI epitope................................................................................................ 98
Chapter 4
Table 4.1: Cell surface phenotype of lymphocytes derived from the blood and a lymph
node melanoma metastasis......................................................................................................107
Table 4.2: IFN-y release from TALs in response to different stimuli................................. 111
Table 4.3: The TCR repertoire of anti-melanoma class II-HLA restricted T cell clones from
Ptl5392.................................................................................................................................... 114
Table 4.4: Functional characterisation of anti-melanoma CD4+ T cell clones derived from 
TALs ofPtl5392..............................   115 f
Chapter 5
Table 5.1: An overview of the major inhibitory and stimulatory functions of IL-10........123
Table 5.2: A comparison of the profile of cytokines secreted by the high releasing IL-10 
CD4+ T cell clones of Ptl5392 (T15392) and the known cytokine profiles of CD4+ T cell 
subsets..................................................................................   139
Chapter 6
Table 6.1: Amounts of cDNA obtained in fractions #7 to #12 after size fractionation.... 150 
Table 6.2: Calculation of the number of transformants that can be expected in the li -  
cDNA fusion library applying the ElectroMAX approach for transformation  ............ 152
Xll
In d e x
Table 6.3: Qualitative and quantitative features of the li -  cDNA fusion libraries........... 156
Chapter 8
Table 8 .1 : TAAs with a putative role in neoplastic transformation.................................... 202
xm
In d e x _______________________________________________________________________________________________________
ABSTRACT
CD4+ T cells are central in regulating most adaptive immune responses and essential for 
sustaing CD8 + T cell activation and efficient tumour destruction. Therefore, a better 
understanding of the CD4+ T cell-mediated mechanisms involved in anti-tumour responses 
will be crucial to improve vaccination strategies. The objective of this thesis was to 
evaluate the anti-tumour CD4+ T cell response in a metastatic melanoma patient, Ptl5392, 
disease free after 1 2  years from surgical removal of lymph node metastasis and who was 
previously shown to display a CD8 + T cell response against epitopes included in the TRP- 
2  and gplOO antigens.
Several CD4+ T cell clones were isolated from the metastatic lymph nodes by limiting 
dilution assay. TCR analysis defined five groups of clones which all showed a strong TCR- 
dependent cytotoxic activity in response to in vitro stimulation with the autologous 
melanoma. Functional analysis demonstrated that all the isolated T cell clones recognised 
tumour cells in HLA-DR restricted fashion. In addition to exert a cytotoxic activity in 
response to tumor stimulation, these T cell clones released cytokines compatible with a 
Thl profile although they also specifically produced high amounts of IL-10.
An invariant chain (li) - cDNA fusion library was constructed in an attempt to identify the 
melanoma antigen recognised by these CD4+ T cell clones. The screening resulted in the 
detection of a mutated form of the human protein tyrosine phosphatase receptor kappa 
(PTPR-k) gene, as a DRp 1*10011 -restricted tumour antigen. All the T lymphocyte clones 
isolated in vitro were directed against a DRp 1 * 1 0 0 1 1  presented peptide that contained the 
mutation while none of these T cells were activated by the wild type peptide. Thus, the 
favourable clinical outcome observed in Ptl5392, may be correlated with a strong 
polyclonal CD4+ anti-tumour response. These data emphasise that continued monitoring of
x iv
In d e x
CD4+ T cell immune responses in cancer patients may allow the identification of new class 
II HLA-restricted antigens to be used for designing more effective cancer therapies.
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OUTLINE OF THE THESIS
The overall aim of this thesis was to perform a thoroughly analysis of anti-melanoma 
specific CD4+ T cell clones involved in the anti-tumour response of a long time surviving 
melanoma patient (Ptl5392). In particular, I aimed at better understanding the T cell 
mediated anti-tumour effector functions at a molecular level by the evaluation of the 
cytokine release by CD4+ T cells derived from a metastatic lymph node, and the antigen 
involved in this tumour recognition. In this context this thesis was aimed at answering the 
following questions:
• Which is the repertoire of T cells, recognising the metastatic melanoma in vivo in this 
patient?
• Which is the molecular nature of the antigens that presumably contributed to the 
positive clinical course observed for this patient?
X X ll
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Chapter 1 summerises the current state of the art in the field of tumour immunology related 
to the study performed in this thesis. In addition, each of the following result chapters is 
preceded by a more specific summary focused on addressing the question investigated in 
that chapter.
1.1 M e la n o m a
1.1.1 What is a tumour?
Cancer was first described by the Greek word oncos meaning altered, relating to the 
changes of a normal cell that leads to malignancy (Figure 1.1). Today it is well known that 
cancer is a multi-step and multi-cause genetic disease which progresses to a metastatic 
phenotype gradually by accumulating diverse mutations and other genetic changes.
An established tumour is an autonomous unit of heterogeneous cells, which do not respond 
to the normal cellular signals that control growth and cell division. It respects only its own 
needs for survival and progression, as it develops from one changed single cell towards a 
metastatic phenotype. The ancestral cell gradually acquires additional changes causing 
mutations in key genes directing cellular processes, in particular genes that regulate growth 
and signalling (Figure 1.1). A solid malignant tumour mass contains many heterogonous 
cells with individual features: independent cells that are invasive, cells that have lost their 
antigen expression, cells that require fewer growth factors for survival and cells that are 
highly metastatic.
1.1.2 What is melanoma?
Malignant cutaneous melanoma is a form of cancer occurring after metastatic 
transformation of normal skin cells, i.e. melanocytes. These cells are lined in the epidermis 
(the top layer of the skin) and produce melanin, the brown pigment, in response to 
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FIGURE 1.1: The multi-step pathway to tumour development. Cancer is a genetic disease that arise 
through the gradual accumulation mutations. The transformation process starts with a genetic alteration in 
one cell that become the precursor cell to all the subsequent more aggressive forms that develop by the 
acquisition of additional mutations in genes critical for growth regulation. The invasive metastatic tumour 
is composed of a heterogeneous array of cells with diverse features. This figure has been reproduced from 
Cotran et ai, 1997.
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has two phases of growth: the initial horizontal growth phase, which can be followed by a 
vertical (i.e. invasive) growth phase. The second condition may lead to the formation of an 
autonomous malignant progression and finally the occurrence of metastasis. The main 
factors that predispose for melanoma are exposure to sun light, severe sunburns (especially 
during childhood), a fair phenotype with blond hair and light eyes, freckles, family history 
and atypical (dysplastic) nevi. Melanoma is the most aggressive form of skin cancer and 
although the death rate of malignant melanoma is only approximately 1 %, the incidence of 
melanoma cases is among the fastest increasing world wide (reviewed in (Bastuji-Garin 
and Diepgen, 2002; Diepgen and Mahler, 2002)).
Primary melanoma is cured in over 80% of cases by surgery. However, once metastasized 
to distant organs, the cancer usually kills more than 90% of the patients since the tumour 
appears to be resistant to all availble anti-tumour drugs. New therapeutic approaches are 
thus urgently needed to improve such slim chance of survival for metastatic melanoma 
patients and imunotherapy represents one such possible new approach.
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1.2 A n t ig e n  PROCESSING
1.2.1 The HLA system
An antigen is defined as any substance that can induce a cellular or humoral immune 
response, since the immune system has evolved to fight disease agents. Antigens 
recognized by T cells are generally foreign proteins, derived from pathogens (bacteria, 
viruses) that have invaded the body. Depending on the physiological routes used to enter 
the body, antigens will follow separate pathways for the processing and presentation by the 
host cells: the endogenous or the exogenous pathway. However, independently from their 
origin, all antigens are presented to T cells as peptides bound to human leukocyte antigen 
(HLA) molecules.
The HLA system is crucial for the presentation of antigens. It is a highly polymorphic 
locus of approximately 200 genes located on chromosome 6 (reviewed in (Klein and Sato,
2000)). However, several of these genes are related to immunity and they are divided into a 
region encoding HLA-A, -B and -C  alleles (class I HLA) and a region encompassing 
HLA-DR, -DP and -DQ alleles (class II HLA). The class I HLA molecules are composed 
of a heavy chain with three a-domains, a l  and a2 forming the peptide binding cleft and 
a3, an immunoglobulin-like domain, that is non-covalently bound to a light chain, p2m. 
Class II HLA molecules are instead heterodimers consisting of one a  and one p chain, with 
the a l  and pi domain of each chain forming the peptide binding cleft and the 
immunoglobulin-like a l  and P2 domains located in proximity to the membrane.
HLA class I molecules are expressed on all nucleated cells except spermatocytes (Jassim et 
a l, 1989), whereas the expression of class II HLA is restricted to antigen presenting cells 
(APCs) like dendritic cells (DCs), macrophages and B cells. The HLA molecules can
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present peptides derived from endogenous as well as exogenous proteins: the class I HLA 
preferentially present endogenous peptides of 8 - 10 amino acids to CD8+ T cells while 
class II HLA present peptides of an average of 12 - 20 amino acids (mainly derived from 
exogenous proteins) to CD4+ T cells.
Endogenous antigens are synthesised by ribosomes on the endoplasmatic reticulum (ER) 
and then, as mature proteins, are released into the cytosol where they are processed to 
antigenic peptides and targeted to the cytosolic pathway for antigen presentation. In 
contrast, exogenous antigens are taken up from the extracellular environment and then 
degraded into peptides inside different intracellular compartments.
1.2.2 The endogenous (cytosolic) pathway for antigen presentation
All endogenously expressed proteins, including tumour antigens derived from normal or 
mutated self proteins become processed in the cytosolic pathway (Figure 1.2) and then 
presented on the cell surface in the groove of class I HLA molecules. In addition, RNA or 
DNA released by viruses can be replicated in the cell nucleus and translated to viral 
proteins for presentation to CD8+ T cells.
In the first step of this pathway (reviewed in (York and Rock, 1996)), ubiquitinin becomes 
attached to proteins and targets them for degradation in a barrel-shaped multi-catalytic 
complex, the proteasome. The resulting peptide fragments are then imported to the ER 
lumen through a pore complex formed by the transporter associated with antigen 
processing (TAP) proteins, TAPI and TAP2, which allow an adenosin triphosphate (ATP)- 
dependent entrance of peptides (Hammond et a l, 1993; Neefjes et a l, 1993). Inside the 
ER, the peptides become modified to a suitable length to fit into the closed peptide binding 
groove of class I HLA molecules. The association of a peptide with the class I HLA heavy 
chain and the light beta 2 microglobulin (p2m) chain stabilises the complex, which
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becomes exocytosed from the ER and then exported to the cell surface through the Golgi 
network.
1.2.3 The endocytic pathway
CD4+ T cells are reactive against peptides from processed exogenous antigens in 
association with class II HLA (reviewed in (Cresswell, 1994; Pieters, 2000)). These 
exogenous antigens may be either soluble proteins released from inflammatory agents, 
pathogens or whole bacteria. The process of clearance and elimination of those invaders 
starts with their internalisation through macropinocytosis, phagocytosis or receptor- 
mediated endocytosis (reviewed in (Lanzavecchia, 1996)). In this way they have access to 
the endosomal/lysosomal system for HLA class Il-dependent processing and presentation, 
where they become degraded along a path initiated in lightly acidic early endosomes, that 
gradually transform into endosomes, then to endolysosomes to finally end up in highly 
acidic lysosomes (reviewed in (Geuze, 1998)).
Different from the cytosolic pathway for endogenous antigen processing, the endocytic 
route is characterised by a separation of the degraded antigens and the class II HLA 
molecules in different intracellular compartments. The class II HLA molecules become 
synthesised and assembled in the ER, after which they associate with a chaperon protein, 
the li, and form a nonameric complex (apli)] composed of 3 pairs of class II HLA a  and P 
chains, each pair associated with the li (reviewed in (Cresswell, 1996)) (Figure 1.3). This 
non-polymorphic protein has two functions. It prevents loading of endogenous peptides 
present inside the ER and of unrelated peptides later along the route, as the peptide binding 
groove of class II HLA molecules is occupied by a special part of the invariant chain, the 
class Il-associated invariant chain peptide (CLIP). Moreover, the cytoplasmic tail o f the li 
contains a signal sequence with two di-leucin-like motifs (Bakke and Dobberstein, 1990;
C h a p t e r  I
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Figure 1.3: A schematic view of the 3-dimensional structure of the invariant chain. The invariant 
chain (li) is a chaperon protein involved the endogenous antigen presentation pathway. It contains a signal 
sequence in its cytoplasmic region that directs class II HLA molecules to the endoplasmatic reticulum, 
where they have associated with the li to form a nonameric complex (a|3li)g. Another function of the li is 
to fold in such a way to occupy the groove of class II HLA molecules and prevent binding of irrelevant 
peptides before the complexes have reached the MHC class II peptide loading compartments (MIIC). 
During the passages through the endosomal/lysosomal system for antigen processing, the li gradually 
become degraded until only the part protecting the groove of class II HLA, the class II invariant chain 
peptide (CLIP), remains and can be exchanged for an exogenous derived peptide in a last step, before the 
molecules are routed to the cell surface. This figure has been reproduced from Cresswell et al., 1996.
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Odorizzi et a l, 1994), which direct the nonameric (apli)3  complex to the endocytic 
pathway for antigen processing and presentation. The complex then enters the Golgi 
network, from where it becomes released as a vesicle into the endosomal/lysosomal 
system. This allows the paths for the peptide and (apli)] complex containing endosomes to 
converge. Thus, the peptides from the processed proteins become available to the class II 
HLA molecules first in a special intracellular compartments called MIIC (MHC class II 
containing compartment), where the peptide loading occurs. (Figure 1.4). However, it is 
still matter of debate if the peptide loading only takes place in the MIIC compartment. In 
fact, class II HLA have also been observed in intracellular compartments of DCs (Sallusto 
et a l, 1995) and, moreover, HLA-DR molecules can access directly to endosomes by 
direct internalisation from the cell surface (Roche et a l, 1993).
Regardless of where peptide loading occurs, it requires the assistance of the non classical 
HLA class II molecules, HLA-DM, -DO (Kropshofer et a l, 1998). They are involved in 
the exchange of the CLIP peptide with antigenic peptides. More precisely, the li has 
gradually been trimmed along the endocytic pathway until only the CLIP peptide remains 
when the complex has reached the MIIC compartment. Having fulfilled its protective role, 
it is removed with the assistance of HLA-DM as antigenic peptides present inside become 
loaded onto HLA class II molecules. The presence of a leucine motif in the p-chain of 
class II HLA directs HLA class Il/peptide complexes to the cell surface (Zhong et a l, 
1997), where they become visible for scanning by CD4+ cells.
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1.3 H u m a n  TUMOUR ANTIGENS
1.3.1 Tumour antigens as targets of T cells
1.3.1. i History o f  T cell defined tumour antigens
The first evidence that tumour could be subjected to immune recognition was obtained in 
the murine system. Studies performed on chemically induced fibrosarcomas clearly 
indicated that tumour cells expressed molecules that were perceived by the immune system 
as foreign proteins and towards which a strong and protective immune response could be 
generated.
Tumours induced by chemical treatment in mice could be transplanted in a syngeneic host 
where the tumour was then able to grow with no apparent control by the immune system. 
However, when tumour-bearing mice were surgically made tumour-fi-ee, these mice 
became resistant to a challenge with the same tumour but susceptible to a challenge by a 
different tumour (Prehn and Main, 1957). Additional experiments were then performed 
leading to the conclusion that the mechanism mediating the tumour rejection actively 
involved the T cell compartment of the host immune system. These data provided the first 
evidence that mice first encountering the tumours acquire the capacity to recognise tumour 
antigens uniquely expressed by that particular neoplasm (Basombrio, 1970). The observed 
characteristics of these antigens led to their designation as tumour-specific transplantation 
antigens (TSTAs). Thus, tumour antigens were first defined as antigens capable of 
specifically induce rejection of tumour transplants in syngenic mice. Similar results were 
obtained in other rodents like rats and guinea pigs.
Evidence for the existence of tumour antigens was also provided for tumours with different 
etiologies. Virally induced tumours were immunologically studied with an approach 
similar to the one employed for chemically induced tumours, and in this case, the antigens
12
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mediating the rejection were directly encoded by the viral genome and thus were not 
intrinsic products of the tumour cell itself.
1.3. l.ii Spontaneously arising tumours
In contrast with the results obtained with chemically or virally induced tumours, 
spontaneously arising tumours of different histological origins were althogether poorly 
immunogenic inasmuch as they failed to confer protection against grafts of the parental 
tumour (Hewitt et a l, 1976). These data had such a profound effect in the field of tumour 
immunology that the existence of tumour antigens in tumours not deliberatley induced with 
high doses of chemical carcinogens was doubted. However, two different lines of research 
led to the conclusion that immunogenic and non immunogenic tumours had indeed similar 
features. In fact, the in vivo growth of immunogenic tumours could eventually lead to the 
in vivo selection of growing cells that were no longer immunogenic (Parmiani et a l,  1973). 
On the other hand, starting from spontaneous, non-immunogenic tumours, immunogenic 
variants, unable to growth in syngeneic hosts were generated by chemical treatment. These 
tumour lines were named ‘ tum- ‘ since they were unable to grown in the syngeneic host 
(De Plaen et a l, 1988). However, these tum- variants were able to induce tumors in 
irradiated mice indicating that rejection in the normal syngeneic host was mediated by an 
immune response. An additional indication about their immunogenicity came from 
experiments in which mice that had been injected with tum" variants were clearly able to 
reject the parental, tum+ cells.
The main conclusion obtained from these data was that although derived from non- 
immunogenic tumours, tum- variants and also the parental tumour from which they 
derived, indeed expressed transplantation antigens, mediating the immunological rejection. 
On the basis of these results it could be hypothesised that a similar situation could also be
13
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found in humans and that antigens do exist also in human tumours which, however, may be 
weakly immunogenic (reviewed in (Boon et a l, 1989)).
Tumour antigens were first defined on their capability of mediating rejection of tumour 
transplants in mice; hence they were called tumour specific transplantation antigens. 
Although available data indicated that T cells were involved in such a rejection, no hints 
were available concerning the molecular nature of these tumour antigens nor the 
mechanism allowing their T cell mediated recognition. Initially, the prevailing idea was 
that T cells recognized a structural part of membrane bound cell surface proteins, as neither 
the existence of MHC molecules nor the intracellular antigen presentation pathways were 
elucidated. The interaction between T cells and their nominal antigens was thought to be 
similar to that occurring between antibodies and antigens. This concept shifted drastically 
after the discovery of MHC molecules and their function in the 70-ies. The realisation that 
MHC molecules were working as restriction elements in immune responses, drastically 
shifted the scientific perspective and highlighted the importance of cell mediated 
recognition (reviewed in (Zinkemagel and Doherty, 1997)).
Another significant factor that favored antigen identification was advancements in cell 
culture, which showed that T lymphocytes could be maintained as in vitro cultures in the 
presence of their growth factor, IL-2. Thereby, it became possible to set up in vitro models 
for antigen recognition. However, conclusive data demonstrating that T cells recognise 
their “nominal” antigen as a MHC molecule-peptide complex was not provided until a 
decade later in a now milestone paper by Townsend and co-workers. They were able to 
show that class I MHC-restricted anti-flu T cells killed infected cells through the 
recognition of a nucleoprotein, implying that nucleoprotein derived peptides produced by 
the internal protein processing were displayed at the cell surface by MHC (Townsend et
14
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a l, 1985; Townsend et a l, 1986). This observation has formed the present concept of T 
cell defined tumour antigens, which has become a hallmark for tumour immunology. Then 
the first gene encoding a mouse tumour antigen was cloned by the group of Thierry Boon 
(Lurquin et a l, 1989). A period of 6 years followed until this result was confirmed in 
human by the cloning of the first melanoma antigen recognised by T cells (van der 
Bruggen et a l, 1991). Melanoma became the most studied human tumour, as melanoma 
cells proved to be relatively easy to adapt to in vitro culture in respect to cells from 
histologically diverse cancers. With the availability of melanoma cell lines and autologous 
PBMCs present in the blood of cancer patients or tumour-infiltrating (associated) 
lymphocytes (TILs, TALs) in vitro generation and expansion of tumour-specific T cells 
was possible; eventually this in vitro stimulation also led to the isolation of tumour-specific 
T cell lines and T cell clones. Such expanded tumour specific clones have been shown to 
be the keytools to define tumour antigens recognized by T cells.
In addition to T cell-defined antigens, a recent approach, known as serological analysis of 
recombinant cDNA expression libraries (SEREX) (reviewed in (Tureci et a l, 1997)), that 
takes advantage of the use of cancer patient’s sera led also to the definition of antigens able 
to induce an antibody mediated response in an autologous setting. The present thesis will 
focus on T-cell defined tumour antigens.
1.3.2 Classification of T cell defined tumour antigens
1.3.2. i The nature o f  tumour antigens
In the last decade, an increasing array of T cell defined antigens have been continuously 
cloned using more sophisticated and innovative molecular techniques. These tumour 
antigens have been divided into four different groups according to their histological
15
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expression (reviewed in (Renkvist et al., 2001; Van den Eynde and Van der Bruggen,
2001)) (Figure 1.5).
1.3.2. a Group 1. Class I  HLA-restricted cancer/testis antigens
A milestone in tumour immunology was certainly the cloning of MAGE-1 (van der 
Bruggen et al., 1991) and the subsequent characterization of the first T-cell-defined 
antigenic epitope a year later (Traversari et a l, 1992). Those findings were rapidly 
followed by the identification of new members within this group (Boel et a l, 1995; Van 
den Eynde et a l, 1995). The MAGE, BAGE and GAGE families of genes were added to the 
group. The antigens belonging to this category, now including also NY-ESO-1, were called 
cancer/testis (CT) antigens owing to their expression in histologically different human 
tumours and in normal tissues including spermatocytes and spermatogonia of testis and 
occasionally in placenta. These antigens now represent one of the main components for 
anti-tumour vaccine development. CT antigens result from reactivation of genes normally 
silent in adult tissues (De Plaen et a l, 1994), that are transcriptionally activated in some 
tumors (De Smedt et a l, 1997). Their expression in testis does not provide targets for an 
immune reaction because cells of testis do not express class I HLA on their cell surface 
(Jassim et a l, 1989). Despite the fact that the CT antigens are probably the most 
characterised tumour antigens, their physiological fiinction remains largely unknown.
Considering that several new genes in the CT group of antigens have been cloned (CT9 
(Scanlan et a l, 2000), CTIO (Cure et a l, 2000), LAGE (Lethe et a l, 1998), MAGE-B5, - 
B6, -C2, -C3 and-D (Lucas et a l, 1999; Lucas et a l, 2000), HAGE, SAGE (Martelange et 
a l, 2000)) and that no T-cell epitopes have yet been identified from them, the question 
arises as to how many more genes encoding CT antigens remain to be discovered and how 
many epitopes exist that could be of use in cancer immunotherapy. Furthermore, a new
16
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MAGE-El gene has been found (Sasaki et a l, 2001). In fact, numerous members of the 
MAGE gene family have been identified recently and it now contains 12 subfamilies, 
MAGE-A to MAGE-L2, including 60 different genes of which most belongs to the 
MAGE-A, -B and -C groups (Chômez et a l, 2001).
1.3.2. in Group 2. Class I  HLA-restricted differentiation antigens
Differentiation antigens are only expressed at a defined stage of development and then they 
have a shared expression between tumours and the normal tissue fi*om which the tumour 
arose. Most are found in melanomas and normal melanocytes (Anichini et a l, 1993). Many 
of these melanocyte lineage-related proteins are involved in the biosynthesis of melanin. 
Epitopes recognized by both CD8+ and CD4+ T cells can be derived from melanosomal 
proteins (Boon and van der Bruggen, 1996; Topalian et a l, 1996; Wang et al., 1999a; 
Wang et a l , 1999b).
1.3.2.iv Group 3. Class I  HLA-restricted widely expressed antigens 
Genes encoding widely expressed tumour antigens have been detected in many normal 
tissues as well as in histologically different types of tumours with no particular bias 
towards a certain type of cancer. It is likely that the many epitopes expressed on normal 
tissues are below the threshold level for T-cell recognition, while their overexpression in 
tumour cells can trigger an anticancer response possibly by breaking a previously 
established tolerance. These widely expressed gene products have revealed a broad 
spectrum of mechanisms that are involved in generating T-cell-defined epitopes through 
alterations in gene transcription and translation. To highlight some examples, the epitope 
of iCE (Ronsin et a l, 1999) is derived from a non-AUG-defined alternative open reading 
firame (ORE) (Aamoudse et a l, 1999), while the RU2 gene creates its epitope by reverse 
strand transcription (Van Den Eynde et a l , 1999).
18
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1.3.2.V Group 4. Class I  HLA-restricted, tumour-specific antigens
Unique tumour antigens arise from point mutations of normal genes (like P-catenin, 
CDK4) (Robbins et a l, 1996; Wolfel et a l, 1994), whose molecular changes often 
accompany neoplastic transformation or progression. These antigens are thus expressed 
only in the individual tumour where they were identified since it is unlikely that the same 
mutation may occur in two different neoplasms unless it involves genes (e.g. RAS and 
p53) whose alteration is an obligatory step in neoplastic transformation.
In mouse models unique antigens have been shown to be more immunogenic than the other 
groups of shared antigens (Dudley and Roopenian, 1996); since unique antigens are 
responsible for the rejection of tumour transplants in mice, they have been defined as 
tumour-specific transplantation antigens (TSTAs). The unique antigens are the most 
specific targets for immunotherapy, but this potential advantage must be balanced against 
the difficulty of their clinical use, as they can induce an immune response only against the 
original tumour in which they were found and their identification is cumbersome.
Only few tumour-specific but shared antigens have been described which are generated by 
alteration in splicing mechanisms which occur in tumours but not in normal cells, as in the 
case of TRP-2/INT2 (Lupetti et a l, 1998).
1.3.2.vi Class II  HLA-restricted antigens
Stimulation of the CD4+ T helper cells by tumour antigens is considered to be impaired or 
absent in cancer patients and this may be the reason for an insufficient immune response to 
tumours. Therefore, the identification of tumour antigen epitopes recognized by such 
lymphocytes is a crucial step in the long sought improvement of anti-tumour immune 
responses that may result in clinical efficacy. The first epitope presented by a class II HLA 
and capable of provoking a CD4+ T-cell response was identified in 1994 in melanoma
19
Ch apte r  1___________________________________________________________________________________________________
tyrosinase (Topalian et a l, 1994). Then a gap of 4 years followed during which only one 
additional epitope was characterized (Topalian et a l, 1996), before other genes encoding 
class Il-restricted peptides were discovered. However, as the technical and methodological 
approaches for identifying CD4+ T-cell epitopes of tumour antigens have become 
available, an exponential increase in reporting such epitopes has been seen. In fact, since 
1998 as many as 27 new class II HLA-restricted epitopes from 14 antigens have been 
molecularly identified using, among others, li-cDNA fusion libraries (Wang et a l,  1999a), 
immunized transgenic mice (Zeng et a l, 2000) and biochemical approaches (Pieper et a l, 
1999).
In conclusion, class II HLA restricted epitopes have been identified from several well 
known anitgens such as MAGE, Melan-A/MART -1, NY-ESO-1, gplOO and tyrosinase 
(Table 1.1). Moreover, it is noteworthy that the classification of class I HLA-restricted 
tumour antigens into 4 groups i.e. CT antigens, differentiation antigens, widely expressed 
antigens and unique antigens, seems possible also for class II HLA defined antigens. Some 
antigens, annexin II (Li et al., 1998); HPV-E7 (Hohn et al., 1999); CDC27/m (Wang et al., 
1999a); TPI/m (Pieper et al., 1999), EphA3 (Chiari et al., 2000) and fibronectin (Wang et 
al., 2002) have only been defined by class II HLA epitopes. Considering the wide and 
heterogeneous array of cloned tumour antigens restricted by class I HLA, it is likely that 
the group of class II HLA antigens will be extended.
20
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Table 1.1: Class II HLA restricted antigens. An overview of class II HLA restricted antigens classified
into the same 4 groups as defined for class I HLA antigens.
GENE HLA allele REFERENCE
CANCER/TESTIS ANTIGENS
MAGE-A 1 DR15 (Chaux era/., 2001)
MAGE-Al, -A2, -A6 DRB*1301, (Chaux et al, 1999a)
DRB*1302
MAGE-A3 DRB1*0401 (Schultz et al, 2000)
DRB1*0402
MAGE-A3 DR*1101 (Manici et al, 1999)
MAGE-A3 DRB*1301, (Chaux et al, 1999b)
DRB*1302
NY-ESO-1 DRB4*0101 (Zeng et al, 2000)
NY-ESO-1 DRB4*0101-0103 (Jager et al, 2000b)
DIFFERENTIATION ANTIGENS
Melan-A/MART-1 DRB 1*0401 (Zarour et al, 2000)
GplOO DRB1*0401 (Liera/., 1998)
GplOO DR7 (Kobayashi et al, 2001)
GplOO DR53, DQw6 (Kobayashi et al, 2001)
PSA DR4 (Corman er a/., 1998)
Tyrosinase DRB 1*0401 (Topalian era/., 1994)
(Topalian era/., 1996)
Tyrosinase DRB1*1501 (Kobayashi et a l, 1998a)
Tyrosinase DRB 1*0405 (Kobayashi et al, 1998b)
WIDLEY EXPRESSED ANTIGENS
EphA3 DRB1*1101 (Chiari et al, 2000)
HER2/neu DRl, DR4, DR52, DR53 (Kobayashi et al, 2000)
MUCl DR3 (Hiltbold era/., 1998)
UNIQUE ANTIGENS
HPV-E7 DR*0401, (Hohn era/., 1999)
DR*0407
CDC27/m DRB 1*0401 (Wang era/., 1999a)
Fibronectin/m DR2 (Wang er al, 2002)
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TPI/m DRBI*010I (Pieper e/a/., 1999)
'^Annexin II DRB*040I (Li eM/., 1998)
1) As annexin II has been detected in melanoma, while its tissue distribution in normal 
tissues has not been analysed, there is not enough information to classify this 
antigen.
The prevailing view of antigen based immunotherapy of cancer, supported by numerous 
observations during the last decade, has been discussed in (Coulie et a l,  2001; Parmiani et 
a l, 2002a; Rosenberg, 2001) and can be summarised as follows:
(i) Cancer antigens can be divided into 4 different groups based on their tissue expression 
(reviewed in (Renkvist et a l,  2001; Van den Eynde and Van der Bruggen, 2001)).
(ii) One antigen can contain several epitopes, sometimes restricted both to class I and class 
II HLA (e.g. MAGE-3 and tyrosinase).
(iii) In a few cases, one specific HLA allele may show restriction for more than one 
epitope, as for NY-ESO-1 (Jager et a l, 2000b).
(iv) Neoplasms can have a heterogeneous display of multiple tumour antigens (Brasseur et 
a l, 1995; Dalerba et a l, 1998; Van den Eynde et a l, 1989).
(v) Despite their self origin, tumour antigens can mediate immune responses (reviewed in 
(Parmiani, 1993)).
1.3.3 Melanoma antigens
Melanoma antigens include the largest number of molecularly characterised TAAs. Among 
these, the MAGE (Traversari et a l, 1992), BAGE (Boel et a l, 1995) and GAGE (Van den 
Eynde et a l, 1995) families, are considered as prototype CT antigens. In these groups, 16
22
Ch apte r  1___________________________________________________________________________________________________
antigens, together encoding almost 30 HLA class I epitopes, have been identified, the 
majority of which occur in the MAGE group, which encodes for no less than 25 epitopes 
for CTL recognition: of these 11 belong to MAGE-Al and 8 to MAGE-A3. However, it 
must be remembered that much attention has been focused on the cloning of MAGE and, 
therefore, it may be incorrect to assume that they dominate the antigen repertoire since new 
antigens and epitopes are continuously being described. Nevertheless, they were the first 
antigens used for in vivo vaccination (Marchand et a l, 1995).
The differentiation antigens of melanoma are encoded by at least six different genes 
(Melan-A/MART-1, gplOO, tyrosinase, TRP-1/-2 and MCIR), but numerous epitopes have 
been identified. A good example is given by gplOO with at least 16 reported epitopes 
mainly restricted by HLA-A2. In fact, approximately 90% of the almost 40 epitopes in this 
group are presented by HLA-A alleles. One of the reasons why few HLA-B and -C 
restricted antigens have been identified, may lie in a technical artifact, i.e. the fact that T 
cells with TCRs recognizing HLA-A alleles are more easily expanded in vitro as compared 
to T cells recognizing epitopes restricted by other alleles.
At present, a similar number of melanoma antigens have been described among widely 
expressed and unique antigen groups. Also with these TAAs, the marked tendency is the 
dominant restriction of the HLA-A alleles, preferentially HLA-A2, which is the most 
widely expressed allele among the Caucasian population (Fleischhauer et a l,  1996; Krausa 
et a l, 1995). Thus, the majority of these TAA epitopes are restricted by HLA-A. Whether 
this reflects a bias caused by the fact that most of the studies have been carried out with 
HLA-A-restricted T cells or is due to an immunodominant role of the HLA locus in 
recognition of tumour antigens remains to be established.
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1.4 T h e  im po r ta n c e  o f  jdentieying  n e w  t u m o u r  a n tig e n s
Remarkably, in the last decade TAAs have been identified from 84 genes together 
encoding 213 epitopes; of these 160 restricted by class I HLA, 30 by class II HLA and 23 
originate fi*om fusion proteins (reviewed in (Renkvist et a l, 2001; Van den Eynde and Van 
der Bruggen, 2001)) with new antigens being continuously cloned in a seemingly infinite 
number. So, "Why is it necessary to identify new human TAAs?".
First, an endeavour should be made to clone antigens belonging to cancers other than 
melanoma, not only to gain knowledge on TAAs, but because other tumours such as cancer 
of breast, lung, liver, stomach, colon and pancreas affect a higher number of subjects than 
melanoma does. An increased knowledge on these cancers particularly of those known to 
be quite resistant to standard therapies like lung, colon, pancreatic and ovarian cancers, 
may lead to the development of clinical immunotherapeutic approaches, from which large 
groups of patients could benefit.
Second, although anti-tumour activity has been observed against Melan-A/MART -1, 
gplOO and tyrosinase in in vitro studies (D'Souza et a l, 1998; Jager et a l,  1996a; 
Marincola et a l, 1996b; Rivoltini et a l, 1995b), the clinical efficacy of these antigens 
remain uncertain (reviewed in (Coulie et a l, 2001; Parmiani et a l, 2002a)). In fact, despite 
that an increased T cell fi*equency could be induced in patients vaccinated with epitopes 
derived fi*om these TAAs, tumour regression was only occasionally observed (Cormier et 
a l, 1997; Jager et a l, 2000a; Lee et a l, 1999a), reviewed in (Parmiani et a l, 2002a).
Another obstacle in tumour immunotherapy is the presence of antigen specific anergic T 
cells in patients with tumour progression (reviewed in (Nielsen and Marincola, 2000)). One 
explanation for this "non-responding" state of the T cells, may be that anergy has been
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induced, a phenomenon observed for MART-127.35 and Tyr368-76 specific CD8+ T cells in 
melanoma patients (Lee et a l, 1999b).
Thus, an increased number of molecularly characterised tumour antigens will probably 
contribute to an increased knowledge about their role in transformation and tumour 
progression. In addition, such knowledge will extend the information regarding binding 
motifs and the number of epitopes that can be made avaibable for multi-vaccine 
approaches.
A more detailed understanding of the mechanisms involved in an anti-tumour response, 
may reveal new targets and molecular pathways important for tumour progression. Such 
information may lead to the development of novel strategies that can counteract tumour 
formation at an early stage, diverse from the usual approaches aimed at eliciting strong T 
cell responses against already established tumours.
1.5 F r o m  ANTIGEN DISCOVERY TO IMMUNOTHERAPY
1.5.1 The present concepts
Given the availability of so many TAAs, we must ask the following question: which 
antigens and epitopes are most suitable for immunotherapy, being capable of provoking a 
long lasting and effective anti-tumour immune response in vivol
It has been proposed that antigens involved in driving the oncogenic process should 
represent immunogenic targets for vaccine development. Unique antigens generated by 
point mutations in human tumour cells seem to fall into this group, for example CDK-4/m 
(Wolfel et a l, 1995), p-catenin (Robbins et a l, 1996) and caspase-8/m (Mandruzzato et 
a l,  1997) have all shown to affect critical cellular processes as cell cycle regulation and 
apoptosis. In addition, several unique antigens: CDK-4/m (Wolfel et a l,  1995), MUM-1
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(Coulie et a l, 1995), MUM-2 (Chiari et a l, 1999) and MUM-3 (Baurain et a l, 2000), have 
been described in patients with favourable clinical outcomes or, as in the case of myosin/m 
(Zorn and Hercend, 1999b), in a spontaneously regressing melanoma. Collectively, these 
data may imply that only the mutated antigens are the “true” rejection antigens (TSTAs) 
known from murine studies and that T cells recognising such TAAs could mediate tumour 
regression. However, the clinical applicability of these antigens appears limited due to their 
unique nature, necessitating a single patient tailored immunotherapeutic approach.
A strongly debated issue is the possible use of self-antigens in immunotherapy. Self­
antigens, i.e. those encompassing normal proteins (e.g. Melan-A/MART-1 or MAGE), can 
elicit an immune response with the assistance of appropriate adjuvants. Furthermore, as 
they are expressed by a large set of tumours, their clinical relevance is considered to be 
higher than that of unique antigens (reviewed in (Gilboa, 1999b)). Therefore, efforts 
should be aimed at finding TAAs containing both class I and class IIHLA epitopes that are 
not restricted to only one cancer type and that can provoke an anti-tumour immune 
response against a wide array of cancers. Telomerase could thus be one possible example 
of this TAA (Vonderheide fl/., 1999).
The time has come to find the second generation of TAAs; antigens identified by novel 
techniques such as microarray, algorithm studies etc., antigens with relevant role in tumour 
induction and progression (reviewed in (Schultze and Vonderheide, 2001)), and therefore, 
that cannot be selected against by the immune system of the host.
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1.6 M e th o d s  fo r  h)en tific a tio n  of  t u m o u r  a n t ig e n s
1.6.1 Genetic approach
The pioneering technique that allowed the identification of human tumour antigens 
combined the construction of a tumour-derived cDNA library with the availability of T 
lymphocyte clones. This has become the classical method for the identification of TAAs 
and is based on the construction of a cDNA library from tumour derived mRNA (Figure 
1.6A). The cDNA is cloned into eukaryotic expression vectors and divided into pools of 
100 bacteria carrying statistically 100 independent cDNA vectors (reviewed in (Boon, 
1993)). These cDNA pools are co-transfected into recipient cells such as COS-7 or 293 
together with the DNA coding for the HLA allele mediating the tumour recognition. The 
library screening is performed by the addition of tumour reactive T cells to the transfected 
COS-7 cells, and T cell recognition of a tumour antigen is then measured by evaluating the 
cytokine content, normally IFN-y and TNF-a, of the supernatants fi*om the transfectants by 
enzyme linked immuno sorbent assay (ELISA). The positive cDNA pool or pools are 
subsequently divided into smaller fi*actions, for which the screening is repeated until 
individual cDNAs encoding the antigen have been targeted.
1.6.2 Biochemical approach: Elution from HLA molecules
Tumour epitopes can be also identified by a biochemical approach, where the HLA 
molecules are stripped of their bound peptides by acid buffer treatment and the extracted 
peptides are fractionated on reverse phase high pressure liquid chromatography (HPLC) 
columns (Cox et a l, 1994) (Figure 1.6B). The fractionated peptides are then assessed for 
their ability to sensitise appropriate APC to anti-tumour T cell clone recognition. The 
fi*actions that appear positive by ELISA are selected for a second round of 
chromatography, after which the complexity of peptides contained in the positive fraction
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can be further dissected by mass spectrometry thereby leading to the identification of 
single immunogenic peptides. By applying sophisticated mass-spectrometry analysis, the 
sequence of the immunogenic epitope can be molecularly defined. From the amino acid 
sequence, the immunogenic protein can be identified from protein data bases.
This method requires that an adequate amount of the peptides must be present on the cell 
surface to allow identification. Although this method is somewhat cumbersome as it 
includes the use of HPLC and mass spectrometry, it has the advantage that the defined 
antigen is naturally expressed on the surface of tumour cells, thus increasing the 
probability to be recognised by circulating T cells or antibodies.
1.6.3 SEREX
Tumour antigens can be identified using antibodies by a technique called serological 
analysis of recombinant cDNA expression libraries (SEREX), that has developed firom of 
the classical method for library screening with T cells (reviewed in (Tureci et a l,  1997)). 
Fresh tumour specimens are used to construct a cDNA library, which is then packed into 1- 
phage expression vectors and transfected into E. coli cells. Recombinant proteins are 
released during the lytic phase of the 1-phage growth and are then blotted onto 
nitrocellulose membranes, where they can be screened for reactivity against high-titre IgG 
antibodies present in the antibody repertoire of the autologous cancer patient (Figure 
1.7A). Plaques that express reactive proteins are visualised by a staining with a secondary 
enzyme-conjugated anti-human IgG antibody. In a last step, the single clone encoding the 
serological identified tumour protein is subcloned and the insert sequenced.
The advantage of this method is that it allows the identification of antigens with strong 
immunogenicity, as high-titer IgG antibodies are selected from diluted serum and artefacts.
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such as loss of neoexpression of genes from in vitro culture of tumour lines, are bypassed. 
However, one limitation is that only antigens that induce antibody responses in the patient 
at the time of serum collection can be identified.
1.6.4 Reverse immunology
Candidate peptides with immunogenic potential inside a given protein can be predicted 
using the theoretical information of binding motifs and cleavage specificities for governing 
the rules of antigen processing and presentation. (Figure 1.7B). This has been possible with 
the development of mathematical algorithms that can predict putative peptide targets for T 
cell recognition based on their HLA binding affinity (Lu and Celis, 2000), for example the 
SYFPEITHI database (http://www.uni-tuebingen.de/uni/kxi/).
Reverse immunology represents a method that has the advantage of pre-selecting important 
antigens, which are known to be associated with a particular cancer and then searching 
them for their potential epitopes. The predicted peptides will finally be evaluated for their 
capacity to induce in vitro peptide-specific and tumour-specific T cells.
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1.7 T CELL MEDIATED ANTI-TUMOUR IMMUNITY
1.7.1 Classification of T cells
1.7.L i CD8+ and CD4+ Tcells
The continuous exposure to an infinite number of pathogenic micro-organisms and disease 
causing agents imposes a potential danger to our body. In order to overcome this challenge 
our immune system has evolved protective barriers. The first line of defence is non­
specific and involves granulocytes, mast cells, macrophages and NK cells (innate 
immunity), while T lymphocytes play a central role in specific cellular responses, i.e. in 
acquired or adaptive immunity. CD8+ cytotoxic T lymphocytes (CTLs) directly kill virus 
infected target cells by recognition of class I HLA presented viral peptides, while CD4+ T 
helper cells (Th) recognise class II HLA presented peptides thereby releasing different 
types of cytokines that allow the activation of CTLs (se section 1.7.1.///), but CD4+ Thl 
cells also induce macrophages to kill cells infected with intracellular bacteria or parasites. 
In addition, CD4+ Th2 cells participate in the humoral immune response against helminths 
and support the maturation of B cells into antibody producing plasma cells.
1.7. l.ii T  cell effector killing mechanisms
Two predominant pathways for lymphocyte mediated killing are known (Henkart, 1994; 
Lowin et a/., 1994) that involve perforin-mediated lysis and Fas/FasL induced apoptosis, 
respectively. CTL mediated killing initiates with the binding of the T lymphocytes to the 
target cell by accessory receptors and adhesion molecules. When bound to the target cell, T 
cells secrete lytic granules by exocytosis into the intercellular space, the so called immune 
synapsis. Perforin molecules then form pores in the cell membrane of the target cell 
leading to its osmotic lysis (reviewed in (Liu et a l, 1995)), while released granzymes can 
induce apoptosis (reviewed in (Smyth and Trapani, 1995)).
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1.7.1.in Thl and Th2 subpopulations: Polarised cytokine release
The effector functions of CD4+ T cells are associated with various cytokine patterns, 
which have categorised them into two subgroups; Thl cells release IL-2, IFN-y and TNF- 
P, while IL-4, IL-5, IL-6, IL-10 and IL-13 are characteristic of Th2 cells. IL-3, GM-CSF 
and TNF-a are overlapping for both subsets. Incubation of uncommitted precursor T cells, 
ThO cells, in the presence of IL-12 induces the development of Thl subsets, while IL-4 
directs Th2 polarisation (reviewed in (Glimcher and Murphy, 2000)). Furthermore, a low 
dose of antigen combined with high affinity for the HLA molecule favours a commitment 
to the Thl lineage, whereas the opposite scenario directs the development of Th2 responses 
(reviewed in (Constant and Bottomly, 1997)). Interestingly, the cytokines o f these 
polarized CD4+ T cell subsets also have strong antagonistic effects on the development of 
the other subset, most pronounced is the negative influence of IL-10 and IL-4 on Thl 
responses, while IFN-y and IL-12 inhibit Th2 reactions (reviewed in (Constant and 
Bottomly, 1997)).
The first demonstration of polarised CD4+ T cell responses was observed in studies of 
murine helper T cells (Cher and Mosmann, 1987; Cherwinski et a l, 1987; Mosmann et a l, 
1986). Additional studies showed that this Thl/Th2 dichotomy was a valid concept also in 
humans (Del Prete et a l ,\9 9 \) .
1.7.1.iv Tel and Tc2 cells
Cytotoxic CD8+ T (Tc) cells can be divided into two subpopulations with polarised 
cytokine profiles analogue to CD4+ T cells: Tel cells secreting IFN-y and TNF-a and Tc2 
cells releasing IL-4, IL-5, IL-10 and IL-13 (Sad et a l, 1995). In addition, the 
differentiation of CD8+ T cell precursors into either Tel or Tc2 cells are influenced by 
IFN-y and TGF-p respectively IL-4, i.e. the same cytokines that direct the development of
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Thl and Th2 cells (reviewed in (Mosmann and Sad, 1996)). However, the effector 
functions of CD8+ Tel and Tc2 cells are less well characterised, but both subsets have 
been shown to be cytotoxic and able to produce perforin (Vukmanovic-Stejic et a l, 2000). 
The same study also demonstrated that Tel cells can promote Thl development, while Tc2 
cells sustain Th2 responses. Furthermore, Tel and Tc2 cells have also been shown to have 
a role in tumour protection and to induce long-term antigen specific T cell memory when 
adoptively transferred to mice with pulmonary métastasés (Dobrzanski et a l,  2000).
L7.Lv T regulatory cells
T regulatory (Tr) cells constitute a novel T cell subset, with a cytokine profile different 
firom the classical Thl and Th2 cells. They secrete high levels of IL-10, low levels of IL-2 
and no IL-4, as demonstrated by repeated stimulation of murine as well as human CD4+ T 
cells in the presence of IL-10 or both IL-10 and IL-4 (Groux et a l, 1997). In addition, 
when injected into severe combined immunodeficient (SCID) mice, these new 
CD4+CD25+ T cells, also called Trl cells, were able to suppress the development of 
colitis, a pathological condition caused by autoimmune reactions.
However, several other subpopulations with suppressive functions have been identified 
(Roncarolo and Levings, 2000): Trl cells are suppressive by the secretion of IL-10, while 
Th3 cells secrete TGF-p. The CD4+CD25+ Tr cells can be phenotypically characterised 
by the expression of the IL-2 receptor a-chain (IL-2Ra) (Sakaguchi et a l,  1995), also 
known as CD25 (Sakaguchi, 2000). The presence of a minor population of CD4+CD25+ 
Tr cells with similar properties to murine Tr cells has been demonstrated by analysing cells 
from human blood (Dieckmann et a l, 2001). The human CD4+CD25+ Tr population 
represented approximately 6% of the CD4+ T cells.
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I J .l .v i  T regulatory cells and IL-10
IL-10 is a key cytokine connected to Tr cells, as it possesses the capacity to regulate their 
function; thus it could be considered that IL-10 per se indirectly controls the peripheral 
tolerance, as discussed below. Studies in mice revealed several characteristics of Tr cells. 
They were shown to constitute approximately 5-10 % of the peripheral CD4+ T cells.
These findings stimulated a functional evaluation of the mechanisms used by CD4+CD25+ 
T cells for suppression of autoimmunity. It was demonstrated that CD4+CD25+ T cells 
could not be activated by conventional stimuli involving the T cell receptor, but that the 
combination of anti-CD3 and IL-2 could overcomes their anergic phenotype, while anti- 
CD28 and IL-2 had no effect (Shevach et a l, 2001).
1.7.2 T cells recognition of cancer cells
1.7.2. i Cancer cells as immunogenic targets
In the early era of tumour immunology, the prevailing idea was that the immune system 
had developed to naturally eradicate tumour cells, according to the theory of immune 
surveillance (Burnet, 1970). However, the discovery of tumour antigens as self antigens in 
addition to the notion that actually T cells have evolved to cope with infectious agents, 
changed this concept and provided new insights to the understanding of the effector 
mechanisms involved in tumour recognition and destruction by the immune system.
Recent data suggest that the term “immunoediting” may be more suitable to describe the 
role of the immune system during tumour development as it not only has a protective 
function, but also exerts a pressure on tumour cells by selecting those that can escape 
detection (reviewed in (Ikeda et a l, 2002)). This view is based on several findings that 
together depict IFN-y as a crucial immuno-modulatory molecule that, secreted by cells of 
the innate immune system, first participates in the initial attack against the tumour, then
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favours the activation of adaptive immune response mediated by T cells but can also allow 
tumour escape by imposing a selective pressure on tumour cells and enhancing their 
immunogenicity by up-regulation of class I HLA molecules.
1.7.2. a CD4+ cells in anti-tumour immunity
CD8+ T cells have been considered as the main effector cells in anti-tumour immunity. 
This concept originated from the observation that most non-haematopoietic tumours 
express class I, but not class II HLA molecules (reviewed in (Ferrone and Marincola, 
1995)). Furthermore, CD8+ T cells alone were show to be sufficient to eradicate large 
tumour masses in mice (Kast et a l, 1989; Townsend and Allison, 1993). Nonetheless, 
recent data clearly indicate that CD4+ T cells have a pivotal role in the generation and 
maintenance of CD8+ T cell responses (reviewed in (Pardoll and Topalian, 1998; Toes et 
a l, 1999; Topalian et a l, 1996)). In particular, they are involved in cross-priming of CD8+ 
T cells (Bennett et a l, 1997; Ridge et a l, 1998), (reviewed in (Carbone et a l,  1998)) a 
mechanism in which a professional APC, like a DC, acts like a temporary bridge between 
CD8+ and CD4+ T cells (Figure 1.8).
DCs are central to cross-priming as they are multi-functional. Immature DCs (iDCs) 
residing in the periphery can sample antigens released firom dead tumour cells (Albert et 
a l, 1998) and then migrate to the nearest draining lymph node, where DCs, in their mature 
state, efficient by cross-present TAAs to CD8+ and CD4+ T cells. The simultaneous 
presentation of class I and II HLA epitopes by the DCs allow the activation of naive CD8+ 
and CD4+ T cells in close vicinity to each other. This creates an environment where a local 
cytokine release, especially IL-2 and IFN-y, fi’om the Thl CD4+ T cells efficiently can 
prime and activate naive CD8+ T cells to become mature effector CTLs capable of tumour 
killing. Moreover, by interacting with CD40 on the DC, the CD4+ T cells can instruct the
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APC to up-regulate the B7 (CD80) molecule, which provides B7 - CD28 (CD86) co­
stimulation for the CD8+ T cells.
In an optimal situation, a tumour cells can be attacked in 3 different ways. Direct cytotoxic 
killing by CD8+ T cells through the perforin/granzyme mechanism and indirect killing 
mediated by help of either Thl or Th2 CD4+ T cells. More precisely, IFN-y release from 
Thl cells can stimulate macrophages to release nitric oxide and reactive oxygen 
intermediates. Th2 cells recruit eosinophils to the tumour site, where they release the 
cytotoxic content of their granules. The essential role for Thl and Th2 cells in mediating 
tumour killing has been shown in mice vaccinated with a B16 melanoma vaccine, where 
macrophages and eosinophils were detected at the tumour site in vivo (Hung et a l, 1998).
T cell mediated immunity is central to tumour eradication, (reviewed in (Pardoll and 
Topalian, 1998)) and includes both CD8+ CTLs, and CD4+ T helper cells, that participate 
at different levels in different steps of the anti-tumour response. Whereas CD8+ T cells 
predominantly lyse target cells by a perforin-granzyme mechanism (reviewed in (Griffiths, 
1995)), CD4+ T cells release cytokines that (i) help to maintain and sustain CD8+ T cell 
responses and (ii) attract phagocytic and inflammatory cells like DCs, macrophages and 
eosinophils to the affected site (Hung et a l, 1998). However, cytotoxic CD4+ T helper 
cells have also been described (Williams and Engelhard, 1996). Indeed, anti-melanoma 
CD4+ T cells can kill target cells through a Fas/FasL independent, granule-dependent lytic 
pathway (Rivoltini et a l, 1998) to overcome tumour escape. In addition, another 
mechanism involving the TNF-related apoptosis-inducing ligand (TRAIL) may be 
implicated in apoptotic killing of melanoma (Thomas and Hersey, 1998b).
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1.7.2. in Antibody mediated anti-tumour responses
The knowledge about humoral anti-tumour responses is limited, as the serum of most 
cancer patients do not contain antibodies reactive against TAAs. However, with the 
development of the SEREX technique (reviewed in (Sahin et a l,  1997; Tureci et a l, 
1997)) it has been possible to serologically characterise antigens. As these antibody- 
defined TAAs have been demonstrated to induce high-titer IgG responses in cancer 
patients, this indicates the simultaneous presence of a CD4+ T cell mediated response 
which is necessary to generate IgG antibodies. However, although approximately 1500 
antigens have been identified with the SEREX approach (www.licr.org/SEREX.htm), only 
MAGE-1 (van der Bruggen et a l, 1991), tyrosinase (Brichard et a l, 1993) and NY-ESO-1 
(Jager et a l, 1998; Jager et a l, 2000a) have been demonstrated to induce both T cell 
mediated and antibody responses. The contribution of antibody-defined antigens to clinical 
tumour regression is thus elusive and current vaccine strategies are aimed at activating T 
cell mediated anti-tumour responses.
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1.8 IL-10 IN IMMUNOLOGY
1.8.1 Cytokines and chemokines
The immune system is a highly regulated network in which signalling molecules such as 
cytokines and chemokines are critical regulators in directing the outcome of immune 
reactions. Chemokines recruit leukocytes (mainly DCs and macrophages) to sites of 
inflammation, while cytokines can have an arry of functions depending on their target cell. 
However, both chemokines and cytokines have been shown to play a crucial role in 
different diseases including cancer. For example, (i) tumour cells can express chemokine 
receptors and thereby locate to specific organs and, (ii) inflammatory cytokines present in 
the tumour microenvironment can support tumourigenesis (reviewed in (Balkwill and 
Mantovani, 2001)). Thus, normally cytokines are important factors in regulating different 
steps of immune reactions whose dysfunction can enhance tumour progression. In 
particular, IL-10 is a cytokine with several suppressive functions that can affect anti­
tumour activity.
1.8.2 Early findings
Endowed with pleiotropic activities, IL-10 has been shown to be a key cytokine in multiple 
biological systems only a decade after its identification (Fiorentino et a l, 1989). IL-10 was 
initially characterised for its capacity to inhibit the synthesis of IFN-y, IL-2 and TNF-P by 
Thl cells and was therefore first defined as cytokine synthesis inhibitor factor (CSIF) (de 
Waal Malefyt et a l, 1991a). However, subsequent studies in mice, showed that IL-10 
blocked also the functions of antigen presenting cells like macrophages and thus had an 
indirect effect on cytokine synthesis (Ding and Shevach, 1992; Fiorentino et a l,  1991b). 
Today, IL-10 is known to be a ubiquitously expressed Th2 cytokine with a complex of 
biological functions connected both to inhibition and stimulation of the immune response.
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1.8.3 The IL-10 gene
The human IL-10 (hIL-10) gene (Acession number U16720) has been mapped to the 
junction of IqSl and lq32 on chromosome 1 (Eskdale et al., 1997a; Kim et a l, 1992). It 
contains 5 exons which covers approximately 8.8 kb. The coding region of the mRNA 
includes 536 bp, which corresponds to the genomic sequence of the hIL-10 gene. 
Moreover, the ML-10 gene is highly homologous to the murine IL-10 gene (Moore et a l, 
1990; Vieira et a l, 1991), and they both show a strong nucleotide homology with an open 
reading frame of Epstein-Barr virus (EBV), BCRF-1, also known as viral IL-10 (vIL-10). 
This suggests that the EBV virus may have captured the mammalian IL-10 gene to favour 
its own survival.
The ML-10 encode for a 160 amino acid protein whose molecular weight is 18 kDa (Vieira 
et a l, 1991), which has 84% identity with the protein expressed by viral IL-10. Moreover, 
the IL-10 protein is biological active as a non-glycosylated homodimer and binds with high 
affinity to its dimeric receptor (IL-1 OR), composed of the IL-lORl and IL-10R2 chains 
(Hoover et a l, 1999; Tan et a l, 1995).
1.8.4 The role of IL-10 in the immune system
The various roles of IL-10 in the immune system are in part related to the fact that IL-10 is 
produced by a variety of hemopoietic cells (Figure 1.9): CD4+ ThO, Thl (Yssel et a l, 
1992) and Th2 (Fiorentino et a l, 1989) cells, B lymphocytes, mast cells, monocytes and 
macrophages (reviewed in (Wakkach et a l, 2000)). But even tumour cells have been 
shown to produce IL-10 (Chen et a l, 1994; Dummer et a l, 1996; Dummer et a l, 1995). 
Due to its multifunctional activities, IL-10 does affect several different cell types and it has 
been considered as a powerful immune regulatory cytokine. However, many o f the
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FIGURE 1.9: The pleiotropic activities of IL-10. IL-10 can be produced both by cells in the innate 
(macrophages) and in the adaptive immune defence (T and B cells). In addition, IL-10 release have been 
observed from melanoma cells. The multifunctional effects of IL-10 influence the immune response at 
several different levels. Briefly, B cells are induced to proliferate and secrete IgG antibodies, while 
proliferative responses are induced for precursor T cells, activated CD8+ T cells and mast cells. However, 
IL-10 is mainly known as an immunosuppressive cytokine as it can inhibit antigen recognition, 
proliferation and cytokine production of T cells by interfering with the antigen presenting function of 
macrophages. Also NK cells can be negatively influenced and produce a decreased level of IFN-g. 
Positive response are marked with a pink cross and suppressive effects with a blue line. The green dotted 
lines represents IL-10 production. This figure has been reproduced from Wakkach et al., 2000.
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functions of hIL-10 have been assayed in murine systems. This approach is possible, since 
hIL-10 is active on murine IL-10 receptor, while the opposite combination is not 
applicable, as the binding of the IL-10 protein to its receptor is species specific in humans, 
but not in mouse (Ho et a l, 1993; Liu et a l, 1994).
1.8.5 IL-10 influence on macrophages and monocytes.
The ability of IL-10 to inhibit cytokine production from macrophages and monocytes 
influence the initiation and maintenance of several other immunological events. The effect 
of IL-10 is particularly strong on inflammatory responses, as it suppresses TNF and IL-1, 
two pro-inflammatory cytokines. When activated, monocytes and macrophages can 
produce a wide array of cytokines: IL-1 a , IL-lp, IL-6, IL-10, IL-12, IL-18, GM-CSF, G- 
CSF, M-CSF, TNF, LIF and PAF (de Waal Malefyt et a l, 1991a; Fiorentino et a l,  1991a; 
Fiorentino et a l, 1991b). The inhibitory effect of the IL-10 on the synthesis of these 
cytokines makes IL-10 an important suppressor of inflammation.
The blocking of chemokine production from monocytes also inhibits the recruitment of 
neutrophiles, DCs and T cells to the site of inflammation. Moreover, the inhibitory 
properties of IL-10 also influence the antigen presenting capacity of macrophages by 
inducing the retention of assembled HLA class II molecules in intracellular vesicles 
(Koppelman et a l, 1997). In addition, IL-10 impairs proliferation of T lymphocytes 
stimulated by melanoma cells transduced with the co-stimulatory molecule B7 (Dummer et 
a l, 1998). Thus, IL-10 has the power to modulate a wide range of T cell responses.
1.8.6 IL-10 and B celis
In opposite to its suppressive effects on macrophages, monocytes and DCs, addition of 
hIL-10 to activated human B cells can enhance their growth and differentiation (Rousset et 
a l, 1992). In addition, activation of B cells through their antigen receptor or via CD40 in
43
Ch apte r  1________________________________ __________________________________________________________________
the presence of IL-10 can induce production of immunoglobulin (Ig) IgG, IgM and IgA. 
However, during their initial activation also B cells are subjected to the inhibitory effect of 
IL-10, while IL-10 promotes stimulatory effects upon activated B cells (Itoh and Hirohata, 
1995).
1.8.7 The influence of IL-10 on DCs and T cells
DCs are cells specialized for antigen capture and processing in the periphery then they 
migrate to the draining lymph nodes where they release cytokines and up-regulate HLA 
and co-stimulatory molecules like B7 to efficiently prime T lymphocytes (reviewed in 
(Banchereau and Steinman, 1998)). IL-10 is a cytokine that at various levels can interfere 
with the priming functions of DCs (Corinti et al., 2001). This strongly affects T cells, as 
they are the main modulators of immune responses and depend upon the right priming 
from DCs to become functionally committed. Moreover, in addition to down-regulation of 
costimulatory molecules, IL-10 can inhibit the secretion of IL-12 firom mature DCs (De 
Smedt et a l, 1997) and thus suppress the development of inflammatory Thl responses.
However, IL-10 has also been characterised as a cytokine inducing T cell proliferation and 
pre-incubation of human T helper cells with IL-10 induce their cytokine production 
(Lelievre et a l, 1998). CD8+ T cells show an enhanced proliferation in the presence of IL- 
2 and IL-10 (Groux et a l , 1998).
However, IL-10 has not only been explored as a Th2 cytokine with cross-regulating 
activity on the Thl/Th2 cytokine profiles, but it also has a pivotal role in immune 
suppression (reviewed in (Moore et a l, 2001)). An array of recent findings show that the 
state of the priming DCs is crucial in determining the direction of the subsequent T cell 
response (reviewed in (Jonuleit et a l, 2001)). More precisley, immature DCs (iDCs) 
mediate the maturation of Tr cells, while DCs that have matured in the presence of IL-10
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induce anergic T cells. Indeed, it has been observed that IL-10 modulated DCs are capable 
of suppressing both CD8+ and CD4+ T cells in an antigen specific manner, which can be 
restored by blocking of CTLA-4 (Steinbrink et a l, 2002). Thus, a current hypothesis is that 
IL-10 somehow influences the conditions of the DCs in a way that impedes their priming 
capacity.
1.8.8 IL-10 in tumour immunity
IL-10 is an important mediator of the immune response in the tumour microenvironment 
(reviewed in (Mocellin et a l, 2001)). The regulatory role of IL-10 is complex as it not only 
is expressed as a transcript in several human tumours like breast (Venetsanakos et a l, 
1997), ovarian (Pisa et a l, 1992), lung (Huang et a l, 1995) and renal cell carcinoma 
(Nakagomi et a l, 1995) and melanoma (Kruger-Krasagakes et a l, 1995), but it is also 
secreted by CD4+ T helper cells (Fiorentino et a l, 1989; Yssel et a l, 1992).
In particular, both inhibitory and stimulatory effects have been described for IL-10 in 
melanoma. For example, elevated IL-10 expression in metastatic lesions (Dummer et a l, 
1996; Dummer et a l, 1995; Sato et a l, 1996), may allow melanoma cells to escape 
detection by down-regulation of HLA (Yue et a l, 1997) and induction of anergy in DCs 
(Enk et a l, 1997). In addition, elevated serum levels of IL-10 have been detected in 
patients with metastatic melanoma (Fortis et a l, 1996), a finding that is compatible with 
the report that melanoma cells use IL-10 as an autocrine growth factor for proliferation 
(Yue et a l, 1997) as a way of escape immune reaction. Thus, tumour cells can also favour 
their progression by direct secretion of IL-10 in the tumour microenvironment.
Moreover, IL-10 can synergise with TGF-p to suppress anti-tumour responses (D'Orazio 
and Niederkom, 1998). However, other data report that IL-10 and TGF-P have been 
detected at increased levels in regressing versus progressing melanoma (Conrad et a l,
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1999). In deed, several anti-tumour mediated functions can be attributed to IL-10. Transfer 
of the mouse IL-10 gene into human melanoma cells resulted in inhibition of growth and 
reduced metastasis, which could be connected to inhibited tumour blood vessel formation, 
i.e. angiogenesis in vivo (Huang et a l, 1999; Huang et a l, 1996). Systemic administration 
of IL-10 to melanoma bearing mice inhibited further tumour establishment and led to 
complete regression (Berman et a l, 1996). In addition, anti-metastatic activity of IL-10 has 
been observed through NK cell dependent mechanism in mice models of melanoma 
(Zheng et a l, 1996). However, positive roles have also been described for IL-10 in 
humans. Recent data show that vaccination with IL-10 producing glioma-specific CD4+ T 
cells can mediate tumour rejection (Segal et a l , 2002).
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2.1 T h e  m e l a n o m a  pa t ie n t  15392
The study of this thesis has been focused on a melanoma patient, who has remained disease 
free for 12 years, an unusually favourable outcome, after her lymph node metastasis had 
been resected in 1990 at the Istituto Nazionale dei Tumori of Milan.
In September 1989 a 35 year old lady had a wide excision of a pigmented lesion on the 
right forearm in another hospital. The patient was referred in October 1990 to the Istituto 
Nazionale dei Tumori after she had noticed a mass in her right axilla. There were no signs 
of local recurrence or in transit metastasis. Chest X-ray and liver ultrasonography were 
uneventful.
In November 1990, the patient underwent a right axillary lymph node dissection. The 
pigmented lymph node was at the surface of the specimen, with no surgical margin 
involved. In contrast with the primary tumour, extensive lymphocyte infiltration within the 
tumour tissue was present. The remaining 22 lymph nodes were free of tumour. Post­
operative recovery was uneventful. Up to date, during further routine follow up, including 
clinical examination, routine chest X ray and liver ultrasonography, the patient remained 
free of recurrence, metastasis or second primary tumour formation.
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2.2 C e l l u l a r  M eth o d s
2.2.1 Statistics
Statistical analysis was performed using the 2-tailored ''Student-Newman-Keuls test”. Only 
data with p values of 0.05 or less were considered as statistically significant.
2.2.2 General principles for eukaryotic cell culture
All eukaryotic cell culture procedures were performed in strictly sterile conditions 
provided by Bluebeam 4 Class II Type A/B3 Biohazard Laminar Flow Cabinet hood 
(Arredi Tecnici Villa spa, Varese, Italy). Conventional standard procedures were applied 
for preparation of cell culture mediums and reagents.
Human serum (HS), obtained from healthy donors at Istituto Nazionale dei Tumori in 
Milan, or fetal calf serum (FCS) (Biological Industries, Beit Haemek, Israel) were passed 
through a 0.22 pm Stricup® Millipore Express'^^ high flow rate filter (Millipore S.A., 
Bedford, MA) and divided into 50 ml aliquots, which were heat-inactivated at 56°C for 30 
minutes. These preparations were stored at 4°C until use or for up to one month.
Culture media, i.e. either RPMI 1640 (BioWhittakerEurope, Vervires, Belgium) or 
Dulbecco’s Modified Eagle's Medium (DMEM) (Euroclone, Europe, TQ4 5ND Devon, 
UK) were purchased as 500 ml solutions and supplemented with different reagents 
(described below) depending on the requirements for each cell line or clone. L-Glutamine, 
HEPES buffer, NaPyruvate solution and phosphate buffered saline (PBS) were all 
purchased from BioWhittakerEurope (Vervires, Belgium). For practical reasons, pencillin 
and L-glutamine were prepared as stock solutions. More precisely, 2 g (1x10^ U) of 
pencillin (Pharmacia & Upjohn S.p.A., Milan, Italy) was left to dissolve in 10 ml of PBS 
(BioWhittakerEurope). The dissolved pencillin was then added to L-glutamin together with 
10 ml (400 mg) of Gentalyn (Schering-Plough S.p.A., Milan, Italy). This solution was
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passed through a 0.22 or 0.45 pm Millex®-GS Duropore® (PVDF) membrane (Millipore 
S.A., Bedford, MA), distributed as 6 ml stocks, stored at -20°C and rapidly thawed at 37°C 
just prior to use. One such pre-optimised stock solution was added to each 500 ml batch of 
culture media providing a final concentration of 200 U/ml pencillin (Pharmacia & Upjohn 
S.p.A, Milan, Italy), 2 mM L-glutamine and 40 pg/ml Gentalyn.
2.2.3 Cell lines and clones
Cell line or clones used in the present thesis are shown in Table 2.1. All cell lines were 
mycoplasma negative. 293-Epstein Barr Nuclear Antigen (EBNA) cells (293wt) were 
purchased from Invitrogene (CA, USA) while 293 cells engineered to constitutively 
express the class II trans-activator (CIITA) protein, 293/CIITA cells, were kindly provided 
by Dr. Paul Robbins (National Institute of Health, Bethesda, MA). COS-7 cells and the 
K562 cell line were purchased from American Type Culture Collection (ATCC), 
(Rockville, Maryland).
The melanoma cell line (Mel 5392) were established in vitro from the single cell 
suspension obtained from the lymph node metastatis of Ptl5392 (HLA-A typed as 
A*0301, B*40012, B*1402, C*0602, C*0802, DR|31*01021, DRpl*1001 and 
DQP1*0501), while the autologous lymphoblastoid cell line, LCL15392, was established 
from peripheral mononuclear cells (PBMCs) after EBV infection. Allogenic tumour cell 
lines, Allo-Mel (HLA-All, -A28, -B14, -B35, -C4, -C8) and Allo-Me2 (HLA- A3, -A2, - 
B14, -B44, -C5, -C8), were established in our laboratory.
The M el5392 and LCL15392 cell lines and T2 cells were maintained in RPMI 1640 
supplemented with 10% FCS, 200 U/ml pencillin, 2 mM L-glutamine, 40 pg/ml Gentalyn 
and 20 mM HEPES buffer. The Afiican green monkey cell line, COS-7, the human
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embryonic kidney cell line, 293-EBNA cells, and the NK cell susceptible and class IHLA 
deficient K562 chronic myelogenous leukemia cell line were maintained in DMEM 
supplemented with 10% FCS, 200 U/ml pencillin, 2 mM L-glutamine, 40 pg/ml Gentalyn, 
20 mM HEPES buffer and 0.5 mM Na Pyruvate solution. Lymphocyte activated killer 
(LAK) cells were cultured in RPMI 1640 in the presence of 10% HS, 200 U/ml penicillin, 
2 mM L-glutamine, 40 pg/ml Gentalyn, 20 mM HEPES buffer and 100 U/ml IL-2.
Established CD8+ and CD4+ T cell clones were cultured in DMEM supplemented with 
10% FCS, 200 U/ml penicillin, 2 mM L-glutamine, 40 pg/ml, Gentalyn, 20 mM HEPES 
buffer, 0.5 mM Na Pyruvate and 50 U/ml of recombinant human IL-2 (EuroCetus, 
Amsterdam, The Nederlands).
2.2.4 General procedures of cell culture
All cell lines and clones were left to expand at 37°C in a humidified atmosphere of 5% 
CO2 in a Forma Scientific CO2 Jacketed Incubator for 3-4 days before being split and 
passed on as new subcultures. Recipient cells such as Mel 5392, COS-7 and 293-EBNA 
cells (Table 2.1) were normally seeded at a concentration of 1x10^ cells/flask and grown to 
90-95% monolayer confluence in 75 cm^ Costar Cantec Neck Cell Culture flasks of 
polystyrene (Coming Incorporated, Coming, New York, USA) sealed with Plug Seal Caps. 
At this stage, the cells were detached by trypsination: the culture medium was discarded, 8 
ml (0.2 mg/ml EDTA, 0.5 mg/ml Tris) of Trypsin-EDTA (BioWhittakerEurope) was added 
to the cellular monolayer and after 5-10 min of incubation, the trypsin was deactivated 
with FCS or, altematively, with HS (1/10 volume of the volume Trypsin-EDTA used). 
LCL15392 cells were grown in suspension in vertically standing 75 cm^ Costar Cantec 
Neck Cell Culture flasks, incubated under the same conditions as adherent cells. All 
cellular preparations were centrifuged at 1500 rpm and 4°C in a table top centrifuge 581 OR
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Table 2.1: Cell lines and clones used in this study. All autologous cell lines (Mel5392 and LCL15392) 
were established from melanoma Ptl5392. LCL cells express the full HLA haplotype of the patient from 
whom they were derived. The CD8+ T cell clone, TB686 derived from tumour associated lymphocytes 
(TALs) of Ptl5392 (Castelli et al, 1999). CD4+ T cell clones (TB39, TB48, TB57, TB189 and TB515) were 
established by mixed lymphocyte tumour culture (MLTC) and limiting dilution approach of TALs. The 
allogenic melanoma lines (Allo-Me) shared the HLA-B14 and -Cw8 alleles with Ptl5392. The LAK cells 
were derived from PBMCs of a healthy donor.
Name Origin Culture Medium
293-EBNA A human embryonic kidney cell line DMEM 10% FCS
COS-7 An African green monkey cell line DMEM 10% FCS
K562 A human chronic myelogenous leukemia cell line DMEM 10% FCS
T2 A human TAP deficient lymphoma line RPMI 10% FCS
Mel5392 Autologous melanoma cells of Ptl5392 RPMI 10% FCS
LCL15392 Autologous LCL cells of Ptl5392 RPMI 10% FCS
CD8+ T cell clones Autologous tumour specific clones RPMI 10% HS, 50 U/ml IL-2
CD4+ T cell clones Autologous tumour specific clones RPMI 10% HS, 50 U/ml IL-2
Allo-Me Allogenic melanoma cells RPMI 10% FCS
LAK Lymphocyte activated killer cells RPMI 10% HS, 100 U/ml IL-2
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(Eppendorf S.r.L, Milan, Italy). Cellular aliquots were stained with trypan blue at a 1:1 
volume ratio and applied onto a Burker’s chamber glass slide, after which counts were 
carried out with an Olympus BX41 microscope.
2.2.5 Cryopreservation of cells in liquid nitrogen
Long term storage of cells was performed in liquid nitrogen. Cells were first normally 
detached by trypsination (see section 2.2.4), centrifuged and counted. Recovered cellular 
pellets were resuspended to a density of 10  ^or 10  ^cells/ml in pre-chilled RPMI or DMEM 
supplemented with either 30% FCS or HS together with 10% dimethylsulphoxide 
(DMSO). Aliquots of 1 ml were then directly added to 1.5 ml Nalgene cyrotubes (Nalgene 
Nuc International Corporation, Rochester, USA) sealed with screw taps, placed in plastic 
containers containing 100% isopropanol and then immediately stored at -80°C overnight, 
before storage at -196°C in liquid nitrogen.
2.2.6 Recovery of frozen cells
Cyrotubes with fi*ozen pellets were thawed in a water bath adjusted to 37°C and rapidly 
withdrawn upon melting. The cells were then regenerated by the drop-wise addition of 1 
ml of RPMI 1640 or DMEM supplemented with either 30% FCS or HS, transferred to a 15 
ml Falcon tube and filled up with 10 ml of medium. A minimum of 3 successive rounds of 
centrifugation at 1500 rpm for 10 min were performed to remove DMSO, before the cells 
were transferred to the appropriate culture flasks. PBMCs were thawed as described above, 
but in the presence of 2000 U/ml DNase (for 1x10^ cells) supplied to the medium.
2.2.7 Generation of tumor-specific T cell clones
TALs were isolated from a lymph node metastasis of Ptl5392 by Ficoll-Plaque (Pharmacia 
Upjohn, Uppsala, Sweden) density-gradient. The purified lymphocytes were subsequently 
frozen and stored in liquid nitrogen (-120°C) for 7 years. The T lymphocytes were then
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thawed and stimulated weekly with irradiated autologous tumour (10,000 rad) at an 
effectoritarget (E:T) ratio of 10:1 and maintained in RPMI 1640 supplemented with 10% 
HS and 300 U/ml of recombinant human IL-2 (EuroCetus, Amsterdam, The Netherlands) 
in a final volume of 200 pi in U-bottomed 96-well plates. At the end of the 3^  ^week of in 
vitro culture, the MLTC was either (i) maintained in vitro with additional repeated weekly 
tumour stimulations or (ii) responder T cells cloned by limiting dilution. T lymphocytes 
were seeded at 1 or 5 cells/well in 2500 U-bottomed wells (for each ratio) in a total volume 
of 150 pi RPMI 1640 supplemented with 10% HS and 50 U/ml recombinant human IL-2 
and in the presence of 5x10^ irradiated autologous tumour (10,000 rad) cells and 1x10^ 
irradiated allogeneic pooled lymphocytes (3,000 rad) obtained from healthy donors. The 
microcultures were weekly re-stimulated with irradiated autologous tumour cells and 
allogeneic lymphocytes.
The growing T cell clones were screened for the ability to recognize the autologous tumor 
in HLA-dependent fashion by a cytotoxic assay (see section 2.2.14). The specific clones 
were further expanded and stored in liquid nitrogen for additional expansion and functional 
studies. Five of these T cell clones (TB39, TB48, TB57, TB189 and TB515) were then 
analysed for their capacity to recognise autologous tumour.
2.2.8 Restimulation of T cell clones
The CD4+ T cell clones derived fi*om melanoma Ptl5392, were re-stimulated weekly as 
follows: 2-3x10^ CD4+ T cells were stimulated with 1x10^ autologous melanoma cells, 
irradiated at 10,000 rad in a final volume of 2.5 ml RPMI 1640 supplemented with 10% 
HS and containing 50 U/ml recombinant human IL-2. All T cell clones were added to 
transfected cells or used for peptide pulsing on their fifth day after re-stimulation, as they
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then released the maximum amount of cytokines. CD8+ T cell clones were stimulated in 
the same way.
2.2.9 FACS analysis
To identify the expression of specific cell surface molecules, cells were labelled with 
fluorescent antibodies and evaluated by fluorescence-activated cell sorting (FACS). All 
antibodies were purchased from Becton Dickinson (San Jose, USA) except for W6/32 
hybridoma growth in our laboratory and obtained from ATCC (Rockville, Maryland, 
USA).
Briefly, 3-5x10^ cells/sample were centrifuged at 1500 rpm for 10 min, after which the 
pellet was washed once in serum-free medium (RPMI 1640, DMEM or PBS) and 
incubated with a primary antibody following the manufacture instructions and then left 20 
min on ice. The following monoclonal antibodies (mAbs), were used for the primary 
staining: W6/32 (anti-HLA-A, -B and -C), 0K4 (anti-CD4), 0KT8 (anti-CD8) and an 
anti-human HLA-DP, -DR and -DQ Ah. Cells were then washed once to remove excess of 
Ah and incubated with the secondary FITC labelled goat anti-mouse Ab in a 1 to 40 
dilution in PBS for additional 20 min on ice. Finally, the cells were washed again and then 
fixed with Ix PBS containing 2% formalin before they were read in the FACScan® 
machine (Becton Dickinson). Direct immunofluorescence was performed with FITC labled 
mAbs and required only one incubation step. All washes were performed with serum-free 
RPMI 1640.
2.2.10 Transfection: the Lipofectamine method
The conditions for transfection of 293 cells were established according to the guidelines in 
the LipofectAMINE’^ ’^ 2000 reagent protocol for transfection (Gibco, Life Technology, Inc. 
Gaithersburg, MD, U.S.A.). In addition to that, the poly-L-lysine (Sigma Chemical Co.,
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LTD., Irvine, UK) reagent was used to pre-coat the wells to increase the attachment of the 
293 cells during the different steps of transfection. All transfections were performed in 
duplicate.
Thus, two days before transfection, a flat-bottomed 96-well Costar Cluster plate of 
polystirene (Coming Incorporated, Coming, New York, USA) was coated with 50 pi poly- 
L-lysine diluted to 0.1 mg/ml in Ix PBS (BioWhittakerEurope) per well and stored at 4°C 
ovemight. Then, on the day before transfection, the poly-L-lysine was discarded from the 
wells and the plates coated with 5x10"^  293 cells/well in 100 pi DMEM 10% FCS without 
antibiotics and subsequently incubated in 5% CO2 at 37°C for 24h. At 90-95% confluence, 
the 293 cells were double transfected with cDNA pools from the library and the HLA 
alleles of interest.
More precisely, for each well to be transfected, 150 ng of a cDNA pool (approximately 
100 cDNA constmcts/pool) was diluted up to 25 pi in OPTI-MEM I medium (Gibco, Life 
Technology) containing 150 ng of the HLA-DRp 1*01021 or HLA-DRpl*10011 allele in a 
V-bottomed 96-well plate. Then, for each well, 0.9 pi of the LF2000 reagent (Gibco, Life 
Technology, Inc) was diluted up to 25 pi in OPTI-MEM I medium and incubated 15 min in 
room temperature. 25 pi of the diluted LF2000 reagent was added to each well containing 
the DNA. After 20 min incubation at room temperature, to allow DNA-LF2000 reagent 
complexes to form, the DNA-LF2000 reagent mix (50 pl/well) was added to the 
corresponding wells with 293 cells. The plates were subsequently incubated in 5% CO2 at 
37°C for 24h, before the T cell clones were added.
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2.2.11 Transformation: the DËA£-dextran/chloroquine method
Transient transfections were also conducted by the DEAE-dextran/chloroquine method. 
Briefly, 15x10^ COS-7 cells were seeded per well in a 96-well flat bottomed tissue culture 
plate in a final volume of 200pl DMEM 10% FCS. After 24 h incubation in humidified 
atmosphere 5% CO2 at 37°C, the medium was discared and replaced by 50 pl/well of 
DMEM medium containing 1% NuSerum™ (Becton Dickinson, San Jose, USA), 0.4 
mg/ml DEAE-dextran (Pharmacia & Upjohn S.p.A., Milan, Italy) and 0.1 mM cloroquine 
(Sigma Chemical Co., St Louis, USA) admixed with 100 ng of DNA of interest and 200 ng 
of plasmid DNA. Transfection was performed with plasmids encoding known melanoma- 
associated antigens (MAGE-1,-2, -3, -4; BAGE-1 and -2; GAGE-1, -2, -3, -4, -5 and -6; 
Melan-A/MART -1, gplOO and tyrosinase). These vectors were kindly provided by Dr. 
Thierry Boon, Ludwig Institute for Cancer Research, Brussels, Belgium. The plate was 
then centrifuged at 900 rpm for 7 min and then incubated for 48 h in 5% CO2 at 37°C, 
After 48 h incubation, supernatants were carefully removed and 15x10"  ^T cells (on the fifth 
day after their restimulation) were added to each well. The transfected cells were incubated 
for a minimum of 18 h with the T cells and then supernatants were collected and directly 
evaluated for their content of IFN-y in an ELISA assay.
2.2.12 Cytotoxic assay
Cytotoxic activity of CD4+ T cells was measured in a standard 4 h ^^Cr assay. Target cells 
(2x10^ cells), Mel 5392 and LCL15392 (control), were washed once with RPMI 1640 10% 
HS and the pellet resuspended in 100 pi (100 pCi) sodium-(^^Cr)-chromate, Na(^*Cr)0 4 , 
(Amersham Biosciences, NJ, USA) and incubated for 1 h at 37°C. The labeled target cells 
were then washed once in 5 ml RPMI 1640 10% HS and then three times in 10 ml RPMI 
1640 10% HS to remove excess of the ^^Cr isotope. The target cells were then 
resuspended in RPMI 1640 10% HS and seeded as triplicates of 1000 cells/well in a U-
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bottomed 96-well plate in a volume of 100 pi, after which T cells were added at a serial 
effectoritarget (E:T) ratio of 100:1, 50:1 and 25:1 at a final volume of 150 pi.
The cytotoxic activity was always evaluated in the presence of controls for inhibition of 
lysis, i.e. the target cells were incubated for 40 min at 37°C with 2 pg/ml of either W6/32 
(anti-HLA-A, -B and -C), B 1.23.2 (anti-HLA-B and -C) or L243 (anti-HLA-DR). The 
involvement of the T cell receptor (TCR) in the target recognition was evaluated by 
incubating the CD4+ effector T cells for 40 min at 37°C with 2.5 pg/ml of 0KT3 (anti- 
CD3). Spontaneous lysis was measured by incubating target cells with medium alone. The 
level of maximum lysis was obtained by incubating target cells with 2% Nonidet P-40 
(BDH Limited Pool, England). The samples were incubated for 4 h, after which the plates 
were centrifiiged for 10 min at 800 rpm. 100 pi of the supernatant was transferred to a 
LumaPlate^^ - 96 solid scintillation plates (Packard BioScience Company, PerkinElmer, 
Meriden, CT), which were let to dry ovemight. The radioactivity was measured in an 
A9912 Top Count beta counter (Packard Instmments). Percentage of inhibition was 
calculated in counts per minute (cpm) by the following equation, i.e. [(experimental release 
-  spontaneous release) / (maximum release -  spontaneous release)].
2.2.13 Stimulation of T cells using OKT3
To achieve an effective T cell stimulation, 2 pg/ml of 0KT3, was coated onto a 24-well 
plate and incubated for 1 h, after which T cells (5x10^ cells/well) were added in a final 
volume of 0.2 ml RPMI 1640 10% HS. The plates were incubated at 37°C in 5% CO2 
ovemight. This allowed the TCRs to be cross-linked by the plate-bound antibodies and 
produce an optimal cytokine release. The supematants were then harvested and assayed for 
their content of IFN-y by ELISA (see section 2.2.17).
58
Ch apte r  2___________________________
2.2.14 Cytokine release assay 
Lymphocytes were seeded (5x10^ in 50 pi) in 96-well U-bottomed plates with 10*" 
cells/well of autologus or allogenic melanoma cells in a final volume of 0.2 ml of RPMI 
1640 supplemented with 10 % of HS. After ovemight incubation at 37°C, supematants 
were collected and cytokine content evaluated by ELISA (Endogen, Wobum, MA 01801, 
USA) (see section 2.2.17).
TCR involvement was evaluated by blocking experiments performed using the OKT3 Ab. 
Briefly, T cells before being added to the wells containing melanoma cells, were pre­
incubated in the presence of 1 pg/ml of the blocking Ab for 45 min at 37°C. The T cells 
were then added to melanoma cells and supematants was collected after 18 hour incubation 
and evaluated for their cytokine content by ELISA (see section 2.2.17).
The involvement of class I and class II MHC molecules in the recognition of tumour cells 
was evaluated by incubating the target cells with 1 pg/ml of W6/32 (anti-HLA-A, -B and - 
C), B 1.23.2 (anti-HLA-B and -C), L243 (anti-HLA-DR), for 45 minutes at 37°C and then 
the T cells were added to the wells; supematants was collected after 18 hour incubation 
and evaluated for their cytokine content by ELISA (see section 2.2.17).
2.2.15 Peptide synthesis
Peptides were synthesised by conventional solid phase chromatography using Fmoc for 
transient NH2-terminal protection and characterised by mass spectrometry. All of the 
peptides were > 95% pure (Neosystem, Strasbourg, France). The peptides were dissolved 
at 5 mg/ml in DMSO and stored at 4°C. Prior to use, the peptides were diluted in RPMI 
1640 containing 10% HS.
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2.2.16 Peptide pulsing
LCL15392 cells were seeded in U-bottomed 96-well micro-plates (5x10"  ^cells/well) in 100 
pi RPMI 1640 10% HS and then pulsed with different concentrations of the synthetic 
peptides for 2 h at 37°C. To ensure an optimal cytokine release, T cells (1.2x10"  ^cells/well 
in 150 pi) were added to the wells (on their fifth days after re-stimulation) with the 
autologous tumour and incubated ovemigth at 37°C. The supematants were collected after 
18 h and evaluated for their IFN-y content by ELISA (see section 2.2.17).
2.2.17 ELISA
Supematants collected from cellular experiments were ftirther evaluated for the cytokine 
content (IFN-y, TNF-a, GM-CSF, IL2, 11-4, IL- 6  and IL-10) by ELISA (Mabtech AB, 
Stockholm, Sweden) according to the manufactures guidelines.
On the day before the ELISA, a Nunc-Immuno™ Plate with MaxiSorp"^^ Surface (Nunc"^^ 
Brand Products, Nalgene Nuc Intemational, Denmark) was coated with 50 pi of the 
primary Ab, diluted to 1 pg/ml in Ix PBS (BioWhittakerEurope) and incubated ovemight. 
On the day of the assay, the first Ab was removed by blotting of the plate onto paper 
towels. The plate was then incubated Ih with 200 pi Assay Buffer (Ix PBS with 4% BSA, 
pH 7.2) per well and washed 3 times with 200 pl/well of a Wash Buffer (50 mM Tris, 
0.2% Tween-20, pH 8.0). The samples, supematants and 1:1-dilutions of cytokine standard 
(1000 pg/ml), were added as duplicates (50 pl/well) to the plate in parallel and, 50 pl/well 
of the Biotin-Labled second Ab, diluted to 1 pg/ml in Ix PBS, was added directly to the 
plate. After 90 min incubation, the plate was washed as described above and then further 
incubated for 30 min with horse radish peroxidase (HRP)-conjugated Streptavidin, diluted 
1:15000 in Assay Buffer (100 pl/well). Finally, the plate was washed as described above, 
after which the samples were incubated with TMB Substrate Solution for 30 min (100
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pl/well), after which 100 pi Stop Solution (0.18 M H2SO4) was added per well. The ELISA 
plate was subsequently read in a MRX® II microplate photometer (Dynex Technologies, 
Inc., Chantilly, USA).
The content of TGF-pi in culture supematants was evaluated by a special ELISA approach 
involving an acid pre-treatment which converts its released, latent form to a bioactive, 
detactable protein. More precisely, according to the guidelines in the TGF-pl ELISA 
protocol (BioSource Intemational, Inc, Califomia, USA) each supematant (50 pi) was 
admixed with 10 pi Extraction Solution (i.e. a ratio of 5:1), vortexed and incubated for 30 
min at 4°C. After this treatment, 50 pi of Standard Dilutent Buffer was added to each 
sample resulting in a 2.2-fold dilution of the supematants. The following steps of the TGF- 
pl ELISA were performed exactly as described in the manufacture’s protocol.
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2.3 M o l e c u l a r  M e th o d s
2.3.1 General principles
All molecular reactions were prepared in Eppendorf tubes and kept on ice. Restriction 
enzymes were always kept in a thermo block (Stratacooler) when used. Gloves were used 
for handling of all RNA samples and IsoTip Filter tips (Costar, Coming Incorporated, 
Coming NY, USA) were used for work with restriction enzymes, PCR reagents and RNA. 
Centrifugations were carried out in a table-top Biofuge, Heraeus Instmments centrifuge at 
a maximum speed of 13000 rounds per minute (rpm) or in a SIGMA Laboratories 
refrigerated table-top centrifuge (B. Braun Biotech Intemational GmbH, Melsungen). All 
DNA samples were diluted in 10 mM Tris-HCl, pH 8.0, if  not otherwise indicated. 
Chemical solutions were sterilised by filtrated with Stericup™ Millipore Express™ high 
flow rate filter 0.22 pm microfilter (Millipore S.A., Bedford, MA).
2.3.2 mRNA extraction
RNA was extracted following a modified version of the acid guanidinium thiocyanate- 
phenol-cloroform method. Briefly, a cellular pellet prepared of a minimum of 1x10^ cells 
was thawed in room temperature and then immediately resuspended in 2 0 0  pi of 
RNAzol™ B (Tel-Test, Inc., Friendswood TX, USA); the homogenisation was optimised 
to the use of 200 pi of RNAzol™ B to achieve an efficient lysis of 1x10^ cells. The sample 
was vortexed well to dissolve the RNA pellet and then left for 5 min at room temperature. 
The lysis reaction was stopped by addition of 200 pi chloroform per 2 ml of homogenate 
(i.e. 2  pi chloroform in 2 0 0  pi homogenate) and agitated vigorously by inverting the tube 
4-6 times, after which the sample was incubated on ice for 5 min and then centrifuged for 
15 min at 4°C and 12000 g. This treatment resulted in a separation into one upper aqueous 
phase (transparent) containing the extracted RNA and one lower organic phase (blue) with 
DNA and proteins. The RNA containing supematant was carefully transferred to a new
62
Ch apte r  2______________________________________________________________ _ ___________________ ________________
tube and precipitated with the addition of an equal volume of 100% isopropanol. More 
precisely, the sample was inverted 4-6 times and left for a minimum of 5 min on ice before 
it was centrifuged for 15 min at 4°C and 12000 g. The recovered pellet was washed once 
with 1 ml 70% ethanol, vortexed and centrifuged for 10 min at 4°C and 7500 g. The 
retrieved RNA pellet was dried in a speed vacuum centrifuge, Eppendorf Concentrator 
5301 (Eppendorf S.r.L, Milan, Italy), for maximum 10 min and then resuspended in 50 pi 
diethylpyrocarbonate (DEPEC) RNase-ftee water. All RNA preparations were stored at - 
80°C.
2.3.3 cDNA synthesis
The reagents for cDNA synthesis were purchased from Promega (Promega Corporation, 
Wisconsin, USA) and all steps were performed on ice. The first strand was synthesised 
from 2 pg of mRNA in a final volume of 21 pi containing 0.01 pg/pl oligo(dT) primer, 
0.76 mM dATP, 0.76 mM dTTP, 0.76 mM dGTP, 0.76 mM dCTP, 0.02 M DTP, 19 U/pl 
of reverse transcriptase (RT) superscript BR2 and 1.9x RT First Strand buffer PCR. More 
precisely, a volume corresponding to 2 pg of mRNA was resuspended up to 19 pi with 
sterile water and then incubated with 0.6 pi (0.5 pg/pl) of oligo(dT) for 10 min at 65°C to 
add a thymidine (T) overhang to the mRNA template. Thereafter, the reaction was stopped 
for 2 min in ice and centrifuged for 2 min to receive a pellet. A master mixture (dNTPs, 
DTT and 5x RT First Strand buffer PCR) of 18.4 pi was added to the sample, which was 
incubated at 45°C for 2 min and then supplied with 2 pi of RT superscript BR2. The 
reaction was left to proceed for 1 h at 45°C and then stopped on ice. The second cycle was 
started by denaturing the mRNA/cDNA hybrid at 90°C for 5 min, after which the sample 
was put on ice and 2 pi of RT superscript BR2 was added. The sample was then incubated 
at 45°C for 1 h and finally stopped on ice. Prepared cDNA samples were stored at -20°C.
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2.3.4 RT-PCR
The reverese transcriptase - polymerase chain reaction (RT-PCR) allows an exponential 
amplification of complementary cDNA strands in cyclic flow schedule: double stranded 
dénaturation, primer annealing and single strand extension (polymerisation). This is 
possible due to the action of a thermophilic enzyme, Taq polymerase, extracted fi*om a 
bacterium called Thermus aquaticus.
All amplifications were performed on a GeneAmp® PCRSystem 9700 PCR machine 
(Applied BioSystems, CA, USA) with primers indicated in Table 2.2 with reagents 
purchased fi*om Perkin Elmer, Roche Diagnostics GmbH, Mannheim, Germany (if not 
otherwise indicated) and using p-actin as a positive control of the PCR reaction. The PCR 
for P-actin was performed in a 25 pi reaction mixture containing 2 pi of cDNA sample, all 
four dNTPs at 1.25 mM, Ix PCR buffer II, 20 pM of each primer, 25 mM MgCh and 0.25 
pi (5 U/ml) of AmpliThg Gold"^  ^polymerase according to the following PCR program: 
94°C, 10 min; 21 cycles (94°C, 30 s; 6 8 °C, 60 s; 72°C, 90 s); 72°C, 14 min and 4°C (hold). 
The synthesis of the HLA-DRp 1*01021 and HLA-DRpi* 10011 alleles was performed in 
a 25 pi mixture of 2 pi of cDNA, all four dNTPs at 1.25 mM, Ix PCR buffer II, 20 pM of 
each primer, and 0.15 pi (5 U/ml) of AmpliThg Gold™ polymerase as follows: 94°C, 5 
min; 30 cycles (94°C, 1 min; 57°C, 2 min; 72°C, 2 s); 72°C, 7 min and 4°C (hold). The 
minigenes were synthesised by amplifying 1 pi (1 ng/pl) cDNA in a total reaction mixture 
of 25 pi of Ix PCR buffer, all four dNTPs at 1.25 mM, 25 mM MgCb, 20 pM of each 
primer, and 0.5 pi (2.5 U/ml) of Platinum® Pfx. DNA polymerase
64
Ch a p t e r ! ___________________________________________________________________________________________________
Table 2.2 The primers used to amplify P-actin, HLA-DRpi*01021, BQLA-DRpi*10011 and the 
minigenes. The primers used to amplify the HLA alleles were specific for conserved 5’ and 3’ regions of the 










(Gibco, LifeTechnologies, Garthersburg, MD) following a dénaturation at 94°C for 5 min, 
then 15 cycles of polymerisation (dénaturation for 1 min at 94°C, annealing for 2 min at 
50°C and extension for 2 min at 72°C), synthesis completion for 7 min at 72°C and 
permanent hold at 4°C.
PCR analysis of the TCRAV and TCRBV repertoire was conducted using a panel of 
described oligonucleotide primers (Genevee et a l, 1992). The amplification was
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performed in 25 pi of reaction mixture in presence of 1 pi of cDNA, 2.5 pi lOx PCR 
buffer, 200 pM of each dNTP, IpM of each primer and 0.625 U of AmpliTh^® DNA 
polymerase (Roche Diagnostics Ltd, UK) on a DNA thermal cycler (Perkin Elmer Cetus 
Corporation, Emeryville, CA) for 25 cycles of amplification under the following condition: 
95°C, 30 s dénaturation; 60°C, 30 s annealing; 72°C 60 s extension. Negative controls 
were included with no cDNA in the mixture.
The RT-PCR preceding the subcloning of IL-10 was performed differently (see section 
2.5.1). Moreover, PCR with single colonies has been described as a part of “Library 
Construction” (see section 2.4.12).
2.3.5 Subcloning of HLA-DRP 1*01021 and DRpi*10011
The poly(A)+ RNA was extracted from the lymphoblastoid cell line (LCL15392) of 
melanoma Ptl5392 using the Fast Track kit (Invitrogen, NV Leek, The Netherlands) and 
subsequently converted to cDNA as previously described. RT-PCR was performed using 
primers specific for the conserved regions of the HLA-DRp 1 chains (see section 2.3.4 and 
Table 2.2). The amplification reaction was carried out with Platinum® Pfic DNA 
polymerase (Gibco, Life Technology), after which the amplification products were cloned 
into the pcDNA3.1W5-His-TOPO TA cloning vector (Invitrogen Corporation, Calsbad, 
CA). Single colonies were screened for the presence of the insert and the clones bearing 
the HLA-DRp 1*01021 and -DRpi*10011 alleles were identify by DNA sequencing.
2.3.6 Electrophoresis
Standard high or low melting agarose gels were prepared from EuroClone® agarose 
(Euroclone Ltd, UK), while Molecular Biology Certificated agarose (BioRad, CA) was 
used to separate DNA samples from which fragments were to be purified. All gels were 
prepared as follow: agarose powder (0.7-1.5% w/v) was added to Ix Tris-acetate-EDTA
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buffer, prepared from a 5Ox stock solution (2 M Tris, 1 M glacial acetic acid, 50 mM 
EDTA), and was boiled in an microwave until a clear, transparent solution was obtained. 
The melted agarose was cooled to 50°C, after which it was stained with ethidium bromide 
(EtBr) to a final concentration of 0.5 pg/ml and casted in a gel tray. 1 pi of gel-loading 
buffer (Invitrogene’^ ’^  LifeTechnologies) was added to each 10 pi DNA sample. The 
samples were analysed on agarose gels run at a constant voltage (90 V) for Ih in a Gibco 
BRL Horizontal Electrophoresis Apparatus (Invitrogene™ LifeTechnologies) with Ix TAE 
buffer, after which the DNA fragments in the gel were visualised under UV light. The 
molecular markers 100 bp DNA Ladder and 1 kb DNA Ladder (Invitrogene™ 
LifeTechnologies) and MassRuler™ DNA Ladder, High Range (MBI Fermenta, Dasit 
S.p.a, Italy) were used to size the DNA on the gel.
2.3.7 Purification of DNA bands from gel
DNA fragments were extracted from agarose gels according to the guidelines in the 
QIAquick Gel Extraction Kit Protocol (Quiagen S.p.A., Milan, Italy). Briefly, an excised 
gel slice (containing the DNA fragment of interest) was placed in an Eppendorf tube and 3 
volumes of QG buffer was added per 1 volume of gel, i.e. 100 pi Buffer QG buffer to 100 
mg gel. The sample was then incubated at 50°C with vortexing every 2 min until the gel 
was completely dissolved (approximately 10 min). The hereafter yellow sample was 
precipitated with 1 gel volume of 100 % isopropanol, added to a QIAquick column and 
centrifuged for 1 min at 13000 rpm. Next, 0.5 ml Buffer QG was added to the column that 
was centrifuged for 1 min at 13000 rpm, a step that removes all traces of agarose. The 
column was then washed with 0.75 ml Buffer PE and centrifuged for 1 min at 13000 rpm. 
To remove also residual ethanol, the column was centrifuged one additional time for 1 min 
at 13000 rpm. The pure DNA sample was eluted with 50 pi of 10 mM Tris-HCl, pH 8.0 by 
centrifugation for 1 min at 13000 rpm after 1 min rest.
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2.3.8 Ligation of DNA insert to an expression vector
All ligations were performed according to the manufacturers’ guidelines in the DNA 
Ligation Kit Version 2 protocol (TaKaRa Biomedicals Inc., CA, USA). A reaction mixture 
was prepared with the dephosphorylated vector and the purified insert at a molecular 
insert: vector ratio of 3:1 to a final volume of 10 pi containing 5 pi Solution I (contains T4 
DNA ligase). Transformation was performed immediately after the ligation (see section 
2.3.21).
2.3.9 Dephosphorylation of vector DNA prior to ligation
To avoid re-ligation of digested vector DNA, calf intestinal alkaline phosphatase (CEP) was 
used to remove the 5’ phosphate group from the vector backbone. Dephosphorylation was 
performed according to the guidelines provided by the manufacturer (Promega 
Corporation, Wisconsin , USA). A digestion mixture was prepared as follows: the digested 
expression vector (0.1 pg/pl) was incubated with CIP (0.01 U/pl), lOx CIP buffer and 
distilled water up to a volume of 70 pi for 15 min at 37°C. The DNA was then incubated 
for 15 min at 56°C. 7 pi of CIP (0.01 U/pl) was added to the sample, after which the two 
incubation steps were repeated. Then the reaction was stopped by the addition of stop 
solution (a volume corresponding to 1/10 of the original sample volume). Finally, the 
vector DNA was boiled for 10 min at 6 8 °C.
2.3.10 Precipitation of DNA
DNA samples were precipitated as follow: 0.1 volume of 3M NaAc, pH 5 was added to 1 
volume of DNA, after which 3 volumes of 100% ethanol (-20°C) was added. This solution 
was then left to precipitate on dry ice for 30 min or ovemight at -80°C. After precipitation, 
the sample was centrifuged at 4°C for 20 min and 13000 rpm to recover the DNA. The
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pellet was washed 3x with 70% ethanol and then left to evaporate at room temperature for 
30 min, before it was resuspended in 10 mM Tris-HCl, pH 8.0.
2.3.11 Preparation of DNA for sequencing
All samples were prepared for sequencing by the same sequential steps: 1) ovemight 
precipitation with 3 NaAc, pH 5; 2) resuspension of the pellet in 10 pi sterile water and 3) 
preparation of the samples for sequencing. Each sample was prepared as a 15 pi mixture 
containing 1.3 pg DNA template and 9 pmol of primer. DNA sequencing of IL-10 and the 
HLA-DRp 1*01021 and DRp 1*10011 alleles were performed with primers specific for the 
vector regions adjacent to the multiple cloning site, forward primer: 5’-
TAATACGACTCACTATAGGGAGA-3’, reverse primer 5’-
TAGAAGGCACAGTCGAGG-3’.
2.3.12 Digestion
DNA samples (0.5-1 pg) were digested with 3-10 U of enzyme per pg of DNA by 
incubation for 2-3 h in a 37°C water bath. The enzyme buffer was present as a 0.1 volume 
of the final reaction volume. Enzymes were purchased either from New England BioLabs, 
MA, USA or Amersham Pharmacia Biotech, Buckinghamshire, England.
2.3.13 Preparation of antibiotic stocks
All stock solutions of antibiotics were dissolved in distilled water and sterilised by 
filtration through a 0.22 or 0.45 pm Millex®-GS Duropore® (PVDF) membrane 
(Millipore S.A., Bedford, MA, USA). Ready solutions were divided as 1 ml aliquots and 
stored at -20°C for a maximum of 4 months. To avoid inactivation of ampicillin (Sigma 
Chemical Co., St Louis, USA) due to its sensitivity to light, residual stocks were not re­
frozen and used a second time.
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2.3.14 Glycerol storage of bacteria
All glycerol stocks were prepared from ovemight cultures of bacteria mixed with 20% 
glycerol (autoclaved), i.e. 800 pi ovemight culture and 200 pi glycerol ratio. The bacterial 
stocks were stored in 2 ml tubes with screw caps at -80°C.
2.3.15 Plating of bacteria
All bacterial host strains were preserved as glycerol stocks at -80°C. Prior to DNA 
preparation, all bacteria were recovered as follows: a sterile loop stick was used to scrape a 
layer of bacteria from a frozen glycerol stock and then streak them onto Luria-Bertani (LB) 
agar plates (see section 2.3.16), which were incubated upside down at 37°C over night and 
fiirther stored at 8 °C for 1-2 weeks.
2.3.16 Preparation of agar plates for bacterial growth
Agar plates were prepared from a Ix LB stock solution, pH 7 (1% w/v NaCl (Fluka, 
BioChemica, Sigma-Aldrich S.r.L, Milan, Italy), 1% w/v tryptone (Acumedia™, Acumedia 
Manufacters, Inc., Baltimore, Maryland, USA), 0.5% w/v Bacto Yeast extract 
(DifcoLaboratories, Detroit, Michigan, USA) and 1.5% w/v Bacto® Nutrient Agar 
(DIFCO Laboratories)). Sterile Petri dishes were filled to 2/3 with Ix LB medium and left 
to solidify under a bacterial hood. If selective plates were prepared, the antibiotic 
(normally ampicillin at 50 mg/ml) was added to the autoclaved medium after it had cooled 
to approximately 40°C. All LB plates were stored upside down at 8 °C for a maximum of 4 
months.
2.3.17 Small scale preparation of plasmid DNA: Mini-preparation
Today standard protocols for preparation of plasmid DNA have been adapted from a rapid 
alkaline lysis method for extraction of plasmid DNA (Bimboim and Doly, 1979) and 
become optimised by a procedure that mediates adsorption of DNA silica glass surfaces by
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high salt treatment (Vogelstein and Gillespie, 1979). All small scale plasmid preparations 
were performed according to the guidelines in the QIAprep Spin Miniprep Kit (250) 
protocol (Quiagen S.p.A., Milan, Italy). Escherichia coli DH5a (E.coli) was used as a host 
strain, as it is effective in propagating plasmid DNA. All centrifugations were performed in 
a table-top Biofuge, Heraeus Instruments centrifuge at a maximum speed of 13000 rpm, if 
not otherwise indicated. Prior to DNA preparation, all bacteria were recovered from 
glycerol storage (see section 2.3.15) prepared as fresh out streak on LB agar plates, from 
which single colonies were streaked onto individual selective LB plates to assure a clonal 
origin for the plasmid DNA.
As a first step of the mini-preparation, one single bacterial colony was picked from such a 
fresh outstreak of E.coli DH5a, inoculated with 3 ml of Ix LB medium containing 50 
mg/ml of ampicillin and incubated ovemight at 37°C in Orbital Incubator, Model 4520 
(Forma Scientific, Inc.) with vigorous shaking, i.e. 200 rpm. A volume of 0.8 ml ovemight 
culture was prepared as glycerol stock (see section 2.3.14), while 2.2 ml was used further 
for plasmid DNA extraction. The cellular pellet was recovered by centrifugation for 10 min 
at a maximum speed of 13000 rpm in a table-top centrifuge, carefully resuspended in 250 
pi of PI Buffer and transferred to 1.5 ml Eppendorf tubes. The cells were lysed by the 
addition of 250 pi of P2 Buffer and the tube gently inverted 4-6 times. The lysis reaction 
was stopped after exactly 5 min by the addition of 350 pi of N3 buffer, the tube was then 
immediately inverted 4-6 times. This treatment caused precipitation of denatured proteins, 
chromosomal DNA, cellular debris and sodium dodecyl sulphate (SDS), while the plasmid 
DNA was released in the supematant. This solution was centrifiiged for 1 min, the 
supematant was transferred to a QIAprep Spin column placed in 2 ml collection tube and 
centrifugated for additional 1 min. Residual wash buffer was removed by centrifugation of 
the empty column for 1 min and left the purified plasmid DNA bound to the silica-gel
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membrane. In the last step, the QIAprep Spin column was left for 1 min with 100 pi of 10 
mM Tris-HCl, pH 8.0, before the pure plasmid DNA was eluted by centrifugation for 1 
min. The collected DNA was stored at -20°C.
2.3.18 Large scale plasmid preparation of plasmid DNA: Maxi-preparation
All large scale plasmid preparations were performed according to the guidelines for low 
copy-plasmids described in the QIAGEN Plasmid Maxi Kit (25) protocol (Quiagen S.p.A., 
Milan, Italy). E.coli DH5a was used as a host strain. A Sorvall® RC-5C Plus Superspeed 
Centrifuge (Kendro Laboratory Products, Germany) was used for all centrifugations.
A single colony was picked from a fresh out streak of a glycerol stock (see section 2.3.15), 
inoculated with 500 ml Ix LB medium, 50 pi (50 mg/ml) of ampicillin (Sigma Chemical 
Co., St Louis, USA) and 200 pi (1%) glucose (prepared from 18% w/v glucose in 
deionized water) and left to incubate ovemight at 37°C with vigorous shaking, i.e. 250 
rpm. This pre-culture was then inoculated with 500 ml LB medium containing 500 pi (50 
mg/ml) of ampicillin and incubated ovemight at 37°C and with shaking at 250 rpm. The 
bacterial pellet was harvested by centrifiigation for 15 min at 6000 rpm and carefully 
resuspended in 10 ml of Buffer PI. 10 ml of Buffer P2 was added to the cells, which were 
left to lyse at room temperature for maximum 5 min to avoid irreversible dénaturation of 
the plasmid DNA. The reaction was neutralised by the addition of 10 ml pre-chilled Buffer 
P3 and left on ice for 15 min to allow full precipitation of genomic DNA, proteins, cellular 
debris and SDS. The sample was then centrifuged for 30 min at 12000 rpm, after which the 
plasmid containing supematant was applied to a pre-equilibrated QUIAGEN-tip 500 (10 
ml Buffer QBT) and allowed to enter the resin by gravity flow. The plasmid DNA was 
washed twice with 30 ml of Buffer QC to remove contaminants as RNA, carbohydrates 
and proteins. The DNA was eluted with 15 ml of Buffer QF, precipitated with 10.5 ml of
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isopropanol and collected by centrifugation for 30 min at 4°C and 9500 rpm. The DNA 
pellet was washed once with 70% ethanol, air dried (5-10 min) and resuspended in 250 pi 
10 mM Tris-HCl, pH 8.0.
2.3.19 Spectrophotometric measurement of DNA concentration
The absorbance of all DNA and RNA samples were measured at 260 nm and 280 nm in an 
Ultrospec® 3000 Spectrophotometer (Amersham Pharmacia Biotech UK Limited, 
England). The concentration was automatically calculated using the convention that an 
absorbance unit at 260 nm corresponds to 50 pg/ml for double stranded DNA and 40 
pg/ml for RNA samples. An optical density ratio (OD260/OD280) of 1.8-indicated that a 
pure DNA sample free from protein or phenol, only such samples were used further.
2.3.20 Preparation of competent cells
A smear of colonies (see section 2.3.15) was taken from a freshly streaked E.coli DH5a 
cells and resuspended in 2 ml of Ix SOC medium (1% w/v tryptone (Acumedia™, 
Acumedia Manufacters, Inc.), 0.5% w/v Bacto Yeast extract (DifcoLaboratories) and 
0.05% w/v NaCl (Fluka, BioChemica, Sigma-Aldrich S.r.l.), 10 mM MgS04 and 0.4% w/v 
glucose). This 2 ml suspension was then used to inoculate 100 ml SOC medium. The cells 
were then incubated at 37°C and 250 rpm for approximately 2-3 h, i.e. until an optical 
density (CD) of 0.3 - 0.6 at 600 nm was reached. The culture was then divided into two 
pre-chilled centrifuge tube, left on ice for 20 min and centrifugated at 4°C at 3000 rpm for 
15 min. All steps hereafter were performed on ice. The pellet was careftilly resuspended, in 
30 ml prechilled TBI buffer (30mM Ko Ac, 50mM MnCl2*4H20, 100 mM RbCl, 10 mM 
CaCl2*2H20 pH5.8 and 15% glycerol,). The cells were left on ice for 15 min and then 
centrifuged as described above before the pellet was resuspended in 4 ml prechilled TBII 
buffer (10 mM MOPS, 75mM CaCl2*2H2O,10 mM RbCl pH6.8 and 15 % glycerol). The
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cells were left for additional 15 in on ice and then divided as 2 2 0  pi aliquots of competent 
cells into Eppendorf tubes that had been prechilled for 2 min on dry ice and ethanol. The 
competent cells was then stored immediately at -80°C and kept for a maximum of 4 
months.
2.3.21 Transformation with competent ceils
To preserve the transformation efficiency of the competent cells (see section 2.3.20), E. 
coli DH5a, all steps were performed on ice with pre-chilled tubes. The competent cells 
were thawed on ice and immediately upon thawing, 100 pi of cells were added to 15 ml 
Falcon tubes. In a subsequent step, the cells were treated with p-mercaptoethanol (prepared 
as a stock solution of 14.4 mM in water) to a final concentration of 25 mM. The cells were 
gently swirled every 2 min for a period of 10 min, after 2 pi (1 ng/pl) DNA was added and 
the samples left for 30 min to allow the DNA to adhere to the cell surface. The samples 
were then heat pulsed for 45 seconds in a 42°C water bath and placed on ice for 2 min. The 
physically stressed cells were subsequently recovered by the addition of 900 pi of pre­
heated (42°C) SOC medium (2% w/v tryptone (Acumedia™, Acumedia Manufacters, 
Inc.), 0.5% w/v Bacto Yeast extract (DifcoLaboratories) and 0.05% w/v NaCl (Fluka, 
BioChemica, Sigma-Aldrich S.r.l.), 10 mM MgS0 4  and 0.4% w/v glucose) incubated for 1 
h at 37°C and shaken at 250 rpm. The cells were plated as 50 pi, 100 pi and 150 pi 
aliquots onto LB/ampicillin plates (see section 2.3.16) and incubated ovemight at 37°C. 
Plates with colonies of interest were stored at 4°C for up to 1 month. Each transformation 
was performed with 1 ng of the highly transfectable pUC19 (NewEngland BioLabs, MA, 
USA) as positive control of the reaction and as a reference for the transformation 
efficiency (i.e. colonies/pl) of the samples.
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2.4 C o n s t r u c t io n  o f  t h e  m e la n o m a  cDNA l i b r a r y
2.4.1 Extraction of polyA-mRNA
In order to isolate mRNA from melanoma cells, the guidelines reported in the FastTrack"'’^  
2.0 Kit for Isolation of mRNA (Invitrogen) were followed. Briefly, 40x10^ in vitro cultured 
melanoma cells, derived from melanoma Ptl5932, were lysed, filtered 4 times through a 
plastic syringe (0.22 pm) and then incubated for 40 min at 45°C to digest residual proteins 
and ribonucleases. To further ensure an isolation of cleaner mRNA, the sample was 
adjusted to a final NaCl concentration of 0.5 M and filtered 4 additional times through a 
plastic syringe to shear any remaining DNA. The mRNA sample was gently rocked for 60 
min at room temperature together with oligo(dT) cellulose to increase its binding to the 
oligo(dT) cellulose. Additionally, the oligo(dT) cellulose was centrifuged and after 
removal of the supematant, the resin bed containing the mRNA, was submitted to various 
washing steps. The resin bed was resuspended in Binding Buffer, centrifuged and then 
repeatedly washed and centrifuged 4 times with Low Salt Wash Buffer to remove SDS and 
contaminating rRNA. The oligo(dT) cellulose was then transferred to the spin-column. 
Finally, the column was filled with Low Salt Wash Buffer and centrifuged. This wash 
procedure was repeated until the OD260 of the flow-through was < 0.05. In a final step the 
mRNA was eluted with 2 washes using the Elution Buffer and then centrifuged. The two 
eluates were pooled together in one tube and then precipitated with 3 M NaAc and 100% 
EtOH, stored at -80°C ovemight and then centrifuged at 13000 rpm for 20 minutes. The 
mRNA pellet was resuspended in 20 pi Elution Buffer and its concentration determined by 
Ultrospec 3000 UVWisible Spectrophotometer (Amersham Pharmacia Biotech).
In order to obtain a more pure mRNA, a second round of washing was performed. More 
precisely, the previously obtained pellet was dissolved in 1.5 ml Elution Buffer and then
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adjusted with 150 pi 5 M NaCl to a NaCl concentration of 0.5 M (corresponding to the 
composition of the Binding buffer) to favour the binding of the mRNA to the resin.
All the subsequent steps were performed as described for the first purification. The final 
mRNA was then resuspended in 400 pi and the content of RNA determined using a 
Ultrospec 3000 UVA^isible Spectrophotometer (Amersham Pharmacia Biotech). mRNA 
was then stored at -80°C.
2.4.2 cDNA synthesis
With the aim to construct a cDNA library, the SuperScripfi^ Plasmid System for cDNA 
Synthesis and Plasmid Cloning (Gibco, Life Technology, Inc.) was used as a guideline.
However, in order to obtain the li-cDNA fusion library corresponding to our demands, 
another adapter and an expression vector different fi*om the ones indicated in the protocol 
were used (see section 2.4.5 and 2.4.8 respectively); otherwise the suggested conditions 
were followed. Furthermore, no radioactive labelling with [a^^PJdCTP was used neither in 
the first or the second cDNA strand synthesis to calculate the yield.
2.4.3 First strand cDNA synthesis
6 . 6  pg of polyadenylate (polyA) mRNA were use for cDNA construction. mRNA was 
thawed and centrifuged at 4°C at 16000xg for 30 min, washed once in 70% ethanol. Then, 
in order to perform the first strand synthesis, the protocol recommendations were carefully 
followed. The starting amount of 6 . 6  pg of mRNA was dissolved in 6  pi DEPC-treated 
water, incubated for 10 min at 70°C with 2 pi an oligo(dT) primer [5’- 
pGACTAGTTCTAGATCGCGAGCGGCCGCCCmi<-3'l containing a Xba I site 
(underlined) and quickly chilled on ice. The additional components for the reaction, 4 pi 
5x First Strand Buffer, 2 pi 0.1 M DTT and 1 pi 10 mM dNTP Mix, were added and
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following 2 min incubation at 37°C the Superscript II reverse transcriptase (RT) was 
added. The quantity of enzyme was related to the starting amount of mRNA used. More 
precisely, 5 pi of Superscript II RT (1000 U) was used to convert the 6 . 6  pg of polyA- 
mRNA into first strand cDNA during 1 h incubation at 37°C. The reaction was terminated 
on ice.
2.4.4 Second strand cDNA synthesis
In order to synthesise the second cDNA strand, the following components were added to 
the 20 pi of first strand cDNA: DEPC-treated water (91 pi), 5x Second Strand Buffer (30 
pi), 10 mM dNTP Mix (3 pi), E. Coli DNA Ligase (10 units/pi), E. Coli DNA Polymerase I 
(10 units/pl) and E. Coli RNase H (2 units/pl) to a final reaction volume of 150 pi. The 
second strand synthesis has been conducted for 2 h at 16°C. Then 2 pi (10 units) of T4 
DNA polymerase was added, and the tube was left for additional 16 min incubation at 
16°C. The reaction was stopped on ice and 10 pi of 0.5 M EDTA was added. The new 
synthesised cDNA was purified from contaminating proteins by the usage of 
QuickClean'^’^ Enzyme Removal Resin (Clontech Laboratories, Paolo Alto, USA). 
According to this protocol, a volume of QuickClean Resin corresponding to 1/10* volume 
of the cDNA sample should be used for purification; in our case 16 pi QuickClean Resin 
was added to the synthesised cDNA (162 pi). The tube was centrifuged at 14000 rpm for 1 
min and the procedure was repeated once with the supernatant, now using 18 pi of 
QuickClean Resin to a total volume of 180 pi cDNA.
Finally, the purified cDNA was precipitated with 98 pi 7.5 M NH4OAC and 0.7 ml 100% 
ethanol and left overnight at -80°C. The next day, the cDNA was centrifuged at 4°C and 
16000xg for 30 min, washed twice with 70% ethanol with equal centrifugations and finally
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dried in a speed vacuum centrifuge. The cDNA pellet was dissolved in 25 pi DEPC-treated 
water and stored at -20°C until the adapter ligation reaction was performed.
2.4.5 BstXI adapter ligation
With the purpose to ligate the Bst XI adapter to the synthesized cDNA, the following 
components were added to the cDNA pellet: 25 pi DEPC-treated water, 10 pi 5x T4 DNA 
Ligase Buffer, 10 pi Bst XI Adapters (1 pg/pl) and 5 pi T4 DNA Ligase (1 unit/pl) to a 
final volume of 50 pi. The reaction was left to proceed at 16°C overnight (i.e. for a 
minimum of 16 h). The next day, the cDNA was deproteinised as previously described 
using the QuickClean'^’^ ^Enzyme Removal Resin protocol (Clontech Laboratories, Palo 
Alto, CA, USA) and then precipitated with 30.2 pi 7.5 M NH4OAC and 18.5 ml 100% 
ethanol and left at -80°C overnight.
2.4.6 Digestion with Xba I
cDNA was centrifuged at 4°C and 13000 rpm for 30 min, washed twice with 70% ethanol 
and the cDNA pellet resuspended in 36 pi DEPC-treated water; 5 pi lOx NEB 2 buffer, 5 
pi lOx BSA and 4 pi Xba I (16 U/pl) was then added and the mixture incubated at 37°C for 
5 h. In an additional step, the digested sample was heat inactivated at 65°C for 20 min. 
Moreover, the sample was further purified from contaminating proteins and precipitated 
and washed as described above.
2.4.7 Column chromatography
With the aim to obtain a high quality library with large inserts, the Xba I digested-cDNA 
was size fractionised by liquid chromatography. This procedure optimises the size of the 
cDNA fractions in a way such that unwanted components like smaller cDNAs (< 500 bp).
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residual adapters and primer-adapter fragments released by the Xba I digestion can be 
separated from the larger inserts.
Briefly, cDNA Fractionation Column was equilibrated exactly as described in the 
Superscript protocol by 4 complete washes with 0.8 ml TEN buffer each. The pellet of the 
Xba I digested cDNA was diluted in 100 pi TEN buffer (10 mM Tris-HCl, pH 7.5; 0.1 mM 
EDTA, 25 mM NaCl) and then left to hydrate on ice. After this time, DNA was loaded 
onto column, which was left to drain completely, and the eluted buffer collected in tube 1 . 
Next, 100 pi TEN buffer was added to the top of the column and collect in the sample n 2. 
These two first fractions just contained the flow through of the TEN buffer and were thus 
not further considered. A second aliqout of 100 pi TEN buffer was added to the column. A 
total volume of 550 pi was collected in separate fractions of 35pl each. The fractions # 3 to 
#12 were further analysed for their content of large cDNA inserts, while the remaining 
ones were not considered.
2.4.8 Library construction
With the aim of a constructing a special cDNA library, in which the invariant chain (li) 
was fused in frame with the cDNA, the pEAK vector containing the first amino acid of li 
(pEAK8 /Ii) was used. This vector was kindly provided by Dr. Paul Robbins, National 
Institute of Health, Bethesda, MA.
2.4.9 Digestion of the pEAKS/Ii vector
The pEAK8 /Ii vector was submitted to double digestion as follows; 2.8 pg pEAK8 /Ii 
vector, 30 U Bst XI, 6 pl BSA (lOx) and 6  pi NEB 2 buffer (lOx) was diluted with water to 
a final volume of 58 pi, incubated at 55°C for 7 h and then heat inactivated for 20 min at 
65°C. The second digestion proceeded immediately with the addition of 2 pi Xba I (16
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U/pl) and an incubation for 7 h at 37°C. The double digested vector was heat inactivated 
and stored at -20°C. The Bst XI - Xba I digested vector was later on deproteinised twice 
using the QuickClean™Enzyme Removal Resin protocol (Clontech Laboratories), as 
previously described. The vector was then resuspended in 30 pi TRIS 10 mM, pH 8 . Its 
concentration was determined equal to 47 ng/pl by an Ultrospec® 3000 UV/Visible 
Spectrophotometer (Amersham Pharmacia Biotech). The Bst XI -X b a  I digested pEAK8 /Ii 
vector was used for cDNA ligation
2.4.10 Ligation of cDNA to the pEAK8/Ii vector
For each ligation a 2:1.molar ratio of cDNAivector was used. The ligation was performed 
as follows: 4 pi 5X T4 DNA ligase buffer, 80 ng of Bst XI - Xba I digested pEAK8 /Ii 
vector (47 ng/pl), 25 ng cDNA and 1 pi T4 DNA ligase (1 U/pl) were diluted with DEPC- 
treated water to a final volume of 2 0  pi per ligation and incubated for 6  h at room 
temperature. cDNA was obtained from fi*actions #7 and # 8  (pooled together; 1.14 ng/pl), 
#9 (3 ng/pl) and #10 (4.5 ng/pl).
2.4.11 Electroporation
The ligation samples from above (after 6  h incubation) were precipitated with 1 pg/pl 
tRNA, 750 mM ammonium acetate and 2.5 volumes of 100% ethanol and lefl; at -20°C 
overnight. The following day, the precipitated cDNA washed with 70% ethanol, dried for 
10 min at 37°C in a speed vacuum centrifuge. Finally, the DNA pellet (totally 105 ng) was 
dissolved in 4 pi DEPC-treated water resulting in a maximum DNA concentration 100 
ng/pl, as advised in the protocol. Thus, for each fraction (# 7 + # 8 , # 9 and # 1 0  now 
ligated to the pEAK8 /Ii vector) 2 pi purified DNA was added to 40 pi ElectroMAX^^ 
DHIOB™ Competent Cells (Gibco, Life Technology) in a pre-chilled microcentrifuge tube
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(the samples were prepared in duplicate) and then directly electroporated. Immediately 
after, room temperate SOC medium (2% w/v tryptone (Acumedia™, Acumedia 
Manufacters, Inc., Baltimore, Maryland, USA), 0.5% w/v Bacto Yeast extract 
(DifcoLaboratories, Detroit, Michigan, USA) and 0.05% w/v NaCl (Fluka, BioChemica, 
Sigma-Aldrich S.r.l.), 10 mM MgS0 4  and 0.4% w/v glucose) was added (up to 1ml) to the 
electroporated cells that were left to shake for 1 h at 37°C . The transformed cells from 
each fraction (each ligation) were pooled together and diluted for subsequent plating onto 
LB / ampicillin plates (see section 2.3.16).
2.4.12 Evaluation of colonies by PCR
In order to evaluate the li-cDNA fusion library in a quantitative and qualitative way, 
individual colonies were picked from the LB/Amp plates and further analysed by PCR for 
their content of cDNA inserts with the 5-ACCTCGATTAGTTCTCGAGCTT-3' forward 
primer and 5’-ATTAGGACAAGGCTGGTGGGCACT-3’ reverse primer, specific for the 
pEAK8  vector. The PCR was performed as follows: 5 min of dénaturation at 95°C, 25 
repeated cycles with 30 sec dénaturation at 95°C, 1 min annealing at 54°C and 2 min 
extension at 72°C and then 7 min final extension at 72°C. The PCR cycle ended with the 
samples were kept at constant temperature of 4°C.
2.4.13 Multi-screen Minipreparations
The electroporated bacteria from fraction #9 and #10 of the li-cDNA library were divided 
in pools of about 100 bacteria and seeded in 96 deep wells in 2x LB (double strength LB 
without NaCl) containing 50 mg/ml of ampicillin (Sigma Chemical Co., St Louis, USA) 
Bacteria , cultured for 20 h, were then collected by centrifugation for 15 min at 2500 rpm 
and the cellular pellet resuspended in 80 pi of Solution I (30 mM glucose; 15 mM Tris- 
HCl, pH 8 ; 30mM NaiEDTA; 60 pg/ml RNase A ) . 80 pi of Solution II (0.2 N NaOH; 1%
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SDS) was added to the deep well blocks, and then incubated for 2 min at room 
temperature. Then, 80 pi of Solution III (3.6 M potassium; 6 M acetate) was added and the 
cultures mixed vigorously for 2 min.
Approximately 240 pi of lysate was removed from each well and applied to a MultiScreen- 
NA lysate clearing plate (Millipore S.A., Bedford, MA, USA), that then was placed above 
the MultiScreen-FB plates in a special designed vacuum manifold equipment. The two 
different plates were then fixed onto the vacuum mainfold by applying the vacuum to 
maximum 8 inches Hg vacuum for 3 min. The supplied vacuum mediates a rapid transfer 
of the cell lysate from the wells in the MultiScreen-NA lysate clearing plate to the 
MultiScreen-FB plates filled with Binding Solution and their absorbance was read in an 
Ultrospec® 3000 Spectrophotometer (Amersham Pharmacia Biotech).
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2.5 Su b c l o n in g  a n d  se q u e n c in g  o f  il -10 pr o d u c e d  b y  m e l a n o m a  
SPECIFIC cd4+ t  c ell  clo n es
2.5.1 Subcloning of IL-10
To subclone the coding region of the IL-10 gene, a pair of primers (Table 2.3) was 
designed with the forward initiating at the start codon for the IL-10 gene and the reverse 
ending with the stop codon, i.e. these primers lie in the exon regions contained in the 
complete coding sequence of the human IL-10 gene (Accession number U 16720 in the 
GenBank). They were used to generate the full length IL-10, using as template the RNA 
purified from the stimulated CD4+ T cell clones (Vieira et ah, 1991).
Thus, mRNA was extracted from anti-CD3 Ab (0KT3 used at 100 ng/ml) stimulated 
CD4+ T cell clone and then converted to cDNA (see sections 2.3.2 and 2.3.3). The RT- 
PCR for IL-10 was performed in a 50 pi reaction mixture containing 2 pi of cDNA 
template, all four dNTPs at 1.25 mM, lOx PCR buffer, 20 pM of each primer, and 0.4 pi (5 
U/ml) of Taq polymerase according to the following PCR program: 94°C, 3 min; 30 cycles 
(94°C, 60 s; 60°C, 45 s; 72°C, 120s); 72°C, 7 min and 4°C (hold). The obtained full length 
(536 bp) PCR product of the IL-10 gene was subcloned into the pcDNA3.1W5-His-TOPO 
TA cloning vector (Invitrogen Corporation).
The amplified fiill length IL-10 gene, from two individual amplifications, was prepared for 
subcloning by the addition of 3’A overhangs to both ends using the TOPO cloning kit 
(Invitrogen). These modified IL-10 fi*agments were subcloned into the pcDNA3.1/ V5-His- 
TOPO TA cloning vector using TOPO cloning kit (Invitrogen) and then transformed into 
E.coli DH5a cells. After 24h incubation of the transformed cells, plated onto LB/Amp- 
plates, single colonies were picked up and analysed directly in RT-PCR for the presence 
insert using external primers mapping in the polylinker region of the vector. The cloning
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procedures gave several positive colonies that were all found to contain the IL-10 cDNA 
(not shown).
Table 2.3: The primer sequences used to amplify the full length sequence of the IL-10 gene. The
forward (F) primer cover the ATG start site of the genomic IL-10 gene (Accession number U16720 in the 
GenBank) and the reverse (R) primer cover the stop site.
Name of primer Primer sequence
IL-10-F 5’-ATG CAC AGO TCA GCA CTG CTC TGT TGC CTG-3'
IL-IO-R 5'-TCA GTT TCG TAT CTT CAT TGT CAT-3'
2.5.2 Preparation of genomic DNA (for IL-10)
Genomic DNA was prepared from 10-15x10^ cells by centrifugation for 10 min at 1800 
rpm. The pellet was washed with 1.5 ml Ix PBS (BioWhittakerEurope), diluted in 2 ml Ix 
PBS and transferred to a 2 ml Eppendorf tube and centrifuged for 45 s at 13000 rpm. The 
pellet was resuspended with 500 pi of lysis buffer (50 mM Tris-HCl, pH 8.0; 100 mM 
EDTA, pH 8.0; 100 mM NaCl and 1% SDS), after which 10 pi each of freshly prepared 
proteinase K (10 mg/ml) and pronase (10 mg/ml) were added. The sample tubes were 
placed horizontally and left to shake at 55°C overnight, which caused the break down of 
cellular membranes and components leaving only nucleic acids intact. On day 2, 30 pi of
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RNase (10 ng/ml) was added and the tubes were incubated for 2 h at 37°C and then 
centrifuged for 8 min at 14000 rpm to separate the DNA from the debris of digested RNA. 
The DNA-containing supernatant was transferred to a tube containing 1 ml cold 100% 
ethanol and then mixed gently until chromosomal DNA was visible. The DNA was winded 
around a 5 pi glass micropipette and transferred to a new tube containing 750 pi cold 70% 
ethanol. The micropipette with the attached DNA was then inverted and the DNA left to air 
dry in this position for at least 10 min. Hereafter, the DNA was placed into a tube 
containing 150 pi Ix Tris EDTA (TE) buffer (10 mM Tris-HCl, pH 7.5 and 1 mM EDTA). 
The micropipette was broken and the tip with the attached DNA was left to shake at 55°C 
overnight to dissolve the DNA. On the third day, the tubes were vortexed for 5 min at 
14000 rpm and the pellet dissolved in 150 pi of lOmM Tris-HCl, pH 8.0. The genomic 
DNA was stored at -20°C.
2.5.3 Cytokine genotyping
The cytokine genotyping tray (One Lambda Inc) is a PCR based assay that uses primers 
specific for polymorphism detectable in the 5' promoter region of cytokine genes. The kit 
includes TNF-a, TGF-pl, IL-10, IL-6 and IFN-y promoter-specific primers. These genetic 
polymorphisms strongly influence the capacity of IL-10 secretion and each genotype is 
associated with a low, intermediate or high phenotypes. Reagents were provided in pre­
optimized quantities and used according to manufacturer’s instructions. In addition, as the 
CD4 + T cell clones were too precious to use for this analysis, the genomic DNA was 
obtained from LCL of Ptl5392.
The PCR-single strand polymorphism (SSP) analysis was performed in a 96-well 0.2 ml 
thin-walled tube tray for PCR divided into 6 sections with dried, pre-optimized primers for 
TNF-a (2 wells), TGF-pl (4 wells), IL-10 (5 wells), IL-6 (2 wells) and IFN-y (2 wells)
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present in a detailed pattern related to each specific polymorphism (see Figure 5.4). More 
precisely, 1 pi of Taq DNA Polymerase (5 U/pl) was added to 180 pi of a D-mix (i.e. a 
pre-set dNTP-buffer mix), which was vortexed for 5 s and then pulsed-spinned to collect 
the whole mixture of which 9 pi was added to the negative control reaction tube containing 
1 pi of deionised water. Then, 19 pi of genomic DNA (30 ng/pl) derived firom LCL cells 
of Ptl5392 (see section 2.5.2) was added to the reamining D-mix. The tube was vortexed 
for 5 s and then pulsed-spinned, after which 10 pi was added to each reaction tube except 
the negative control tube. Amplification was run on a GeneAmp® PCRSystem 9700 PCR 
machine (Applied BioSystems, CA, USA) according to the following protocol: 1 cycle 
(96°C, 130s; 63°C, 60 s), then 9 cycles (96°C, 10s; 63°C, 60s), followed by 20 cycles 
(96°C, 10s; 59°C, 50s; 72°C, 30s) and finally 1 cycle at 4°C (hold). The samples were run 
on a 2.5% low melting EuroClone® agarose gel (0.5 pg EtBr/ml) (Euroclone Ltd, 
Whetherby West Yorkshire, UK) with 0.5% TAE running buffer containing 0.5 pg/ml of 
EtBr at 50 V for approximatley 2 h. The DNA bands were then visualised with UV ligth.
2.5.4 Transwell experiments
Co-culture experiments were performed using polycarbonate transwells (Costar Inc., 
Acton, MA, USA) with 0.4 pm pores to allow passage of the cytokine containing medium 
but not of cells. PMBCs (5x10^ cells/ml) from Ptl5392 were added to the lower chamber 
and restimulated with the irradiated autologous melanoma (M el5392) (5x10^ cells/ml) in a 
total volume of 2 ml RPMI 1640 10% HS. The transwell (upper chamber) contained an 
activated CD4+ T cell clone (5x10^  ^ cells/well), added to the well on its fifth day after 
restimulation with irradiated Mel 5392 (1x10^ cells) at an effector:target (E:T) ratio of 4:1. 
After 2 weeks of co-culture PBMCs were tested for the presence of generated T cell 
populations by incubation with autologous melanoma (Mel 5392) or LCL (LCL15392) 
cells in the presence or absence of W6/32 (anti-HLA-A, -B and -C ) or L243 (anti-HLA-
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DR) mAbs. The supernatants were evaluated for their IFN-y content by ELISA (see section 
2.2.17). In a second setting, PMBCs (5x10^ cells/ml) from Ptl5392 were added to the 
lower chamber and pulsed with 1 pg/ml of the MART-127-35 peptide in the presence of an 
activated CD4+ T cell clone (5x10^ cells/well) in the upper transwell. This clone was 
added to the well on its fifth day after restimulation with 1 pg/ml of the MART-127-35 
peptide. Generated T cell populations were evaluated as described above.
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HLA-Cw8 RESTRICTED RECOGNITION OF A GPlOO EPITOPE BY 
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3.1 In t r o d u c t io n
Several studies have been conducted on the immune biology of melanoma and this tumour 
has been found to express a variety of antigens as targets for T cell mediated recognition 
(as reviewed in (Robbins and Kawakami, 1996; Van den Eynde and van der Bruggen, 
1997)). The majority of these antigens are self antigens, derived from transcription of 
normal, non-mutated genes (reviewed in (Kawakami and Rosenberg, 1996)), which, 
despite this feature, have been shown, under ceartain circumstances, to break self tolerance 
and generate cytotoxic T lymphocytes (CTLs) in vitro (Anichini et a l, 1993; Anichini et 
a l, 1996; Bakker et a l, 1994). In addition, the differentiation antigens MART-1 and gplOO 
have been reported to be recognised by tumour infiltrating lymphocytes (TILs) derived 
from melanoma patients (Kawakami et a l, 1995; Robbins et a l,  1994) and adoptive 
transfer of CTLs reactive against gplOO can mediate tumour regression (Kawakami et a l,  
1995). Melanoma patients vaccinated with such antigens have occasionally been shown to 
deelop vitiligo as a side effect, especially in clinical responsive subjects (Rosenberg and 
White, 1996). This demonstrates that immune recognition of differentiation antigens can 
mediate destruction of melanocytes and therefore, immunotherapy of melanoma should be 
considered carefully for the risk of autoimmunity. In addition, recent studies have reported 
the first evidence of skin and eye damage in melanoma patients as a direct consequence of 
adoptive transfer of T cells directed to differentiation antigens (Dudley et a l,  2002; Yee et 
a l, 2000).
The differentiation antigen gplOO has been associated with tumour regression (Kawakami
et a l, 1994b) and several of its T cell epitopes, presented by different HLA alleles, induce
in vitro reactivity against melanoma (Kawakami et a l, 1995; Salgaller et a l,  1995).
Moreover, CTLs directed against an epitope of gplOO (gplOO 209-2M), modified to have
stronger HLA-A2 binding capacities, have been detected at the metastatic site (Kammula
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et a l, 1999). Thus, peptide-based vaccine is a promising approach for cancer therapy, but 
peptide-specific immunity is not always associated with clinical response and tumour 
regression has only been observed in 10 -  30% of treated patients (reviewed in (Parmiani 
et a l,  2002a)) with the exception of one study in which 42% of subjects showed a clinical 
response (Rosenberg et a l, 1998). Reasons for this partial failure can be found in all the 
mechanisms activated by tumor cells to evade immune recognition and destruction. Many 
of these mechanisms have been identified by studies performed in melanoma patients 
(reviewed in (Marincola et a l, 2000)). One well documented strategy used by tumour cells 
to escape T cell control is represented by the down-regulation of HLA and/or of the target 
antigens (reviewed in (Garrido et a l, 1997)). The latter phenomenon has been well 
documented for Melan-A/MART -1 and gplOO in melanoma (Marincola et a l, 1996a).
Moreover, the fact that several of the most common tumour antigens (MAGE-3, 
tyrosinase, gplOO and Melan-A/M ART -1 ) are presented by HLA-A2 (Kawakami et a l, 
1995; Kawakami et a l, 1994c; van der Bruggen et a l, 1994; Wolfel et a l,  1994) that is 
fi*equently down modulated in melanoma (reviewed in (Ferrone and Marincola, 1995)), 
highlights the importance of finding other antigens and/or epitopes restricted by alternative 
HLA-A, -B and -C alleles. A combination of epitope loss and down regulation of HLA 
alleles facilitates tumour escape. Therefore, to be effective, a tumour vaccine should 
induce and sustain a broad CTL anti-melanoma response directed against multiple antigens 
restricted by alternative HLA alleles (Thomson et a l, 1998).
In this context, the study presented in this chapter was focused on the identification of 
antigens that can be presented on non-HLA-A2 alleles. A melanoma patient (Ptl5392), still 
disease-fi-ee 12 years after surgical resection of lymph node métastasés, was selected for 
the study. A previous analysis of the anti-tumor CD8+ T cell mediated response in this
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patient revealed an immune response directed against gplOO and TRP-2 derived epitopes 
presented by HLA-A3 and -Cw8 alleles, respectively (Castelli et a l, 1998; Castelli et a l, 
1999). However, additional tumor-specific CD8+ T cell clones were available and their 
nominal epitopes remained to be defined. One of these clones, not previously 
characterised, was used for my study. The results presented in this chapter indicate that this 
selected CD8+ T lymphocyte clone, namely TB686, is directed against a new gplOO 
derived epitope presented by the HLA-Cw8 allele.
3.2 A im  o f  t h e  c h a pt e r
• To functionally characterise an anti-melanoma CD8+ T cell clone and define its 
nominal epitope.
3.3 R esu l ts
3.3.1 The selected CD8+ T cell clone TB686 recognises the autologous tumour in the 
context of HLA-B or -C.
The immune response directed against the autologous tumour in the melanoma Ptl5392 
has been analysed at the clonal level. Previous studies on this patient documented the 
presence at the tumour site of CD8+ T lymphocytes directed against peptides derived from 
melanosomal proteins including gplOO and TRP-2 (Castelli et a l, 1998; Castelli et a l, 
1999; Mazzocchi et a l, 1996). Additional clones were available that, bearing different T 
cell receptor alfa (TCRAV) and beta variable regions (TCRBV), were potentially able to 
recognise different epitopes. With the aim of identifying such additional epitopes, a 
previously uncharacterised CD8+ T cell clone, namely clone TB686, was selected.
In order to define whether clone TB686 was involved in an anti-tumour response directed 
against a unique or shared antigen, TB686 lymphocytes were tested for the ability to lyse 
the autologous and allogeneic, partially HLA-matched melanoma lines (Figure 3.1). From
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FIGURE 3.1: Cytotoxic activity against a HLA-B or -C restricted antigen expressed on both the 
autologous tumour and allogenic melanoma cells sharing the class I HLA haplotype with Ptl5392.
^^Cr-labled autologous tumour ceils (Me 15392) and allogeneic HLA matched (HLA-B 14 and -Cw 8 ) 
melanoma lines (Allo-Me) (1000 cells/well), were co-incubated with the CD8 + T cell clone TB6 8 6  for 4 
h at an E:T ratio of 20:1. There was a significant difference (*p<0.001) between target cells blocked with 
the mAh W6/32 compared to unblocked controls. Also incubation with B 1.23.2 mAh significantly 
blocked the cytotoxicity in a HLA-B and -C restricted way (**p<0.05) compared to the unblocked 
control. W6/32 = anti-HLA-A, -B and -C mAb; B 1.23.2 = anti-HLA-B and -C mAb. Results are 
expressed as mean ± S.D. for one representative experiments of two.
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these data, it was concluded that TB686 T cells have a strong lytic activity directed against 
the autologous tumor. Tumor lysis was markedly inhibited by the addition of a mAh 
recognising a common HLA-A, -B and -C  determinant, as well as the mAb B 1.23.2 
directed against a common determinant shared only by the HLA-B and -C  alleles. 
Moreover, TB686 was not only activated by autologous tumor cells but also by other 
melanoma cell lines sharing the HLA-B and -C  alleles. This pattern of recognition 
indicated that TB686 was directed against a common shared antigen. Unfortunately, 
normal melanocytes positive for the expression of the indicated alleles were not available 
and, therefore it was not possible to conclude whether or not the shared antigen was a 
differentiation antigen. The pattern of specificity of clone TB686 in the ^^Cr-release assay 
was fully consistent with the data obtained fi*om parallel cytokine release experiments 
where clone TB686 produced a high amount of IFN-y when incubated with the autologous 
melanoma, and with HLA-B 14 and HLA-Cw8 matched allogenic melanoma lines (Figure
3.2). As expected fi*om the cytotoxic profile, the release of IFN-y was inhibited in the 
presence of an antibody specific for HLA-B and-C alleles.
However, while the use of W6/32 did not completely inhibit the cytotoxic release, a 
complete block could be observed after overnight incubation in the IFN-y release assay. 
Although it is possible that W6/32 has a somewhat higher affinity for its determinant than 
B 1.23.2, this partial effect may be due to the short incubation time.
3.3.2 Identification of the gene encoding the TB686 epitope
In order to identify the antigen recognised by TB686, transfection experiments were 
performed. COS-7 cells were double-transfected with either HLA-B 14 or -Cw8 together 
with different known melanoma-associated antigens as shown in Figure 3.3. The screening 
had to be done individually with these alleles as it was not possible to define the restriction
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FIGURE 3.2: HLA-B or -C restricted recognition of an antigen expressed on both the autologous 
tumour and allogenic melanoma cells sharing the class I HLA haplotype with Ptl5392. The CD8 + 
T cell clone TB6 8 6  (5x1 O'* cells/well) was incubated overnight with the autologous melanoma cells 
(Me 15392) or HLA matched (HLA-B 14 and -Cw 8 ) allogenic melanoma lines (Allo-Me) at an E:T 
ratio of 1:1 alone or in the presence of 1 pg/ml of W6/32 or B 1.23.2. A significant difference (*p< 
0.001) was observed for both W6/32 and B 1.23.2 antibodies compared to the unblocked control, except 
for W6/32 in blocking of Allo-Me2. The supernatants were assayed for their IFN-y content by ELISA. 
W6/32 = anti-HLA-A, -B and -C  mAb; B 1.23.2 = anti-HLA-B and -C  mAb. These results are 
representative of the mean ± S.D. of 2 experiments.
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element for the TB686 clone, as the Ab B 1.23.2 can not discriminate between the HLA-B 
and -C alleles and no melanoma cell lines expressing either B14 or Cw8 alone were 
available.
However, each transfectant was then evaluated for the capacity to specifically stimulate 
clone TB686 by a cytokine IFN-y release assay. No positive response was observed upon 
transfection with the HLA-B 14 (data not shown), whereas clone TB686 demonstrated an 
HLA-Cw8 restricted recognition of the gplOO antigen (937 pg released IFN-y per ml) 
(Figure 3.3). Although some variation of the background values could be observed, 
especially for TRP-1 and MAGE-12, these data were not reproducible in subsequent tests 
and therefore disregarded. In addition, a gplOO peptide was shown to reconstitute the 
nominal epitope of TB686, as demonstrated by peptide pulsing of autologous LCLs in a 
IFN-y-release assay (see Figure 3.4).
3.3.3 TB686 and TB254 recognise the same epitope of gplOO
An HLA-Cw8 restricted clone, TB254, recognising the SNDGPTLI epitope of gplOO, had 
previously been identified firom the patient used in this study (Castelli et a l,  1999). 
Therefore, given that clone TB686, derived fi*om the same patient and shown to be 
restricted in HLA-B or -C , also recognised gplOO, TB686 was evaluated for its reactivity 
against SNDGPTLI. Autologous lymphoblastoid cells (LCL15392) were pulsed with the 3 
previously described (Castelli et a l, 1999) overlapping peptides; gplOOyi.yg (SNDGPTLI), 
gp 10070-78 (VSNDGPTLI) and gpl0069-7s (KVSNDGPTLI), and then incubated overnight 
with TB686 lymphocytes. As demonstrated in Figure 3.4, all 3 peptides were well 
recognised by TB686, with the decamer gpl0069-78 stimulating a somewhat higher IFN-y 
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FIGURE 3.4: Reconstitution of SNDGPTLI as the immunogenic epitope for clone TB686.
Autologous LCL ceils (LCL15392) from Ptl5392 were pulsed with 3 overlapping peptides o f gplOO, i.e. 
gplOOyi.yg (SNDGPTLI), gpl0 0 7 o_78 (VSNDGPTLI) and gp 1 0 0 5 9 .7 g (KVSNDGPTLI), at a concentration 
of 1 pg/ml for 2 h at room temperature. Following over night incubation with CD8 + T cell clone TB6 8 6  
(5000 cell/well) at an E:T ratio of 1:1; the supernatants were evaluated for their IFN-y content by ELISA. 
Autologous melanoma cells (M el5392) were used as positive control. Transfection of the 3 peptides of 
gplOO all induced a significant IFN-y release from clone TB6 8 6  (*p< 0.005) compared to unpulsed 
LCL15392 cells. Medium = lymphocytes without peptide. Data are expressed as mean ± S.D. of three 
experiments.
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(Table 3.1) for which gplOOyi.vg was identified, clone TB686 was specific for this same 
peptide.
Table 3.1: The TCR expression of CTL Clones TB254 and TB686, which both recognise the 
gpl007i_78 SNDGPTLI epitope. V = variable; J = joining region of the TCR. S = indicates members that 
belong to the same variable-gene subfamily.
T cell clone TCRVA TCRVB Reference
TB254 V8S1J50 V21S1J2S7 (Castelli et al,  1999)
TB686 V7S2J24 V14S1J2S2C2 ^^Castelli
1) Personal communication.
3.4 D isc u ssio n
The data presented in this chapter show that a long surviving melanoma patient developed 
at the tumor site a CTL response directed against a gplOO-derived epitope. As illustrated in 
Figure 3.3, clone TB686, derived from T lymphocytes purified from a lymph node 
metastasis, recognised the differentiation antigen gplOO. These data are consistent with 
previous results reporting that other differentiation antigens such as Melan-A/MART -1, 
tyrosinase, TRP-1,-2 and gplOO, can be targets for a specific recognition by TILs
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(Kawakami et a l, 1994a; Kawakami et a l, 1994b; Robbins et a l, 1994; Wang et a l, 1996; 
Wang et a l, 1995). Moreover, since this anti-gpl00 response is associated with a good 
clinical prognosis in Ptl5392, the results presented in this chapter further support the 
conclusion, based on previous studies, that melanosomal antigens, despite their self nature, 
are promising reagents for developing more efficient cancer vaccines (reviewed in 
(Kawakami 1998)).
TB686 is not the only CTL clone found in the tumor derived lymphocytes of Ptl5392 
directed against a gplOO derived epitope. The herein analysed CD8+ T cell clone, TB686, 
was shown to be specific for the gplOOyi-yg SNDGPTLI epitope and this same peptide also 
reconstituted the nominal epitope for a previously defined CD8+ T cell clone, TB254, from 
this patient (Castelli et a l, 1999). The TCR sequences for these clones are presented in 
Table 3.1. Although these two clones recognise the same epitope, no obvious constraint in 
their TCR variable chain usage could be observed. The induction of multiple CTL clones 
directed against gplOO in the same patients has been described before (Kawakami et a l, 
1995). In addition, similar results have been obtained for other tumour-specific antigens, 
and a polyclonal response in term of TCR composition of epitope specific CD8+ T cells 
has been observed for the Melan-A/MART -1. Nine AAGIGILTV (Kawakami et a l, 
1994c) and three EAAGIGILTV specific T cell clones (Schneider et a l, 1998) expressed 
TCRs with different VA and VB families. Moreover, as previously shown (Castelli et a l, 
1998; Castelli et a l, 1999), the gp l00 response in this patient also included an additional 
gplOO derived epitope presented by the HLA-A3 allele. Thus, previously published data 
and the results reported in this chapter suggest that the anti-gplOO response was a crucial 
component in the overall immune response of Ptl5392 to the autologous tumour. In fact, 
the anti-gplOO response in Ptl5392 is polyclonal and two different gplOO derived epitopes
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are presented by HLA-A3 and HLA-Cw8 respectively. Moreover, the HLA-Cw8-restricted 
anti-gplOO immunity involved independent CTLs expressing different TCRs.
The SNDGPTLI epitope presented in this chapter differs from other melanosomal antigens 
since it is presented by an HLA-C allele. This finding may have implications for vaccine 
development. In fact, more than half of the 15 previously identified epitopes of gplOO are 
restricted by the HLA-A2 allele, which is also the main restriction element for all other 
differentiation antigens of melanoma defined up to now. In addition, the predominance of 
the HLA-A allele has been exemplified by a recent study where TILs derived from 123 
patients with metastatic melanoma were found to be specific for the HLA-Al, -A2, -A3, - 
A24 or -A31 alleles (Kawakami et al., 2000). HLA-B restriction has been reported in one 
case only for both MART -1 /Melan-A and tyrosinase (Brichard et a l, 1996; Schneider et 
a l, 1998).
Although the HLA-A2 is expressed by a large proportion of the Caucasian population (40 - 
45%) making the HLA-A2 restricted epitopes valuable tools for cancer vaccine, it is also 
true that this allele is frequently lost in metastatic tumors presumably as result of an in vivo 
T cell-driven immune selection (Kageshita et a l, 1993; Maeurer et a l, 1996; Natali et a i, 
1989). Therefore, it has become clear that to induce an immune response potentially able to 
control tumour growth, a vaccine should be polyvalent and include multiple CD8+ 
epitopes derived from different antigenic proteins and presented by different HLA alleles. 
By expressing HLA-B and HLA-C alleles on the cell surface after down regulation of the 
HLA-A allele, a tumour may still be susceptible to recognition by anti-melanoma CTLs 
restricted by those alleles. That the level of expression of a given HLA allele could be a 
crucial factor limiting the efficacy of T cell recognition has been demonstrated in a study 
where the percentage of melanoma cell lysis by an antigen specific HLA-A2 restricted
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CD8+ T cell clone was directly correlated to the expression level of the HLA-A2 at the cell 
surface (Rivoltini et aL, 1995a).
Thus, this newly identified HLA-Cw8 restricted gplOOyi.yg epitope can be useful, in 
conjunction with the previous defined HLA-A restricted epitopes of TRP-2 and gplOO, for 
designing a polyvalent vaccine. Taken together, gp 100 is an antigen which holds promise 
for future immunotherapy and with the identification of epitopes restricted also on HLA 
class II alleles (Kobayashi et aL, 2001), it may be possible to develop polyvalent vaccines 
that can also induce CD4+ T cell responses.
In conclusion, the TB686 anti-melanoma CTL was characterised as HLA-Cw8 restricted 
by showing that its recognition of the gplOOyi.yg epitope results in an IFN-y release that is 5 
times higher than the background (Figure 3.3). These data suggest that epitopes presented 
on the HLA-B and HLA-C alleles can provoke an immune response similar to HLA-A 
restricted epitopes, despite some indications that those alleles and therefore their 
corresponding MHC-peptide complexes, may have a lower cell surface expression 
compared to that of HLA-A. Thus, this epitope can be considered a candidate for a 
peptide-based vaccine in melanoma patients. However, to induce an effective immune 
response it is of importance to also activate CD4+ T cells (Topalian et a l,  1996), reviewed 
in (Pardoll and Topalian, 1998). Thus my next experiments were aimed at characterising 
anti-tumour CD4+ T cells of Ptl5392 (Chapter 4) in an attempt to identify genes encoding 
HLA class Il-restricted melanoma antigens (reported in Chapter 6 and 7).
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Chapte
CHARACTERISATION OF THE CD4+ T CELL RESPONSE IN A 
LONG TERM SURVIVING MELANOMA PATIENT: 
IDENTIFICATION OF TUMOUR SPECIFIC CD4+ T CELLS WITH A 
Thl-ThO CYTOKINE PROFILE
102
Ch apte r  4__________________________________________________________________________________________________
4.1 INTRODUCTION
T lymphocytes are the main effector cells in the immune system that actively participate in 
anti-tumour responses (as reviewed in (Boon and van der Bruggen, 1996; Kawakami and 
Rosenberg, 1997; Pardoll and Topalian, 1998)). To optimise vaccination strategies for 
cancer immunotherapy, it is essential to understand the characteristics of the T cell 
response against the tumour and to elucidate the T cell mediated effector mechanisms 
involved in tumour regression. Several studies clearly documented the involvement of 
CD8+ T cells in the anti-tumor response in vaccinated (Jager et a l, 2000a; Jager et a l, 
1996b; Pass et a l, 1998) and even in non vaccinated patients (Anichini et a l,  1999), or in 
subjects with melanoma undergoing spontaneous regressions (Zorn and Hercend, 1999a; 
Zorn and Hercend, 1999b). Thus, although CD8+ effector T cells, are actively involved in 
controlling tumour growth, CD4+ T cells are crucial for an optimal anti-tumour response, 
as demonstrated in mice (Faiola et a l, 2002) and humans (reviewed in (Pardoll and 
Topalian, 1998)). In fact, by providing co-stimulation, cytokine release and cross-priming, 
CD4+ T cells are essential for the induction and maintenance of specific CD8+ T cells 
(Bennett 1998; Schoenberger er a/., 1998).
Moreover, CD4+ T cells may also participate in the final anti-tumour effector phases 
(Hung et a l, 1998) by using different mechanisms that not only include tumour cell 
cytotoxicity mediated by perforin (Rivoltini et a l, 1998), but also the induction of 
apoptotic death in a calcium-independent fashion (Thomas and Hersey, 1998a). Although 
initial evidence for a role of CD4+ T cells in promoting the generation of tumour specific 
CD8+ T cells in vitro throughout DC activation have been recently provided, (Baxevanis et 
a l, 2000), it is still not completely clarified to which extent CD4+ T cells do actively 
participate in the anti-tumour T cell- mediated response in human cancer (reviewed in 
(Fischer er a/., 1999)).
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Tumour-specific T cells recognise TAAs on target cells. Genetic methods have been 
developed that, taking advantage of established T cells clones generated firom TILs or 
TALs, have led to the identification of these antigens (as reviewed in (Boon, 1993; Coulie, 
1997; Rosenberg, 1997)).
The majority of TAAs identified so far are recognised by CD8+ T cells. Only recently 
efforts have been made to characterise class II HLA-restricted TAAs (as reviewed in 
(Wang, 1999; Wang, 2001); examples of class II HLA-restricted TAAs have been reported 
for melanoma, (Chaux et a l, 1999b; Kobayashi et a l, 1998a; Topalian et a l, 1996; Zarour 
et a l, 2000), and even for breast, colon and pancreatic cancer (Perez et a l,  2002), detailed 
reviewed in (Renkvist et a l, 2001).
Several technological advances now allow a more in dept analysis of the T cell response 
against molecularly defined TAAs both in vitro and in vivo. In fact, tumour-specific 
epitopes in the form of chemically synthesised peptides can easily be prepared and 
represent a crucial tool for dissecting and monitoring the natural tumour-specific immunity 
in cancer patients or to evaluate the immunisation capacity of specific cancer vaccines 
(Chaux et a l, 1998; Hu et a l, 1996; Valmori et a l,  1997). The evaluation o f the frequency 
of antigen specific T cells in the blood firom cancer patients benefits also firom the new 
tetramer technology (Dunbar et a l, 1999), and (reviewed in (Klenerman et a l, 2002)), 
only recently applied for HLA class II presented epitopes (Nepom et a l, 2002). Moreover, 
innovative techniques for enumeration and quantification of antigen reactive T cells allow 
also live sorting (Brosterhus et a l, 1999), making it possible to perform additional 
functional studies on a selected antigen-specific T cell population.
However, instrumental for these methods is the knowledge of the molecular nature of the T 
cell defined TAAs. In this perspective the analysis of CD4+ T cell anti-tumour response in
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cancer patients with conventional techniques including MLTC and limiting dilution 
cloning may be a first step in dissecting the potential role of these cells in the anti-tumour 
response in cancer patient. The subsequent identification of CD4+ T cell epitopes will 
provide new tools for additional fine analysis that may potentially include tetramer 
technologies.
In order to assess an anti-tumour response in an appropriate and quantitative way, it is 
important to consider several parameters (as reviewed in (Romero et a l, 1998; Whiteside, 
2000)):
(i) The characteristics of anti-tumour reactive T lymphocytes, especially their cytotoxic 
function and clonal distribution.
(ii) The molecular nature of the antigens involved in this response.
(iii) The fi*equency of memory T cells recognising the TAA and which are present in the 
blood or tumour tissue, as estimated by techniques as ELISPOT and HLA/peptide tetramer 
staining.
The study presented in this chapter used several of these parameters to assess the nature of 
the CD4+ T cell mediated response developed at tumour site in a melanoma patient 
remaining disease free 12 years after the surgical resection of a lymph node metastasis. In 
this chapter, the CD4+ T cell response has been analysed at the clonal level, while the 
identification of the tumour antigens evoking this response will be the topic of Chapter 6 
and 7.
Some of the work with the establishment of the CD4+ T cell clones has been performed in 
collaboration with Dr. Arabella Mazzocchi (now at the Unit of Blood Transfusion, Istituto 
Nazionale dei Tumori, Milan).
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4.2 A im  o f  t h e  c h a p t e r
• To eveluate the CD4+ T cell mediated response at tumour site in a metastatic 
melanoma patient and isolate tumour-specific CD4+ T cell clones for further antigen 
screening procedures.
4.3 R e su l ts
4.3.1 Characterisation of anti-melanoma CD4+ effector T cells
4.3.1.1 Phenotypic evaluation ofTAL and PEL derived from Ptl5392 by FACS
The anti-tumour CD8+ T cell repertoire fi*om Ptl5392 has been well characterised (as 
described in Chapter 3), while the reactivity against HLA class II restricted TAAs 
remained to be elucidated. Therefore, a clonal analysis of T cells infiltrating the metastatic 
tumour was planned, in order to address the question as to whether CD4+ T cells may have 
played a role in the anti-tumour response of this patient.
The cell surface phenotype of TALs obtained at the day of surgical resection of the 
metastatic tumour (Day 0) was analysed by indirect immunofluorescence and FACS. As 
control, PBMCs also obtained at the day of operation were included. Antibodies directed 
against CD3, CD4 and CD8 molecules were used in order to evaluate the percentage of T 
cells and their composition in terms of CD4+ or CD8+ T cells. As shown in Table 4.1, 
CD3+T cells account for the 70% of all the lymphocytes isolated firom the metastatic 
tumour. CD4+ T cells constituted roughly 50% of the total cell number both in the TALs 
and the PBMCs. CD8+ T cells form a minor population of approximately 30% in these two 
groups. The intensity of the overall staining for the markers is consistent, which correlates 
with the expected phenotypic distribution of lymphocyte populations not yet manipulated 
by in vitro culture.
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Table 4.1: Cell surface phenotype of lymphocytes derived from the blood and a lymph node melanoma 
metastasis. Tumour associated lymphocytes (TALs) and peripheral blood mononuclear cells (PBMCs) were 
obtained from Ptl5392 at the day of surgery (Day 0) and then analysed for their expression of cell surface 
markers by indirect immunofluorescence followed by FACS analysis. W6/32 (anti-HLA-A,-B and -C), 
0KT3 (anti-CD3), 0KT4 (anti- CD4) and 0KT8 (anti-CD8) mAbs.
W6/32 OKT3 OKT4 OKT8
TALs % positive cells 90 71 44 34
Intensity 192 128 95 136
PBMCs % positive cells 98 90 58 26
Intensity 174 131 99 147
4.3.1.a Cytotoxic responses o f the TAL and PEL populations
With the aim of characterising the anti-tumour response of TALs, these T cells were 
stimulated in vitro with the autologous tumour. After 10 days of in vitro culture, the 
functional activity of growing T cells was evaluated in a 4 h ^^Cr-release cytotoxic assay. 
The involvement of the TCR in the cytotoxicity of these populations was assessed by the 
usage of the 0KT3 Ab. Figure 4.1 clearly shows inhibitions of the tumour lysis when the 
TAL derived T lymphocytes were pre-incubated with the anti-TCR antibody OKT3 before 
being added to the autologous melanoma. These data demonstrated that the T cell 
population expanded in vitro displayed a cytotoxic activity directed against the autologous 
tumour and that this activity involved TCR triggering. Only a very low lytic activity 
directed against the autologous tumour was found with T cells obtained fi*om the in vitro
107
Ch apte r  4












□  Mel5392 
■  Mel5392 + OKT3
*
TALs PBMCs LAKs
FIGURE 4.1: TCR-dependent lysis of the autologous tumour by T cell derived from TAL. TALs and 
PBMCs autologous to tumour Mel5392 were re-stimulated weekly in a MLTC. After 10 days of in vitro 
culture T cells were tested for their cytotoxic activity against the autologous melanoma in standard 4 h in 
'^Cr - release assay at E:T ratio of 100:1 in the presence or absence of an anti-CD3 mAb (0KT3) (1 
pg/ml). Me 15392 was lysed by TALs by a TCR-dependent mechanism since lysis in the presence of 
0KT3 was significantly reduced in respect to the lysis achieved in the absence of mAb (*p<0.001). 
Lymphocyte activated killer cells (LAKs) were used as positive control as they are known to kill by a 
TCR-independent mechanism. TAL = tumour associated lymphocytes; PBMCs = peripheral blood 
mononuclear cells. Data are representative of one experiment performed in duplicate.
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stimulated PBMCs. Moreover, this activity was not affected by the presence of 0KT3 in 
the test, indicating that no tumour-specific reactive T cells were detected in that 
population. Lymphocyte activated killer (LAK) cells were used as an internal positive 
control of the cytotoxic assay, as LAKs are known to exert their lytic activity through a 
TCR-independent mechanism. As further control, the lysis of the NK sensitive and HLA- 
deficient target cell line K562 was not affected by the presence of 0KT3 (Figure 4.2) and 
no differences were seen in K562 cytotoxicity for either the TALs or PBMCs derived T 
cell effectors.
These data showed that as early as at 10 day of in vitro culture, TAL-derived T 
lymphocytes already displayed a tumour-specific recognition, suggesting that tumour- 
specific T cell precursors were already present in vivo at tumour site. These T cells were 
then further expanded in vitro by stimulation with autologous tumour cells.
4.3.1. iii The in vitro cultured T cells released IFN-y in response to tumour stimulation 
After the 3rd week of in vitro culture with autologous irradiated M el5392 cells, TALs
were analysed for the capacity to produce IFN-y in response to stimulation with autologous
tumour. In addition, to evaluate the TCR involvement in the recognition of the tumour, the
stimulation assay was performed using T cells pre-incubated for 45 min at 37°C alone
without or with 0KT3.
The data shown in Table 4.2 clearly indicate that T cells derived from TALs were able to 
produce IFN-y in response to the autologous tumour and that cytokine production was 
largely dependent upon TCR triggering since pre-incubation of T cells with an anti-CD3 
mAh resulted in a marked decrease of the IFN-y release.
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FIGURE 4.2: NK-like activity of TALs and PBMCs. Tumour associated lymphocytes (TALs) and 
peripheral blood mononuclear cells (PBMCs) were stimulated in vitro with autologous tumour. After 10 
days of in vitro culture the lymphocytes were tested for their cytotoxic activity against the NK susceptible 
and HLA-deficient cell line K562 in a standard 4 h ^^ Cr - release assay in the presence or absence of an 
anti-CD3 mAb (0KT3, 1 pg/ml). The K562 cells were lysed by TALs, PBMCs and lymphocyte activated 
killer cells (LAKs). As expected no significant inhibition was observed in the presence of mAh OKT3. 
LAK cells were used as controls. Data are representative of mean ± S.D. of one experiment performed in 
duplicate.
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Table 4.2. IFN-y release from TALs in response to different stimuli. After 3 weekly restimulations in 
MLTC, tumour associated lymphocytes (TALs) (1x10'* cells/well) and melanoma cells (Me15392) (1x10'* 
cells/well) of Ptl5392 were incubated alone or in the presence of an anti-CD3 mAb (1 pg/ml) for 45 min, T 
cell recognition of Mel5392 was measured by analysing the IFN-y release by ELISA.
IFN-y release (pg/ml)
TALs + medium 15
TALs + Mel 5392 1900
TALs + 0KT3 + Mel 5392 800
4.3.LÎV Characterisation o f  the CD4+ T cell subset
In order to characterise the anti-tumour response in these TALs at the end of the 3rd week 
of in vitro culture, T lymphocytes were cloned by limiting dilution. Cloning was performed 
in two parallel settings; 96 well plates were coated with one and 5 T cells/well, 
respectively, for a number of 2500 wells each and cultured in RPMI 1640 supplemented 
with 10% pooled HS, 50 U/ml rIL-2 in the presence of 5x10^ autologous tumour cells and 
1x10^ allogeneic pooled lymphocytes obtained from healthy donors. The T lymphocytes 
were re-stimulated after one week with irradiated autologous melanoma cells and 
allogeneic lymphocytes and screened at day 14 for the presence of growing clones. 120 
growing clones were selected and transferred to 24 well plates. Their capacity to recognise 
the autologous melanoma was assessed by a 4 h ^^Cr-release cytotoxic assay. 40 clones 
showing specific tumour recognition were selected, further expanded and then frozen in
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liquid nitrogen. The ftinctional characterisation of some of these clones is reported in 
Figure 4.3.
The T cell clones isolated from the in vitro expanded TALs displayed different patterns of 
reactivity. The cytotoxic assay was performed in the presence or in the absence of the class 
I HLA (W6.32) and class II HLA-DR (L243) mAbs. The data clearly show that some of 
the clones recognised tumour cells in a class I HLA restricted fashion (TB164, TB311, 
TB361, TB670), while for other lytic T cell clones tumour recognition was independent 
from both class I and HLA-DR molecules (TB120, TB335). However, several clones 
(TB39, TB48, TB89, TB426, and TB515) showed a strong anti-tumour lytic activity that 
was HLA-DR-restricted.
4.3.1.V TCR expression o f  established CD4+ clones
T cell clones displaying HLA-DR restricted tumour-specific activity were selected for 
further analysis. In order to group all the sister clones, i.e. clones derived from the 
expansion of a single common precursor, and with the aim of evaluating the repertoire of 
the restricted melanoma- specific response in TALs, the TCR expression of each of the 
HLA-DR restricted T cells was molecularly defined by RT-PCR. cDNA, prepared from 
each of these clones, was submitted to amplification with primers specific for the different 
families of the variable (V) alpha and beta regions paired with reverse primers specific for 
the constant (C) alpha and beta regions.
Each of the 5 identified CD4+ T cell clones expressed different TCR specificities (Table
4.3). Comparing their TCR composition, the results showed a dominant representation of 
the TCRAV13 and TCRBV21 chains among the analysed HLA-DR-restricted clones. The 
clones TB515, TB39 and TB426 all expressed TCRAV13, while TB48 and TB89 
expressed TCRAV3 and TCRAV17.
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Table 4.3: The TCR repertoire of class II-HLA restricted anti-melanoma T cell clones from Ptl5392.
cDNAs derived from various well proliferating clones were analysed by RT-PCR using primers specific for 
the variable (V) and constant (C) regions of the T cell receptors (TCR).
CLONE TB515 TB48 TB39 TB89 TB426
TCRAV 13 3 13 17 3
TCRBV 21 21 13 21 13
4.3.1.vi Functional characterisation o f  established CD4+ clones
With the aim of identifying which T cell subset these anti-melanoma T cell effectors 
belonged to, clones TB515, TB39, TB48, TB89 and TB426 representing different TCR 
specificity were selected and then analysed for their capacity to recognise the autologous 
melanoma. Cytokine release assays were performed to define the cytokine expression 
pattern. The data obtained for TB39, TB48 and TB515 are reported in Table 4.4. All the 
clones tested were able to release IFN-y, GM-CSF and IL-2, characteristic of a Thl subset. 
However, upon tumour stimulation, IL-10, the hallmark cytokine for Th2 subsets (Kelso, 
1995), was also detectable in the supernatant, whereas neither IL-4 nor TGF-p could be 
found. Thus, this stimulation assay implies the existence of anti-melanoma CD4+ T cells 
able to release cytokines not only belonging to the Thl subset, but also the typical Th2 
cytokine IL-10.
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Table 4.4: Functional characterisation of anti-melanoma CD4+ T cell clones derived from TALs of 
Ptl5392. Cytokine release from TB515, TB48 and TB39 (upper, intermediate and lower panels, respectively) 
cells in response to different stimuli. The 0KT3 Ab was used as a positive control as it induced an optimal 
release of cytokines by cross-binding of the TCRs, whereas the LCL cells were used as a negative control. 
LCL = lymphoblastoid cell line that express all the HLA molecules of the patient, from whom LCL cells 
were derived; Auto-Me = autologous melanoma; Auto-LCL = autologous LCL cells; 0KT3 = anti-T3 mAh.
Cytokine release (pg/ml)
Stimulus IFN-y GM-CSF TNF-a IL-2 IL-10 IL-4 TGF-P
Auto-LCL 250 355 24 5 15 0 0
Auto-Me 2800 2890 850 252 2490 0 0
0KT3 3350 3250 410 198 2480 0 0
Auto-LCL 155 412 45 11 22 0 0
Auto-Me 1950 3360 1250 369 2215 0 0
0KT3 2155 3120 955 355 1850 0 0
Auto-LCL 214 122 25 15 12 0 0
Auto-Me 3855 2750 980 232 1560 0 0
0KT3 2520 2845 1040 245 1890 0 0
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4.4 D isc u ssio n
Due to the key role of CD4+ T cell in viral and tumour immune response (reviewed in 
(Pardoll and Topalian, 1998; Wang, 2001)), it was interesting to address the question as to 
whether a CD4+ T cell response could have been developed in the long time surviving 
melanoma Ptl5392. This analysis started by considering T cell composition at tumour site. 
Comparing the phenotype of lymph node derived TALs with those of peripheral blood 
obtained simultaneously, i.e. at the day of operation, no major differences in the percentage 
of CD4+ versus CD8+ T cells were observed. Nevertheless, with the aim of identifying a 
possible CD4+ T cell mediated tumour-specific immune response at tumour site, 
conventional MLTC was set up using T cells derived from TALs. A tumour specific, CD3- 
dependent killing could be observed at the second week of in vitro culture suggesting the 
presence of a relative high number of tumour-specific precursors in the original T cell 
population in vivo. In order to better characterise this response and with the precise aim of 
evaluating the presence of CD4+ tumour-specific T cells, we resorted to a clonal analysis. 
120 individual T cell clones, growth out in the 96-well plate, were tested for their tumour 
recognition in a ^^Cr-release cytotoxic assay. Among these T cell clones, 40 were tumour- 
specific and HLA-DR restricted. By TCR analysis, performed using RT-PCR, the HLA- 
DR-restricted T cell clones could be classified in 5 different groups according their TCR 
specificity. One clone representative for each TCR specificity and demonstrating a good 
proliferative response in vitro to IL-2 and tumour stimulation, was used for further 
functional characterisation.
T cells involved in anti-tumour responses can be characterised by their profile of cytokine 
production, which has been extensively studied in melanoma (Goedegebuure et al., 1994; 
Maccalli et al., 1994; Markus et a l, 1995; Salmeron et a l, 1992). Taken together, these 
published studies showed that tumour reactive CD4+ T cells secrete the classical pattern of
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Thl and Th2 cytokines (Mosmann et a l, 1986), but that these profiles can be modulated 
depending on the source of stimulus. In agreement with these data and besides being 
cytotoxic, the CD4+ clones of Ptl5392 were able to release cytokines in response to 
tumour stimulation. However, their cytokine pattern was surprising, since, in addition to 
release cytokines belonging to the Thl subset, they also released high amount of IL-10 
while no IL-4 or TGF-p were detected. These findings are in accordance with the 
continuously increasing complexity observed for CD4+ T cells (as first reviewed in (Kelso, 
1995) and then in (Mosmann and Sad, 1996)). Nevertheless, the high levels of IL-10 in the 
absence of IL-4 are consistent with a cytokine profile described for murine and human 
CD4+ T cells upon repeated stimulation with ovalbumine (OVA) peptide (Groux et a l,
1997). These previously described CD4+ T cell subsets did not produce IL-2, but released 
high amounts of IL-5, which rendered them different firom the CD4+ cells identified in 
Ptl5392. A strong release of IFN-y by T cells upon recognition of antigenic epitopes is 
highly advantageous for anti-tumour response, as IFN-y mediates up-regulation of HLA 
class I molecules on tumour cells (as reviewed in (Anichini et a l,  1993; Garbe and 
Krasagakis, 1993)) and thus render them susceptible for T cell killing.
A study evaluating cytokine profiles of CD8+ and CD4+ T cell subsets in melanoma 
patients by stimulation with anti-CD3 mAh 0KT3 and with autologous tumour cells 
revealed different patterns of cytokine secretion (Maccalli et a l,  1994). Both IL-4 and 
IFN-y could be released firom some anti-melanoma CD4+ T cell clones induced by soluble 
anti-CD3 mAb, while activation of another panel of CD4+ T cell clones with autologous 
tumour did not result in production of IL-4. Different findings have been obtained with the 
CD4+ T cell subsets of Ptl5392, as they secreted comparable amount of IFN-y, GM-CSF, 
TNF-a, IL-2 and IL-10, but not of IL-4 or TGF-P in response to activation by the anti-CD3 
mAh 0KT3 or mediated by the autologous tumour. Indirectly these findings indicate that
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the TAA presented on melanoma cells could induce a full activation of its nominal T cells. 
This may suggest (i) that the TCR expressed by the examined T cells clones have a good 
affinity for the peptide/MHC complexes and/or (ii) that their nominal antigen(s) is/are 
highly expressed by the tumour cells. These T cells are therefore fiilly activated by the 
encounter with their nominal TAA. Such complete T cell activation by tumour cells is not 
always observed; some anti-melanoma CD8+ T cells may be suboptimally activated as a 
result of low expression of HLA/peptide complexes or low avidity interactions (Gervois et 
a l,  1996).
Furthermore, it is of note that CD4+ T cells fi*om Pt15392 did express TCR that shared 
some common features. In fact, the CD4+ T cell clones of Ptl5392 do share TCRBV21 or 
TRCAV3 and TCRVA13 indicating that a selection of TCR expression could have been 
occurred. These data suggest that these TCRs indeed are directed against the same 
antigenic determinant and, moreover, that they could have been selected for having a better 
affinity/avidity for the nominal MHC/peptide complexes. With the molecular identification 
of the nominal peptide I will be able to partially address these questions.
Taken together, the study presented in this chapter led to the identification of melanoma- 
specific CD4+ T cells with an atypical cytokine profile; they can be considered mainly Thl 
cells, releasing high amount of IL-10. No other CD4+ T cell subsets, reactive against 
tumour cells or viral and bacterial determinants, have been defined that displays a cytokine 
profile compatible with the pattern released by the anti-melanoma CD4+ T lymphocyte 
clones of Ptl 5392.
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The question that will be addressed in the next chapter is whether the CD4+ T cells, owing 
to the release of IL-10 in their cytokine cocktail, may exert a suppressive role in the anti­
melanoma response. IL-10 has actually been reported as mediating the immune- 
suppression activity of the CD25+ CD4+ T cells (Brady et a l, 1999); moreover, IL-10 
plays a central role in the regulation of immune network (reviewed in (Lalani e/ a l,  1997; 
Moore et a l, 2001)). However, since different molecules have been described having high 
homology with IL-10 and since also for cellular and viral IL-10, differences in the primary 
sequence may account for different functional activities, the question was also asked 
whether the IL-10 produced by CD4+ T cells clones from P tl5392 was indeed a wild type 
IL-10 or if  some mutations could have been present in the mRNA transcripts of our CD4+ 
T cell clones.
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ANTI-MELANOMA CD4+ T CELL CLONES RELEASING HIGH 
AMOUNTS OF NON-INHIBITORY IL-10
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5.1  In t r o d u c t io n
5.1.1 Functions of IL-10
The hallmark of a T helper response is the specific pattern of cytokines secreted upon 
recognition of antigenic peptides. This has been clearly demonstrated both in mice 
(Cherwinski et a l, 1987; Mosmann and Sad, 1996) and humans (Del Prete et a l, 1991). 
Among these cytokines, IL-10 has a major role, as it regulates a complex pattern of both 
immune suppressive and stimulatory activities (as reviewed in (Wakkach et a l,  2000)). 
Released by Th2 cells and associated with inflammatory responses (reviewed in (Lalani et 
a l, 1997)), produced by cancer cells to evade immune recognition, (reviewed in (Salazar- 
Onfi*ay, 1999)) and recently found to be specifically expressed by regulatory T cells (Tr) 
(reviewed in (Roncarolo and Levings, 2000), IL-10 has a central role as a regulator of 
CD4+ T cell mediated responses
Indeed, the opposing functions of IL-10 in the immune system may be symbolised with the 
Chinese metaphor of Yin and Yang; a theory representing two opposite aspects, which are, 
at the same time, both interdependent and in conflict (Kuby, 1997). For example, it is 
proposed that IL-10 can be secreted by tumour cells as an escape mechanism to promote 
their own progression (Chen et a l, 1994; Dummer et a l, 1996; Dummer et a l,  1995), a 
concept compatible with recent observations of tumour progression in B6 mice treated with 
IL-10 transduced B 16-melanoma cells (Garcia-Hemandez et a l, 2002). In contrast to these 
findings, human melanoma cells that have been transduced with the murine IL-10 gene 
show a lower metastatic ability in nude mice (Huang et a l, 1999). The anti-metastatic 
activity was linked to the inhibition of angiogenesis.
An additional controversial function of IL-10 lies in the ability of this cytokine to influence 
the expression of MHC molecules. For example, IL-10 by down-regulating class I and
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class II HLA expression in melanoma cells promotes immune escape of tumour cells 
(Matsuda et a l, 1994; Yue et a l, 1997). However, the lack of HLA molecules also renders 
tumour cells sensitive to lysis by natural killer (NK) cells which have also been detected at 
the tumour site in mice injected with IL-10 (Zheng et a l, 1996). IL-10 strongly impairs 
antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity 
of monocytes via down regulation of class II MHC expression (de Waal Malefyt et a l, 
1991b).
IL-10 has been demonstrated to have a protective anti-tumour effect either when 
systemically administered to tumour-bearing mice or when expressed locally at very high 
levels by the engineered tumor cells (Berman et a l, 1996; Dorsey et a l, 2002; Kundu and 
Fulton, 1997). The mechanisms involved in such a protection are not completely clarified, 
but they include anti-angiogenic activities (reviewed in (Huang et a l,  1999)) and possibly 
direct stimulatory action of IL-10 on tumour specific T cells (Fujii et a l,  2001; Santin et 
a l,  2000). On the other hand, IL-10 has been reported to impair the ability of T cells to 
release cytokines. Indeed, IL-10 mainly inhibits the fimctional activities of T cells by 
affecting different types of antigen presenting cells (APCs). IL-10 has been reported to 
suppress cytokine production by modulating the functions of monocytes (de Waal Malefyt 
et a l,  1991a), macrophages (Fiorentino et a l, 1991a Ding, 1992 #251) and DC (Caux et 
a l , 1994; Macatonia et a l , 1993).
Other findings support a stimulatory role of IL-10 for B lymphocytes. First, IL-10 
enhances the in vitro viability of B cells and mediates up-regulation of their class II HLA 
(Go et a l, 1990; Thomssen et a l, 1995). In addition, IL-10 augments both proliferation 
and differentiation of human B cells into antigen secreting plasma cells (Defi*ance et a l,  
1992; Rousset et a l, 1992). Moreover, IL-10 has been shown to be a differentiation factor
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for CD8+ T cells and to stimulate their growth when cultured together with IL-2 (Chen and 
Zlotnik, 1991).
Table 5.1: An overview of the major inhibitory and stimulatory functions of IL-10.
INHIBITORY FUNCTIONS STIMULATORY FUNCTIONS
Inhibits production of IFN-y, IL-2 and TNF-a by Enhances some NK functions.
Thl cells.
Inhibits production of IL-la, IL-lp, IL-6 , IL-12, IL- Enhances proliferation of B cells and supports their 
18, GM-CSF, G-CSF, M-CSF, TNF, LIF and PAF differentiation into antibody producing plasma cells 
from activated monocytes and macrophages; i.e. (IgM, IgG and IgA). Upregulates class I HLA on B 
anti-inflammatory properties. cells.
Down-regulates the expression of class II HLA Shows anti-tumour activities by inhibition of
molecules on monocytes, dendritic and Langerhans angiogenesis.
cells.
Inhibits proliferation of ThO, Thl and Th2 cells. Increases proliferation of activated of CD8 + T cells.
Decreases IFN-y production from NK cells.
Inhibits antigen dependent proliferation of T cells.
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5.1.2 Polymorphism of the IL-10 gene promoter
The importance of IL-10 as a regulatory cytokine with possible therapeutic implications 
(Volk et a l, 2001), has generated interest in how IL-10 is regulated at the genetic level. In 
particular, IL-10 has been associated with several auto-immune diseases (reviewed in 
(Moore et a l, 2001)) as well as with several types of cancer (Fortis et a l, 1996). Analysis 
of constitutive IL-10 expression in Epstain Barr virus (EBV)-positive Burkitt’s lymphoma 
cells resulted first in the identification of the hIL-10 promoter (Kube et a l,  1995) and then 
in the mapping of the AÆ-70 gene (Eskdale et a l, 1997a). It was found that the 5’-flanking 
region of the hIL-10 gene contains positive and negative regulatory sequences important 
for the IL-10 gene. More precisely, the promoter region of IL-10 is heterogeneous with 
three polymorphic sites present at positions -1082, -819 and -592. This polymorphism has 
been linked to the level of IL-10 production in vitro by stimulated peripheral blood 
lymphocytes (PBLs) (Hurme et a l, 1998; Turner et a l, 1997). In addition, the hIL-IO gene 
encodes two microsatellites (IL-IO.R and IL-IO.G), associated with polymorphism 
(Eskdale and Gallagher, 1995; Eskdale et a l, 1996).
In this context, the gene sequence associated with an IL-10 phenotype was proposed to 
constitute a prognostic marker for diseases associated to IL-10. However, the IL-10 
promoter sequences have been analysed in several patients with various auto-immune 
diseases and, although some correlations do exist between polymorphic sites of IL-10 and 
IL-10 production, no general conclusions could be drawn (Eskdale et a l, 1998; Eskdale et 
a l, 1997b; Hurme et a l, 1998; Kube et a l, 1995; Turner et a l, 1997).
As described in Chapter 4, the CD4+ T cell anti-tumour immune response was studied in a 
melanoma patient (Ptl5392), who experienced a favourable prognosis. Several anti­
melanoma specific CD4+ T cell clones were isolated from metastatic lymph nodes
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obtained at the time of surgery. As further demonstrated in Chapter 4, these CD4+ clones 
showed a cytotoxic activity against the autologous tumour and, after stimulation by tumour 
cells, released high levels of IL-10, IFN-y, GM-CSF, TNF-a and IL-2, but not IL-4 and 
TGF-p (Chapter 4/Table 4). This cytokine pattern does not correlate with the classical 
Thl, Th2 (Mosmann et a l, 1986) or to the newly reported Tr profiles (reviewed in 
(Mosmann and Sad, 1996)). Thus, it is important to further evaluate the role of such a 
CD4+ T cell population.
To explain the role of IL-10 in the atypical cytokine profile observed for the anti­
melanoma CD4+ T cell clones described in the previous chapter, experiments were 
designed to assess the immune-suppressive role mediated by the cytokine cocktail released 
by these T cells in response to tumour stimulation.
5.2  A im s  o f  th e  c h a pt e r
• To evaluate a possible inhibitory activity of the cytokines released by CD4+ T cells 
upon tumour stimulation.
• To perform a molecular analysis of the IL-10 gene with the objective of finding 
possible changes in the nucleotide sequence of the promoter and coding region of IL-10 
released by the CD4+ T cells of Ptl5392.
5.3  R e su l ts
5.3.1 Analyses of CD4+ T ceUs releasing high amounts of IL-10
5.3.1.1 IL-10 present in the cytokine cocktail did not result in T cell inhibitory activity 
To assess whether the IL-10 containined in the cytokine mixture released from the anti­
melanoma CD4+ T cells of Ptl5392 could exert an inhibitory effect on the generation of 
anti-tumour T cells, two different in vitro experiments were performed. In these
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experiments, the activated high IL-10 releasing CD4+ T cells of Ptl5392 were added to 
semi-permeable upper wells and their ability to affect the induction of tumour or MART- 
127-35 specific T cells in the lower wells was evaluated, as depicted in Figure 5.1. Generated 
T cells were fiirther tested for recognition of the same targets, used to stimulate the T cells.
In the first experiment (Figure 5.1, left panel A and B) PBMCs obtained from an HLA-A2 
metastatic melanoma patient were cultured with the autologous tumour (Me2) in the lower 
wells. Normal medium or stimulated CD4+ T cells of Ptl5392 were added to the upper 
wells. At the end of the second week of in vitro culture, the T cells generated in the lower 
well were tested for their tumour specificity. They were incubated with medium, 
autologous LCL cells (LCL2) and melanoma cells (Me2) in the absence or in the presence 
of the mAbs W6/32, a mAb directed against class IHLA or of mAb L243 directed against 
class II-HLA. The supernatants were collected and T cell activation evaluated by 
monitoring the amount of IFN-y released. The results of this experiment are shown in 
Figure 5.2 and demonstrate that the cytokine mixture released by the CD4+ T cell clones of 
Ptl5392 did not reveal any suppressive effect on the generation of tumor-specific T cells. 
In fact, the amount of IFN-y obtained in the presence of the cytokine cocktail was similar, 
or even higher, than that achieved when T cells were generated in the presence of medium 
alone. Furthermore, the IFN-y release was significantly blocked by W6/32 mAb (p<0.001), 
a finding suggesting that class I MHC-restricted CD8+ T cells had been generated in the 
co-culture setting.
A second experiment was similarly conducted but, in this case, patient’s PBMCs were 
stimulated directly with the MART-127.35 peptide in the presence of either stimulated 
CD4+ T cells or of medium alone (Figure 5.1, right panel A and B). At the end of the 
second week, the T cells generated in the lower well were then tested for peptide and
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tumour specificity. T cells were incubated with medium, T2 cells alone, T2 cells pulsed 
with 1 pg/ml of MART-127-35 peptide, the autologous melanoma, and the autologous 
melanoma together with mAbs W6/32 or L243. A significant blocking of the IFN-y release 
(p<0.001) was observed for W6/32 indicating that a MART-127.35 peptide specific CD8+ T 
cell population was generated in the presence of the high quantity of IL-10 released from 
the stimulated CD4+ in the transwell (Figure 5.3). This supports the conclusion that these 
CD4+ T cell clones are not exerting a suppressive activity.
Thus, the IL-10 released from the anti-melanoma CD4+ T cell clones of Ptl5392 showed 
no suppression on the generation of a T cell-mediated anti-tumour response in the lower 
chamber of the transwell system (Figure 5.2 and 5.3) supporting the conclusion that the IL- 
10 released at the tumour site may not impair the anti-tumour response. However, as IL-10 
is a pleiotropic cytokine, it was interesting to investigate if other functional aspects of IL- 
10 could explain the high quantity produced by the anti-melanoma specific CD4+ T cells 
ofPtl5392.
5.4 D ete r m in a t io n  o f  t h e  IL -10 sec r etio n  ph e n o t y pe
5.4.1 Genotyping
In order to further assess the role of IL-10 produced by the CD4+ T cells of Ptl5392, an 
experiment was performed to analyse the genetic polymorphism of the promoter region of 
IL-10 (Figure 5.4A). A commercially available kit (Cytokine Genotyping Tray) was used 
for PCR-single strand polymorphism (SSP). Briefly, multiple PCR reactions were set up in 
a multiwell-plate, each well containing a primer pair unique for each polymorphism 
present in the promoter regions of TNF-a (2 wells), TGF-p 1 (4 wells), IL-10 (5 wells), IL- 
6 (2 wells) and IFN-y (2 wells). More preciseley, genomic DNA was added to a pre­
optimised mixture (D-mix), after which 10 pi aliquots were divided into each well of the
129






+  fS M N
H
+ + + + + +















































































































1 •c qcd g 03<4-1 A







K 1 3 %g oü Wi
1









g 03o _g 3
T3 3’g 2 ■33 1 exT3 g X
4) 3 4>
'g bO >2 B 2a 2 2













o U uy o
£ y=l •i' og
ç/> ex IIc3 co
2 4) m

































o O'■G >cd o





T 3 •5haa 2
■a t»
a - aa p
Æ g







































































I 4-10 wI 1 CSascnIf)
Ü §
8 ex 2
3 1pu ;p .£3.a 0H a g
i êJh a 0.2 0 a.P pa O) Gex p exVO k bû
2 8 •8
8 0u1 8! 0g- 01p
.3 § I—1 pp ‘o CSI 1 ?
.8 1ex a.3 .s
g a p1 I 21 1g •cex I<4-4 a0 p a1 'bog 11 2 81 21 1ê 1 3gpa 01 HI 1ex x><4-, p




C h a p t e r  5



































tray. The well of the negative control was prepared with 9 pi D-mix and 1 pi of deionised 
water. After amplification the samples were run on a low melting agarose gel for 
approximatley 2 h. The individual cytokine typing bands for each polymorphism present in 
TNF-a, TGF-P 1, IL-10, IL-6 and IFN-y of Ptl5392 appear lower than the internal control 
band of 750 bp (Figure 5.5). More precisely, the horizontal pattern of bands for each 
cytokine (i.e. the presence or absence of the individual typing bands), represents the 
polymorphic genotype. For example, IL-10 demonstrates the following pattern: “no band 
(lane 8), band (lane 9), band (lane 10), no band (11), band (lane 12)” (Figure 5.5), which 
corresponds to an intermediated secreting phenotype and the GCC/ACC genotype (- 
1082*G; -819*C and -592*C/-1082*A; -819*C and -592*C) (Perrey et a l,  1998) (Figure 
5.4B) present in the promoter region of IL-10. A similar interpretation of the other 
cytokine secreting phenotypes demonstrated low releasing TNF-a (G/G), TGF-P 1 (C/C 
C/C) and IFN-y (A/A) phenotypes and a high IL-6 (G/G) releasing phenotype (Figure 5.4B 
and 5.5).
5.4.2 Subcloning of IL-10
5.4.2J Subcloning o f the IL-10 produced by the CD4+, class II HLA restricted anti­
tumour T cell clones
It has been shown that one single amino acid was enough to change the imunostimulatory 
properties of viral IL-10 (Ding et a l, 2000). Therefore, it was interesting to subclone and 
sequence the IL-10 produced by the CD4+ T cells of Ptl5392, to directly evaluate if  it 
could exert an immunostimulatory effect due to a similar modification in its primary 
structure. To address this issue, a data base search was first performed to control if  
additional polymorphism was present in the coding region of the human IL-10 gene in 
addition to the sites of its promoter region (Hurme et a l, 1998; Turner et a l, 1997). All 
sequences that matched for IL-10 were aligned with the full length genomic DNA and no
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polymorphism was found in the coding region of the IL-10 as differences were found to 
map only in the promoter region (data not shown). Furthermore, a comparison of the 
cDNA of IL-10 (Accession number M57627 in the GenBank) with the genomic DNA of 
IL-10 (Accession number U 16720 in the GenBank), revealed that the same primers could 
be used to amplify the genomic DNA as well as the cDNA of IL-10. Subcloning and 
sequencing of the IL-10 gene expressed by the CD4+ T cell clones of Ptl5392, showed that 
it was identical to the reported IL-10 gene (Accession number M57627 in the GenBank).
5.5 D isc u ssio n
It has been shown that the original described dichotomy of Thl and Th2 cells (Mosmann 
and Sad, 1996) can not explain all CD4+ T cell responses. A new category of CD4+ T cells 
with novel response profiles has been described: the Tr cells (reviewed in (Kelso, 1995; 
Mosmann and Sad, 1996)). However, this Tr subset can be even further divided into IL-10 
producing Trl (Groux et a l, 1997) and TGF-p secreting Th3 cells (Inobe et a l,  1998). 
However, the high IL-10 producing CD4+ T cell clones of Ptl5392 characterised here do 
not fit with any of the newly defined CD4+ T cell subsets (see Table 4.4). Moreover, the 
significance of the IL-10 in the anti-tumour response of this patient appears to be elusive, 
though I could not study this issue in details. Thus, in an attempt to explain the role of IL- 
10 released by the CD4+ T cell clones of Ptl5392, two hypotheses were put forward:
(i) The high IL-10 content in the cytokine mixture released by the CD4+ T cell clones does 
not have an inhibitory effect;
(ii) A genetic change in the nucleotide sequence of IL-10 may account for a non- 
suppressive function.
The validity of these hypotheses is discussed below.
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5.5.1 Functional role of the IL-10 released by CD4+ T cells
Firstly, although releasing high amounts of IL-10 in response to tumour stimulation (see 
Table 4.4), the cocktail of cytokines produced by these CD4+ T cells did not show any 
suppressive effects on the generation of anti-tumour T cells by the autologous tumour or by 
peptide-pulsed autologous AFC (Figure 5.2 and 5.3). This implied a non inhibitory effect 
of IL-10 at the concentration present in the CD4+ T cell cocktail; a result that was partially 
unexpected since IL-10 has been reported to work as an anti-inflammatory and immune- 
suppressive cytokine (Chen et a l, 1994; de Waal Malefyt et a l, 1991b; Salazar-Onfray, 
1999). However, in the transwell experiments, a supernatant was evaluated that included, 
in addition to IL-10, also IFN-y, GM-CSF, TNF-a and IL-2 and, therefore, the observed 
stimulatory effects could be simply due to the synergistic interaction of all or some of these 
cytokines whose stimulatory activity overcomes the IL-10 immunosuppression.
Thus, based on these considerations and according to hypothesis (i), the "dosage" or the 
"quality" of the IL-10 produced by the T lymphocytes of this particular patient (Ptl5392), 
may account for the non-suppressive activity of the cytokine mixture. In addition, the 
notion that IL-10 indeed may have a stimulatory role has also been reported in the 
literature; both in humans (Go et a l, 1990; Rousset et a l, 1992; Thompson-Snipes et a l, 
1991) and in mice (Adris et a l, 1999; Barth et a l, 1996; Suzuki et a l,  1995).
Moreover, the in vitro finding that the cytokine profile of the CD4+ T cells had non- 
inhibitory activity, is in agreement with data showing that from these same lymphocytes, 
tumour-specific CD8+ T cells could also be generated and that the same patient also 
developed a strong CD8+ T cell mediated anti-tumour immunity (Castelli et a l,  1998; 
Castelli et a l,  1999). This non-inhibitory effect on the induction of class I HLA restricted 
melanoma specific CD8+ T cells (Figure 5.2 and 5.3), correlates with the described lack of
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inhibitory effect of IL-10 on the proliferation and growth of human CD8+ T cells when 
stimulated with anti-CD3 antibodies (Chen and Zlotnik, 1991). The findings reported in 
this and in the previous chapter are also compatible with data showing that IL-10 may have 
a stimulatory activity on CD8+ T cells that are already tumor- specific (Segal et a l,  2002) 
and that CD4+ T cells releasing IL-10 at tumor site may potentiate a local CD8+ T cell 
mediated response (Fujii et al., 2001).
The results of this chapter are consistent with recent data indicating that IL-10 can be 
produced by either Thl or Th2 - like clones and that the "level" of IL-10 production with 
respect to the level of other cytokines, like IFN-y and IL-2, may determine whether a given 
cytokine cocktail results in an activation or inhibition of the generation of anti-tumour or 
anti-MART-127-35 specific T cells respectively. The level of IL-10 production may 
therefore be a crucial step in the regulation of the immune response.
5.5.2 Genotyping and subcloning
Until now, most publications described differences (Eskdale et a l, 1997a; Kube et a l, 
1995; Morse et a l, 1999) and even polymorphism (Cartwright et a l, 1999; Hurme et a l, 
1998; Turner et a l, 1997) in the upstream promoter region of the IL-10 gene that may 
result in high or low IL-10 production.
In fact, the IL-10 secreting phenotypes correspond to three well defined polymorphic sites 
in the promoter region of IL-10 (Hurme et a l, 1998; Turner et a l, 1997). The intermediate 
IL-10 secreting phenotype demonstrated by CD4+ T cells of Ptl5392 (Figure 5.5) was not 
in agreement with the assumption that the high amount of IL-10 in the supernatant of the 
CD4+ T cell clones should correlate with a high IL-10 secreting phenotype. Moreover, the 
patient’s GCC/ACC genotype (-1082*G; -819*C and -592*C/-1082*A; -819*C and - 
592*C) (Perrey et a l, 1998) corresponding to the intermediate IL-10 secreting phenotype,
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is difficult to reconcile with recent data on polymorphism in IL-10. In fact, a large study of 
promoter polymorphism in patients with cutaneous malignant melanoma, showed that 
some IL-10 genotypes could be associated with the clinical prognosis and hence, be used 
as prognostic markers; the high releasing genotype -1082 GG was associated with 
horizontal and non-invasive tumours, while the -1082 AA low secreting genotype was 
found in patients with advanced melanoma and tumours in vertical growth phase (Howell 
a/., 2001).
As the GCC/ACC genotype of Ptl5392 represents a -1082 GA polymorphic site, it was not 
possible to conclude whether Ptl5392 had a favourable or bad prognosis at a genetic level. 
Nevertheless, this patient has now been disease free for 12 years after the surgical removal 
of the lymph node metastasis and the high IL-10 releasing CD4+ T cell clones described 
herein may have been one contributing factor to the favourable clinical outcome. However, 
the data presented in this chapter are insufficient per se to allow any strong conclusion and 
further studies including a larger set of patients might reveal a trend or a pattern of 
association.
5.5.3 Conclusions
To define the role of the high IL-10 releasing cytokine profile of the CD4+ T cells from 
Ptl5392 in regulating the tumour specific immune response, additional experiments should 
be performed. In order to further explore the role of IL-10 it would be crucial to analyse 
the effect of recombinant IL-10 or anti-IL-10 neutralising antibodies, in the transwell 
system described here.
Moreover, the suppressive mechanism of Tr cells has been described to be independent of 
cytokine production and to require cell-cell contact (Chai et a l, 1999; Taams et a l,  1998; 
Thornton and Shevach, 1998; Thornton and Shevach, 2000), but I did not perform this type
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of experiment. However, on the basis of the data presented in Chapter 4 and 5, the CD4+ T 
cells obtained from Ptl5392 are not likely to belong to the IL-10 releasing Tr cells 
involved in maintaining tolerance and suppressing autoimmunity (Groux et a l,  1997).
In this chapter and Chapter 4, data have been presented that show that the cytokine profile 
released by the CD4+ T cell subsets of Ptl5392 is similar but not identical to the profile of 
Tr cells (Table 5.2). These findings thus suggest that Ptl5392 CD4+ T cell subsets could 
constitute a novel group of T lymphocytes with still undefined functional properties.
In conclusion, the characterisation of CD4+ T cell clones together with the molecular 
analysis of IL-10 implies a role for IL-10 as an immunostimulatory cytokine in the anti­
melanoma response observed in Ptl5392.
The analysis of the anti-tumour CD4+ T cell response in other long time surviving 
melanoma patients with emphasis on the cytokine release, might provide additional 
information regarding the relevance of this type of CD4+ T cells in tumor protection. 
However, the particular features observed for the CD4+ T cells of Ptl5392, could remain a 
unique case.
Although the data presented in this chapter were intriguing, they were not investigated 
further as the main objective of this project was to identify the target antigen for the CD4+ 
T cell mediated immune response. With this perspective, an invariant chain (Ii) -  cDNA 
fusion library was constructed and screened for antigen identification (Chapter 6 and 7).
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Table 5.2: A comparison of the profiles of cytokines secreted by the high releasing IL-10 CD4+ T cell 
clones of PtI5392 (T1 53 9 2) and the known cytokine profiles of CD4+ T cell subsets. The classical CD4+ T 
helper (Th) cells are functionally divided into (i) Thl cells participating in cell-mediated inflammatory 
reactions and releasing IL-2 and IFN-y and, (ii) Th2 cells secreting IL-4, IL-5, IL-6 , IL-9, IL-10 and IL-13 
and which are active in humoral responses. In addition to the cytokines indicated below, both subsets also 
release IL-3, TNF-a and GM-CSF, Immunosuppressive, reulatory (Tr) CD4+ T cells are divided into a Trl 
and one Th3 subset. The Trl cells secretes high levels of IL-10, low amounts of IFN-y, TGF-P and TNF-a, 
but no IL-4 or IL-5, while Th3 cells are characterised by their high release of TGF-p. Th3 cells also produce 
IL-4 and IL-10, but only minimal levels of IFN-y. The CD4+ clones from Ptl5392 (T15392) release a high IL- 
10 containing Thl profile, which is different to all the other desribed CD4+ subsets. ND = not done. This 
table has been adapted from (Wakkach et al, 2000).
SUBSET IL-2 IFN-y TGF-P T N F-a IL-4 IL-5 IL-6 IL-10
T h l cytokines Th2 cytokines
'T h l + + + + - - - -
'Th2 - - - +. 4- 4- 4- 4-
^Trl - - t - + - 4- - 4-4-4-
*Th3 - +/- + - H - 4- - - 4-
T 1 5 3 9 2 4- - + - ND ND 4-
1) Originally described for mouse (Mosmann et al,  1986) and for human (Del Prete et al,  1993).
2) Originally described for mouse and human in (Groux et al, 1997).
3) Originally described for mouse (Chen et al,  1994b) and for human (Fukaura et al,  1996).
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Chapte
CONSTRUCTION AND SCREENING OF AN li-cDNA FUSION 
LIBRARY: IDENTIFICATION OF A POSITIVE CONSTRUCT
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6.1 In t r o d u c t io n
The identification of tumour associated antigens (TAAs) has had a crucial impact on the 
development of tumour immunotherapy: in particular the elucidation of the molecular 
nature of TAAs recognised by T cells has opened up a new perspective for the vaccination 
of cancer patients (reviewed in (Rosenberg, 1997)). The discovery of TAAs was mainly 
achieved by the development of cDNA library screening by T lymphocytes (Boon, 1993), 
a technique that allows fast cloning and provides new tools for designing vaccines for 
cancer immunotherapy. In addition to providing moleculary defined TAA peptides 
potentially useful for clinical intervention, increased insight into the nature of class I HLA 
restricted TAAs has been achieved (reviewed in (Coulie et a l, 2001; Van den Eynde and 
Boon, 1997; Wang and Rosenberg, 1999)). Nevertheless, it soon became clear that 
although essential for mediating an anti-tumour response, the quantity and possibly quality 
of CD8 + T cells generated in vivo by different immunological manipulations were per se 
insufficient to activate a strong anti-tumour reaction that could lead to a significant tumour 
regression. One of the reasons for such a limited clinical response could be found in the 
lack of MHC class II epitopes in the vaccine used and, therefore, in a lack of activation of 
CD4+ T cells.
In fact, several studies have demonstrated that CD4+ T cells play an essential role at 
different levels of the anti-tumour responses (reviewed in (Pardoll and Topalian, 1998; 
Toes et a l, 1999; Topalian et a l, 1996)). As helper T cells, CD4+ T cells, (i) augment and 
sustain the cytolytic immune response by cross-priming of CD8 + T cells (Ridge et a l,
1998), (ii) are involved in the generation of CD8 + T cells (Surman et a l, 2000), and (iii) 
are required for maintaining CD8 + T cell numbers and possibly also to promote CD8 + T 
cell infiltration of the tumor (Marzo et a l, 2000).
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Vaccination studies in mice (Mandelboim et a l, 1995) and recent trials in humans (Huang 
et a l, 2002) have demonstrated the importance of both CD8 + and CD4+ T cells in tumour 
destruction. The prominent role of CD4+ T cells has been fiirther corroborated by their 
capacity to eradicate MHC class II deficient tumour cells in mice (Mumberg et a l, 1999; 
Ossendorp et a l, 1998) and recent findings indicate that a CD4+ T cell mediated anti­
tumour mechanism that involves IFN-y release and inhibits angiogenesis (Beatty and 
Paterson, 2001; Qin and Blankenstein, 2000). Thus, successful vaccination with tumour 
antigens relies on the activation of CD8 + as well as CD4+ T cells (reviewed in (Greten and 
Jaffee, 1999)). However, the mechanisms that underline these synergistic actions remain to 
be fully elucidated.
Thus, in order to provide better tools for immune intervention in cancer, it is fundamental 
to characterise molecularly TAAs restricted not only by class I HLA, but also those seen in 
the context of class II HLA. However, the development of a standard technique for cloning 
genes encoding HLA class Il-restricted TAAs has been hampered by the complex nature of 
the MHC-class II processing pathway (reviewed in (Geuze, 1998)). The method for the 
identification of CD8 + T cell epitopes uses recipient cells transfected with plasmids 
encoding tumour cDNA. The cytoplasmatic localisation of these plasmids leads to the 
entrance of the encoded proteins into the class I HLA processing pathway. However, 
modifications in the cDNA library construction and in the recipient cells can provide an 
engineered system that directs the entrance of endogenously synthesised proteins into the 
class II HLA processing pathway. This can be achived by fusing the tumour derived cDNA 
in frame with with an ER (endoplasmatic reticulum) retention signal, provided by the first 
80 amino acids of the Ii (Odorizzi et a l, 1994; Pieters et a l, 1993; Teyton et a l,  1990).
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The resulting chimeric protein, once produced by the biosynthetic machinery of the 
transfected cells, will be preferentially targeted to the endoplasmatic reticulum (ER) 
thereby facilitating entrance into the class II HLA processing pathway (Chervonsky et a l, 
1994; Odorizzi et a l, 1994; Tan gr a l, 1997), where the peptide loading will occur in 
different intracellular compartments (reviewed in (Fineschi and Miller, 1997; Geuze, 
1998)). Furthermore, in order to provide a specific system for monitoring of a CD4+ T cell 
mediated antigenic response, recipient cells must be transfected with the polymorphic class 
II HLA p-chain which can assemble with the endogenously expressed a-chain and form a 
recombinant class II HLA allele (reviewed in (Cresswell, 1994; Pieters, 2000)).
In this chapter I have used an innovative molecular approch to identify candidate TAAs 
recognised by CD4+ T cells obtained firom Ptl5392. This antigen cloning strategy is based 
on the availability of specific immunological reagents; i.e. (i) established tumour reactive 
CD4+ T cell clones (Chapter 4), (ii) subcloned HLA alleles expressed by the patient under 
study, and (iii) a tumour derived cDNA library (presented in this chapter).
Parts of the work with the library construction have been performed in collaboration with 
Dr. Luisa Novellino.
6.2 A im s  OF THE CHAPTER
• Optimising a strategy for construction of a cDNA library capable of directing inserts 
into the endogenous antigen processing pathway.
• Library screening
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6.3 R esu l t s
6.3.1 Rationale for cDNA library construction and screening
The main steps required for cDNA library construction and screening are shown in Figure
6.1. Messenger RNA (mRNA) was isolated from patient derived tumour cells and then 
converted into cDNA. The synthesised cDNA was then ligated to adapters and fractionated 
by liquid chromatography in order to select only large cDNA-adapter inserts (> 500bp). 
These selected tumour-derived cDNAs were cloned into an expression plasmid. The 
plasmid used for library construction was pEAK8 , an eukaryotic expression plasmid in 
which the transcription of the cloned insert is driven by the EF-1 alpha promoter. This 
plasmid has been engineered to contain the first 80 amino acids of the Ii in frame with the 
multiple cloning site, at which the cDNA was inserted (Figure 6.2). This procedure 
resulted in a fusion protein containing the NH2 terminal amino acids derived from the Ii 
protein followed by the amino acid sequence encoded by the tumour-derived cDNA. The Ii 
confers the proper cellular localisation of the fusion protein to the class II processing 
pathway. The detailed steps used to screen this cDNA library are reported below.
In order to screen the li-cDNA fiision library it was necessary to transfect the library into 
appropriate recipient cells. A complex set of molecular steps must co-operate inside the 
recipient cells to allow expression of CD4+ T cell epitopes on the cell surface, as outlined 
in Figure 6.3. In particular it is very important to use highly transfectable recipient cells 
(herein 293 cells), which express a complete HLA-class II processing machinery. To this 
aim, 293 cells engineered to express the class II trans-activator (CIITA) protein, 
293/CIITA cells, were used. It has been shown that CIITA is a key molecule for the 
physiological transcription of genes encoding the HLA-DR, -DQ and -DP alleles, as well 
as the other proteins belonging to the HLA-class II machinery, like the Ii and HLA-DM
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mRNA 5’
mRNA 5 ’ 
3’
—  AAAAA - 3’
Addition of the Not I 
primer-adapter
- AAAAA - 3’ Xba I site
T T T T T  GACTAGTTCTAGATCGCGAGCGGCCGCCC . 5 ’
Xha r primer-adapter 
1st strand synthesis
1st strand 3’ i 1 T T T T T  GACTAGTTCTAGATCGCGAGCGGCCGCCC _ 5 ’
cDN^ Xha 1 primer-adapter
2nd strand synthesis
1st Strand 3’ C






cDNA Xha I primer-adapter
Ligation of the Bst XI adapter
CTGGAAAGI-------1 GACTAGTTjCTAGATCGCGAGCGGCCGCCCCTTTCCAGCACA
ACAC GACCTTTC I-------1 CTGATCAAGATCfTAGCGCTCGCCGGCGGGGAAAGGTC
<-------------------- X —X -------------------   X ------------------ ►
Bst XI adapter cDNA Xha I primer-adapter
Digestion with Xha I
Bst XI adapter
CTGGAAAGI GACTAGTT
ACAC GACCTTTC |-------1 CTGATCAAGATC
-------------- X ----X ------------------
XI adapter cDNA Xha I primer-adapter





The pEAK8/Ii vector 
was cut with Bst XI 
and Xha I.
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molecules (Chang and Flavell, 1995; Kem et a l, 1995; Liu et a l, 1999; Wright et a l, 
1998). Moreover, 293/CIITA cells were genetically modified to express the HLA-DR 
alleles of melanoma Ptl5392 (DRp 1*01021 and DRpi*10011). The a-chain of HLA-DR 
was intrinsically provided by the 293 cells, while the polymorphic p-chain (Andersson, 
1998) was cloned from LCL cells of Ptl5392 and transfected into 293 cells.
Prior to transfecting recipient cells with the li-cDNA fusion library, the library was 
transformed into E.coli cells and divided into pools of approximately 100 bacteria carrying 
independent recombinant inserts. This number of constructs has been quantified as suitable 
for an efficient and quantitative throughput screening of a large number of samples 
(reviewed in (De Plaen et a l, 1997)). Plasmid DNA was extracted from these bacterial 
pools and separately transfected into modified 293/CIITA recipient cells expressing the 
proper HLA allele derived from Ptl5392. This allele conferred specificity into the system 
and worked as a restriction element for the T cell clone. The transfected cells were then 
incubated overnight with the T cell clone whose antigen has to be identified. Finally, T cell 
activation was monitored by evaluating the amount of IFN-y released in the medium using 
a commercially available ELISA. IFN-y release thus indicates T cell triggering and the 
presence of a tumour-derived cDNA encoding the nominal antigen originally recognised 
by the T cell clone used for the screening.
6.3.1J Construction and qualitative evaluation o f  the li-cDNA fusion library 
The high quantitative and qualitative yield obtained for the isolated polyA mRNA is a 
prerequisite to obtain a high quality library corresponding to 1 0  ^ clones according to the 
Superscript^^ Plasmid System for cDNA Synthesis and Plasmid Cloning. This protocol 
indicates that 1 -  5 pg of mRNA are sufficient for the synthesis of a good cDNA library.
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Thus the FastTrack protocol was applied for mRNA isolation and a yield of 6 . 6  pg of 
polyA mRNA was obtained from 40x10^ melanoma cells.
6.3.1. a Library construction : oriented expression
We chose to construct a directional li-cDNA fusion library, as it minimises the number of 
clones needed for the screening. The cDNA was genetically engineered to express two- 
staggered terminus with different restriction sites. The first strand synthesis was copied 
using as template the tumour-derived mRNA and as primer an oligo (dT) primer 
containing ûiQXba /  restriction site at the 5 'terminus (Figure 6.2). The first strand DNAs 
were converted into blunt-ended second strand cDNA and subsequently ligated to the Bst 
XI adapters.
The recombinant cDNA inserts will express 5 ' Bst XI and 3 ' Xba I terminus after digestion 
with the Xba I the enzyme (Figure 6.2). Thus, this approach makes possible the generation 
of cDNAs with asymmetric ends allowing a directional cloning.
6.3. l.iii Library construction: fractionation
The selection of large cDNAs (> 500 bp) by size fractionation polished the cDNA by any 
residual adapters and by all the fragments generated by the double digestion. This 
procedure avoided the production of recombinant plasmid containing irrelevant inserts. 
Moreover, cDNA smaller then 500 bp do not represent full-length copies of mRNA 
transcript. Thus, by selecting large cDNA inserts we improved the quality of our library.
With the purpose of obtaining the highest possible yield, the amount of cDNA obtained 
after the different passages of first and second strand synthesis was not measured, but the 
total quantity was used for the adapter ligation. The cDNA yield was measured after size 
fractionation. As explained in the Material and Methods, cDNA fractions #3 to #12 could
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be considered to contain large inserts with minimal contamination of non-ligated adapters 
and smaller cDNAs. To estimate the quantity of cDNA in these selected fractions an 
ethidium-bromide staining was performed. Samples #3 to # 6  did not contain any cDNA, 
while the amount of the cDNA of the fractions #7 to #12 is indicated in Table 1. According 
to the SuperScripf'^ Plasmid System for cDNA Synthesis and Plasmid Cloning, a cDNA 
yield of 5-10% of the initial mRNA can be obtained. We obtained a total mass of 469 ng of 
fractionated cDNA (Table 6.1), that represents approximately 7% of the initial 6 . 6  pg of 
the melanoma-derived mRNA used for the library construction. Moreover, at individual 
level, fraction #10 was the most concentrated sample. Among the remaining five fractions, 
one differed markedly from the others showing a concentration as low as 0.5 ng/pl. 
Altogether, 4 high standard preparations with an estimated concentration of 3 ng/pl could 
be defined from the size fractionation.
Table 6.1. Amounts of cDNA obtained in fractions #7 to #12 after size fractionation. These fractions are 
considered as containing large cDNA inserts.
FRACTION FINAL VOLUME* CONCENTRATION MASS
#7 35 gl 0.5 ng/gl 18 ng
#8 12 gl 3 ng/gl 36 ng
#9 35 gl 3 ng/gl 105 ng
# 10 37 gl 4.5 ng/gl 167 ng
# 11 12 gl 3 ng/gl 36 ng
# 12 36 gl 3 ng/gl 108 ng
1) Volume remaining in each fraction after the use of 5 gl for a fluorescent evaluation of cDNA 
content.
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6.3.1JV Library construction: quantitative estimation
The ligation of cDNA to the vector backbone as well as the bacteria transformation was 
carefully optimised to reach maximum efficiency. In order to obtain an approximate 
evaluation of which approach would confer the highest transformation efficiency to our li- 
cDNA fiision library, we compared two independent systems of transformation, chemical 
transformation versus electroporation into E.coli ElectroMAX"' '^  ^DHIOB™ competent cells. 
The transformations reported above were performed with empty pcDNA3.1(-)/Hygro 
vectors produced 1.5x10^ positive colonies/pg (Qc) by chemical transformation and 
8.5x10^ positive colonies/pg (Qe) by the ElectroMAX approach (Table 6.2A). The latter 
approach appeared to be 600 times more efficient and the numbers of colonies obtained fell 
80 times above the range indicated for a high quality library. The superiority of the 
ElectroMAX protocol was due to the fact that the DNA was introduced into target cells by 
electroporation, which is more efficient than chemical conditions.
As additional steps for the optimisation of library construction, experiments were set up 
aimed at evaluating the quality of the backbone vectors, selected as possible recipients for 
the expression library and opened up in the cloning site Bst XI and Xba I. For these quality 
controls, cDNA inserts were substituted with a green fluorescent protein (GFP) - derived 
fragment having compatible Bst XI and Xba I sticky ends. The GFP fragments were ligated 
into the Bst XI and Xba I sites of pEAK8 /Ii, pEAK8.5 and pcDNA3.1(+) vectors. The 
E.coli ElectroMAX^^ DHIOB™ competent cells were too costly to be used to set up the 
conditions of the system and, therefore, we performed a chemical transformation 
representative of an equal transformation with the library. The mean value of 
transformation efficiency achieved by the chemical procedure was 3.3x10^ positive 
colonies/pg (Qgfp).
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Table 6.2: Calculation of the number of transformants that can be expected in the li-cDNA fusion 
library applying the ElectroMAX approach for transformation. A) The transformation efficacy, Q, 
obtained by different approaches. The values for the ElectroMAX electroporation and the chemical 
transformation, Qg and Qg. respectively, were obtained for empty vectors, while Q^ pp is the mean value of 
chemical transformations performed with different vectors carrying GFP as an insert; a setting resembling 
the conditions that would be used for transformation of the library. The Qgpp efficiency was further used 
to calculate the approximate number of transformants (NJ that could be expected when performing the 
ElectroMAX electroporation with the library. B) The total number (tot-NJ of expected transformants in 
the library using 80ng of vector in the ligation reaction.
A
The ratio of efficiency 
ElectroMAX (Qg): 8.5x10^ colonies/gg 
Chemically (Q^): 1.5x10^ colonies/pg
Chemically (Qgpp): 3.3x10^ colonies/fig
Q e /  Qc = 6x10^ = k
The approximate number of transformants
Nj =  K X Q gfp = 6x10^x3.3x10^ colonies/pg = 2.0x10^ colonies/pg
B
The total number ftot-N^f of transformants in the library 
Mass to use of vector (m^ gg^ g^ ) = 80 ng
Tot-Nj = NjX myggtor 2.0x10^ colonies/pg x 0.080 pg = 1.6x10^ colonies
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This efficiency was multiplied by the factor of efficiency obtained for E.coli 
ElectroMAX^'^ DHIOB™ competent cells (Qe) (Table 6.2A). The equation puts the number 
of theoretical transformants possibly obtained with the ElectroMAX approach to 2.0x10^ 
per pg. Our results indicate the high quality of all of our backbone vectors and the high 
standard of our experimental procedures.
Finally, according to the guidelines indicated in the Superscript’^ '^  Plasmid System for 
cDNA Synthesis and Plasmid Cloning the ratio between the vector and cDNA quantity is a 
critical parameter affecting the total number of colonies contained in the future library. 
Thus, considering these limits, in the library ligation I decided to use a molecular ratio of 
2/1 for the cDNA insert and pEAK8 /Ii vector i.e. 25 ng cDNA (approximately 1000 bp) 
and 80 ng pEAK8 /Ii vector (6400 bp).
Setting these conditions, the number of expected recombinant clones in our li-cDNA 
fusion library should be close to 1.6x10^ (Table 6.2B) independent clones. This number is 
consistent with the generation of a high quality cDNA library, comprehensive of relatively 
low abundant transcripts.
6.3.l.v  Library construction: cDNA and vector ligation
The amounts of cDNA and pEAK8 /Ii vector to be used in each ligation were carefully 
evaluated (se the calculations above) to theoretically obtain 1 .6 x 1 0  ^ transformants in the 
library (Table 6.2B), a value indicative of a comprehensive high quality library. To 
perform the library ligation, 4 of the obtained fi*actions containing large cDNA inserts 
(Table 6.1) were chosen as reagents. More precisely, fractions #9, #10, #11 and #12 all 
were in the same range of concentration and fi*action #9 and #10 were chosen as 
representative samples. In addition, fraction #7 was pooled with fi*action # 8  to include all 
the cDNA information contained in the relevant fractions for the library ligation. All the 3
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cDNA fractions (#7 + 8 ; #9 and #10) were subjected to individual ligation reactions with 
the pEAK/Ii vector and the ligated cDNAs (L#7+8, L#9 and L#10) were immediately 
electroporated into bacteria (described below).
6.3.1.VÎ Library construction: transformation
The 3 cDNA libraries L#7+8, L#9 and L#10, were thus submitted to electroporation into 
E.coli ElectroMAXT^^ DHIOB™ Competent Cells. Each electroporation reaction was 
performed in duplicate resulting in a total volume of 2 ml per each ligation. 50 pi of each 
electroporation was used for quality control and serial dilutions and plating were set up in 
order to determine the titer of the library. The independent electroporated bacteria were 
then kept overnight at 4°C and amplified according to the Millipore protocol (se below) 
after the assessment of its quality was completed.
6.3.1.vii Qualitative library evaluation
Qualitative evaluation of the recombinant plasmids obtained with the cDNA fractions 
(#7+8, #9 and #10) was performed using a PCR-based approach. DNA from each colony 
was amplified with primers specific for the pEAK8 /Ii sequencing spanning the cloning 
site. The presence and the length of the cDNA insert was deduced from the length of the 
band obtained in this amplification. Bands of 700 bp matched to the empty cloning site 
containing only the li, while bands showing a higher molecular weight identified positive 
fragments. The appropriate length of the cDNA inserts was obtained by subtracting the 
molecular weigh of the amplified sequences with 700 bp. The results shown in Figure 6.4 
clearly indicated many characteristics for each individual ligation. To focus on some 
important features, the L#7 + 8  library contained cDNA inserts of variable length, 
indicative of the variability of mRNA transcripts contained in the original tumour cells. On 
the other hand, this library contained very few transformants (Table 6.3) and a large
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Table 6.3: Qualitative and quantitative features of the li-cDNA fusion libraries. E.coli DH5a cells 
were electroporated with the li -  cDNA fusion library and subsequently plated onto LB/Amp plates that 
were left for overnight incubation at 37°C. The % of recombinants corresponds to the total number of 
single colonies obtained for each library after plating onto LB/Amp plates. The length show the range of 
bands present in each library. The transformation efficiency shows the number of colonies obtained per pi 
and the final column show how many total colonies that were obtained for each library. No = number.
LIBRARY % RECOMBINANTS LENGTH E E ^ffiN C T  TOTAL No
L#7+8 30% 600-1800 bp 26 colonies/pl 52000
L#9 60% 600-1300 bp 5.5 colonies/pl 11000
L#10 50% 500-1200 bp 10 colonies/pl 20000
156
Ch apte r  6__________________________________________________________________________________________________
number of colonies just contained an empty plasmid. On the contrary, the L#9 and L#10 
libraries contained a much higher number of positive recombinants. In addition, they also 
showed a similar yield, both carrying cDNA inserts ranging in size from 700 bp to 1300 
(Table 6.3). However, 50% of the L#10 library was represented by short inserts of just 500 
- 600 bp, while only two recombinants with insert of 1000 bp or more were detectable. As 
an example, lane 15 and lane 16 (Figure 6.4) do contain short cDNA, while the band in 
lane 22 should represent only the empty vector. A high percentage of long inserts reaching 
the 1300 bp in size was included L#9 library. Thus, the L#9 Il-cDNA fusion library was 
shown to constitute a more comprehensive library, as it contained cDNA inserts with a 
wider range of molecular weights and the highest number of recombinants (60%) carrying 
cDNA inserts of proper length.
The total number of colonies obtained for each electroporation was determinated taken into 
account the remaining volume and the bacteria titer (Table 6.3). Library L#9 and L#10 
both demonstrated a low transformation efficiency with only 5.5 colonies/pl and 10 
colonies/pl respectively, while L#7 + 8  was at least 3 times more efficient, with 26 
colonies/pl (Table 6.3). The total number of recombinants for each electroporation is 
reported in Table 6.3. This quantitative data revealed that the total number of recombinant 
plasmids obtained in each ligation was 1 0 -fold lower than the theoretical expected yield of 
1 .6 x 1 0  ^transformants (Table 6 .2 ).
6.3.1. via Library amplification
Library amplification was only performed for the ligations of fraction L#9 and L#10 
ensuring the highest percentage of plasmids carrying cDNA insert with the correct length. 
Bacteria derived from electroporation L#9 and L#10 with a carefully evaluated titer (see 
quantitative evaluation) were derived and grown in liquid cultures containing an average
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of 100 bacteria, were inoculated in 96 deep well blocks in a final volume of 1.5 ml of 
media containing the selective antibiotic ampicillin. This method allowed a rapid high 
throughput method for plasmid minipreparations, outlined in the Millipore 
Multiscreen® Assay System protocol.
6.3.1.ix Preparation o f  the recipient cells 293 suitable for the library screening 
The 293/CIITA recipient cells were employed for the genetic expression of a specific HLA 
class II processing designed to reconstitute the HLA-DR haplotype of Ptl5392, and to 
assure the expression of restriction elements for the CD4+ T cell clones (Figure 6.3). This 
was achieved by the use of 293/CIITA cells, which showed a stable 98% expression of the 
HLA class II alleles (Figure 6.5), due to infection with a retroviral vector expressing 
CIITA. However, the polymorphic DRp 1*01021 and DRpl*10011 P-chains (see section 
2.3.5) had to be provided to the system by transient transfection during the screening 
procedures. This engineered cells allowed the highly specific expression of fully assembled 
class II HLA alleles, as the non-polymorphic HLA-DR a-chain, endogenously supplied by 
the cellular DNA of the 293/CIITA cells, could join with the transfected P-chains of the 
HLA-DR alleles.
6.3.1.x Screening o f  the li-cDNA fusion library and identification o f  a positive pool 
conferring activation o f a CD4+ T cell clone.
Chapter 4 described the functionally characterisation of the CD4+ T cell repertoire of 
Ptl5392 and among the defined clones, TB515 was selected for screening of the li-cDNA 
fiision library. This clone demonstrated a high specificity and, when stimulated with the 
autologous tumour, it released a high amount of IFN-y (Figure 6 .6 ) and showed anti­
tumour lysis even when used at a very low effectoritarget (B:T) ratio (Figure 6.7). 
Unfortunately, since no anti-HLA-DRlO or -DRl specific antibodies are commercially 
available, it was not possible to anticipate which DR allele acted as restriction element in
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FIGURE 6.5; Class II HLA expression on 293-EBNA cells stably transfected with CIITA.
Fluorometric analyses of the surface expression of class I and class II HLA alleles on 293-EBNA cells 
constantly expressing CIITA (293/CIITA) with (A) FITC anti-mouse Ab; (B) FITC anti-HLA-A, -B and 
-C (W6/32) mAh; (C) FITC anti-HLA-DR (L243) mAh. The 293/CIITA cells are positively stained to 
almost 98%.
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FIGURE 6.6: Reactivity of clone TB515 against the autologous tumour. The autologous melanoma 
(Mel5392) or LCL (LCL 15392) cells were incubated with 5x10  ^cells of clone TB515 over nigth at an 
E:T ratio of 1:1. Mel5392 induced a significant IFN-y release fi’om clone TB5I5 (p<0.001). The 
supernatants were collected and evaluated for their IFN-y content by ELISA. The anti-HLA-DR antibody 
L243 added in the test significantly ihnibited the cytokine release (p<0.001). Results are shown as mean ± 
S.D. of two experiments.
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Mel5392 + L243 
LCL15392
FIGURE 6.7: Cytotoxic activity of clone TB515 against the autologous tumour. Clone TB515 (5x10^ 
cells/well) was incubated for 5 h with labelled autologous melanoma (Me 15392) or LCL cells (LCL15392) 
(control) at indicated E:T ratios. The cytotoxic activity was evaluated in a standard 4 h ^^Cr-release assay. 
Lytic activity was significantly blocked (p<0.001) by the addition in the test of the anti-HLA-DR antibody 
L243. Results are mean ± S.D. of three separate experiments.
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the tumour recognition by TB515. For this reason, a double library screening had to be 
performed using either the DRp 1*01021 and DRP 1*10011 molecules independently. 
However, the melanoma cells of Ptl5392, clearly expressed HLA-DR and could be used as 
positive controls in the screening procedure (Figure 6 .8 ).
As a last parameter, to ensure that the expression level of the cDNA was detectable in our 
system, the GFP was used as an internal control for transfection: a good fluorescence was 
observed down to 1 ng/pl of cDNA. This indicated that the system can allow detection of 
one single cDNA construct, expressed together with 100 others in a pool, using only 200ng 
of DNA for transfection. Thus, the tumour derived li-cDNA fusion library was submitted 
for screening by the available CD4+ T cell clone TB515 by co-transfection of either the 
HLA-DRp 1*01021 or -DRpl* 10011 allele together with individual cDNA pools (w 100 
cDNAs/pool) into 293/CIITA cells. Indeed, one positive clone was detected after the 
screening of 5x10^ pools restricted in HLA-DRpi* 10011 (Figure 6.9), while no positive 
clones could be identified after additional evaluation of as many as IxlOf li-cDNA 
constructs restricted in HLA-DRp 1*01021. The positive clone, named pool #D2, was re­
analysed several times with independent transfections and confirmed to mediate CD4+ T 
cell recognition.
6.4 D isc u ssio n
In this chapter, the genetic methodology for cloning of class II HLA restricted TAA has 
been presented. The reported qualitative and quantitative features of the li-cDNA library 
(Table 6.3 and Figure 6.4) and the engineered 293 cells represented an optimal system for 
antigen identification. However, the limitation with the li-cDNA fusion library approach, 
with respect of using a normal cDNA library, is that a triple number of clones need to be 
screened to reach an optimum number of correctly expressed cDNAs. In fact, the li can be
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Figure 6.8: Characterisation of the class II HLA expression on Mel5392 cells. Fluorometric 
analyses of the surface expression of class 1 and class II HLA alleles on autologous melanoma cells 
(M el5392) (left panels) and LCL cells (LCL 15392) (right panels). The cells were stained with the anti- 
HLA-A, -B and -C mAh W6/32 and the anti-DP, -DQ and -DR mAh. Red profiles represent baseline 
unspecific fluorescence (negative control). The LCL 15392 cells express all alleles of Ptl5392, while 
Me 15392 was positively stained for HLA class 1 and HLA-DP and -DR, but did not express HLA-DQ.
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Figure 6.9: Recognition of a a positive HLA-DR(31*10011 restricted pool of the li-cDNA fusion 
library. Recipient 293 cells (1x10^ cells/well), constitutively expressing the class II trans-activator 
(CIITA), were double transfected with 150 ng of either the HLA-DRp 1*01021 or -DRpi*10011 (DRIO) 
allele together with individuals pools of an invariant chain (li) -  cDNA fusion library (approximately 100 
li-cDNAs/pool). The cells were incubated for 24 h before the addition of 2x10"^  cells/well of the CD4+ T 
cell clone TB515. After overnight incubation, the supernatants were evaluated for their IFN-y content by 
ELISA. Autologous melanoma cells (Me 15392) were used as positive control. The screenings o f the 
library were performed twice for each allele with single wells representing 50 different pools. Results are 
collected from 3 experiments and represent the mean ± S.D. No positive pools were found using HLA- 
DRp 1*01021 (not showed).
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ligated to any of the 3 open reading frames of the cDNA insert. However, one advantage 
provided by the use of an li-cDNA fiision library is that it assures the delivery of the 
cDNA construct into the HLA class II pathway of antigen processing.
The method use here required functional characterised CD4+ T cells as initial reagents. 
Other strategies, like reverse immunology (reviewed in (Schultze and Vonderheide, 2001)) 
and computerised peptide algorithms (Maier et a l, 1994; Rammensee et a l, 1999) allow 
the prediction of potential peptides of class II HLA-restricted antigens, but they require to 
know the antigenic sequence. These methods also benefit from the fact that the antigen 
under study can be pre-selected, which is an advantage when TAAs have to be identified 
from cancers other than melanoma, as culture of other neoplastic cells has proved difficult. 
Moreover, it is possible to identify naturally processed epitopes by performing biochemical 
dilution of epitopes presented on the HLA molecules on the cell surface, but this is a 
cumbersome procedure and does not allow a genetic targeting of genes expressed by the 
tumour (Mandelboim et a l, 1994).
The results presented in this chapter demonstrate that clone TB515 was involved in an anti­
tumour response. As antibodies specific for these alleles not are commercially available, 
this result indicated the presence of a tumour antigen restricted in either HLA- 
DRp 1*01021 or HLA- DRp 1*10011 allele expressed by Ptl5392. While antigens such as 
gplOO (Li et a l, 1998), MART -1 /Melan-A (Zarour et a l, 2000), CDC27 (Wang et a l, 
1999a), TPI/m (Pieper et a l, 1999) and LDLR/FUT (Wang et a l, 1999b) encode epitopes 
restricted by HLA- DRp 1*0101, no antigen has previously been described as restricted by 
HLA-DRp 1*10011. This implies two possibilities; first, T cell clone TB515 may recognise 
either a new or already described epitope restricted by HLA-DRp 1*0101 or, second, that
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clone TB515 has mounted an immune response against a novel antigen restricted by HLA- 
DRpi*10011.
Thus, in order to assess the nature of the antigen recognised and define the exact allele 
restriction, clone TB515 was employed in the screening of the li-cDNA library in the 
presence of either of these alleles. One positive pool of the library was identified as 
restricted by the class II HLA allele DRpi*10011 (Figure 6.9), whereas no positive pool 
could be found by co-transfecting the HLA-DRp 1*01021 allele (not shown). This result 
clearly indicated the presence of a novel TAA, restricted by HLA- DRpi* 10011 and 
uniquely expressed by the melanoma cells of Ptl5392. It also opens many challenging 
questions about the identity of this unique antigen and the features of its immunogenic 
epitope, an information that may contribute to a better understanding of the anti-CD4+ T 
cell mediated tumour response in Ptl5392.
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7.1  In t r o d u c t io n
Identification of epitopes firom TAAs enabled clinical approaches for cancer treatment and 
the availability of such immunogenic peptides is also instrumental to better define the role 
of T cells in the anti-tumor response. In fact, such epitopes have also a prominent role in 
the evaluation of T cell associated systemic immune responses (reviewed in (Melief and 
Kast, 1995; Melief et a l, 1996; Ressing et a l, 1996)). The experiments described in this 
chapter are focused on the identification of the antigenic protein expressed by the 
melanoma cells of Ptl5392 representing the specific target for clone TB515 (as reported in 
Chapter 6 ). Moreover, the data reported in this chapter provide a fine molecular 
characterisation of the immunogenic peptide contained in such protein. This peptide 
constitutes the nominal epitope for the TB515 CD4+ T cell clone.
7.2  A im s  o f  th e  c h a pt e r
• Identification of the gene conferring recognition by the CD4+ T cell clone TB515.
• Definition of the immmunogenic epitope of this antigen.
7.3  R esu l ts
7.3.1 Construct/sequence identification
7.3. L i Molecular approaches fo r  sub-cloning the positive pool o f  the li-cDNA library 
In the genetic approach for library screening, the li-cDNA library has been divided into 
pools each containing approximately 100 constructs carrying recombinant inserts. The 
identification of one positive pool, #D2, in this library (as reported in Chapter 6 ) was the 
first step to the molecular definition of the gene encoding this antigen. The subloning 
procedures used to isolate the single cDNA encoding the antigenic protein is shown in 
Figure7.1.
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Firstly, an aliquot of the positive pool #D2 was submitted for electroporation into E.coli 
ElectroMAX^^^ DHIOB™ competent cells. After titration, the electroporated bacteria were 
seeded in a deep well culture block at 150 bacteria per well. Plasmid DNA was prepared 
from these new subpools by the Millipore MultiScreen®Assay System protocol, and after 
transfection into 293/CIITA cells, 10 new pools were identified as being able to stimulate 
TB515 (Figure 7.2). The pool showing the highest IFN-y release, #F6 , was chosen for 
ftirther evaluation. Secondly, the DNA pool #F6 , selected from the 10 pools that resulted 
positive in the previous screening was subjected to a second cycle of sub-cloning and 
electroporated under the same conditions previously used for pool #D2. Subpools of 23 
bacteria each were then grown in a deep well culture block of 96 wells. Plasmid DNA of 
these cultures was prepared following the Millipore MultiScreen®Assay System protocol 
and upon transfection, 23 positive pools were identified out of 189 tested. One of them, 
sub-pool #C8 , was selected for further purification. In the third and last round of 
subcloning DNA from subpool #C8  was eletroporated in bacteria, and plated on soft agar 
containing ampicillin. Single growing colonies were then inoculated in liquid media. 
Plasmid DNA was extracted from 35 bacteria cultures, each derived from a single 
independent colony, by traditional mini-preparations following the Quiagen protocol. 
Finally, in this last step of the subcloning, plasmid DNA encoding these single inserts was 
transfected into 293/CIITA cells together with the HLA-DRp 1*10011 restriction allele. 
Among them, the DNA of Clone #11 was best recognised by clone TB515 (not shown) and 
thus identified as the putative insert encoding the protein containing the immunogenic 
epitope.
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7.3.2 Database search and sequence identification
7.3.2.Î Characterisation o f  the insert from Clone #11
As a first step to characterise our positive Clone #11, DNA form Clone #11 was amplified 
with primers specifically spanning the cloning site of the pEAK8 /Ii expression vector. A 
band of 1500 bp was amplified by this set of primers. The empty cloning site of the 
pEAK8 /Ii vector spans 800 bp, i.e. 500 bp derived fi'om the cloning site and 300 bp 
derived firom the li (Figure 7.3A). Thus, by subtracting the molecular weight of the inserts 
carried by Clone #11 (1500 bp) and the pEAK8 /Ii vector (800 bp), the positive clone #11 
was found to encode an insert of 674 bp (Figure7. 3B).
7.3.3 Database analysis of insert #11
The 700-bp sequence of Clone #11, i.e. the individual construct of the li-cDNA library that 
mediated a positive recognition by the CD4+ T cell clone TB515, was compared with 
sequences in Gene Bank by using the Entrez site available on the web 
(http://www.microbiology.adelaide.edu.au/leam/index.htm). The computerised analysis 
showed that the sequence of Clone #11 was 99% identical to a previously reported 
sequence of the human protein tyrosine phosphatase receptor kappa, the PTPR-k  gene 
(Accession number NM-002844.2). The fine comparison between the two sequences 
revealed that in the cDNA derived fi'om melanoma, a point mutation had occurred at 
position 2249 where a nucleotide replaced the corresponding wild type (wt) base g. The 
triplet sequence of the mutation codon encodes an R (Arg) while the wt sequence contains 
a G (Gly) (Figure 7.4). The mutated version found in the melanoma cells of Ptl5392 will 
hereafter be referred to as PTPR-ic/m.
7.3.3.i An internal ATG codon directs the PTPR-K/m expression
By the sequence analysis it was evident that the cDNA insert was not in frame with the
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FIGURE 7.3: The positive cDNA #11 encodes a 700 bp insert. (A) A schematic view of the invariant 
chain (li) - cDNA fusion insert in the polylinker of the pEAK8 vector. The first 80 amino acids of the li,.gQ 
cover 240 bp (red bar), which have been ligated with tumour derived cDNA (grey bar) selected to contain 
bands of minimal 500 bp after size fractionation. (B) PCR performed using T3 forward primer and T7 
reverse primer (grey arrows in A) with the empty pEAK8 vector alone and vector constructs containing 
either only the li or the full li-cDNA fusion insert. The 1 kb and 100 bp ladders were used to size 
molecular weight of the DNA bands.
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initial ATG inside the li chain. Therefore the part corresponding to the PTPR-K/m cDNA 
was not translated into the PTPR-K/m protein. The existence of an inner ATG directing the 
translation of the cDNA was postulated. By analyzing the sequence of cDNA#l 1, a Kozak- 
like sequence ((g/a)nnatgg ) was found preceding the presence of two internal ATG codons 
(base pair position 2165 and 2204) in the GenBank NM-002844.2 sequence), both in frame 
with the authentic first starting methionine of the PTPR-k  gene (Figure 7.5A). In order to 
evaluate (i) if  cDNA #11 could be translated independently from the li and (ii) which 
impact the li had on its processing and presentation, subcloning was performed: cDNA #11 
was shifted from the pEAK8 /Ii vector and ligated to the pcDNAS.l vector. This new 
construct, lacking the li sequence, was then transfected into 293/CIITA cells together with 
the HLA-DRpl*10011 allele. Indeed, cDNA #11 was efficiently recognised by the 
specific T cells (Figure 7.5B). This result demonstrated that the PTPR-K/m protein encoded 
by cDNA #11 gained access to HLA-class II processing without the requirement of the 80 
amino acid of the li chain. In addition, the recognition of cDNA #11 alone demonstrated 
that the internal ATG positioned at 2165 in the GenBank NM-002844.2 sequence is active 
in directing the protein translation.
7.3.3.U A polyclonal CD4+ T cell response against the PTPR-K/m antigen
The insert Clone 11 was also transfected into 293/CIITA cells in the presence of HLA-
DRp 1*01021 or -DRp 1*10011 and tested for recognition by the other, previously
characterised CD4+ T cell clones TB515, TB39 and TB48. All the three clones, although
expressing different TCR specificity, were induced to release significant amounts of IFN-
y (Figure 7.5B and 7.6). This indicated that their nominal epitopes were all derived from
PTPR-K/m and presented by the HLA-DRpl*10011 allele. On the basis of these results it
?
may be concluded that the PTPR-K/m antigen induced a strong and polyclonal immune 
response at the tumour site.
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7.3.3.in Identification o f the immunogenic region o f PTPR-K/m
As the point mutation was found to be crucial for the recognition of the antigen by T cells, 
3 minigenes (M) spanning the region containing the mutated nucleotide were synthesised 
by amplification with primer F2, starting approximately 150 bp upstream of the mutated 
site in association with the reverse primers EPRl, EPR2 and EPR3 located downstream of 
the forward primer F2 (Figure 7.7A). The amplified products were ligated into the 
pcDNA3.1D/V5-His-T0P0 vector and co-transfected into 293/CIITA cells together with 
the HLA-DRp 1*10011 encoding plasmid. The minigene M l, corresponding to a short 
region of 202 bp surrounding the mutation, was recognised by clone TB515 (Figure 7.7B). 
Furthermore, the minigene M2 (179 bp) was recognised, though less efficiently, while the 
shortest minigene, M3 (159 bp), was unable to stimulate any response by Clone TB515. 
This implies that the small stretch of 7 amino acids (NLPEPAPF), by which minigene M2 
differs from M3 is important for the interactions with the T cell receptor and sets the 
restriction for the COOH end (Figure 7.8). Therefore, a stretch of 28 amino acids 
extending from this region and in the direction of the NH2 end was choosen as a replica 
sequence for the design of putative peptides constituting the epitope of Clone TB515. This 
result was also fully in accordance with our hypothesis that the mutation has a role in the 
recognition.
7.3.3.iv Identification o f the TB515 epitope derived from PTPR-K/m 
HLA-DRp 1*10011 is an allele with an unknown distribution (reported at http://www.ashi- 
hla.org) and although the development of new assay systems has facilitated the definition 
of binding motifs for HLA class II molecules (Southwood et al., 1998), no binding anchors 
have yet been defined for HLA-DRp 1*10011 to assist in the prediction of the putative 
epitope. Thus, in order to further limit the putative epitope region and to understand which 
amino acids are important for recognition, a set of 16-mer overlapping peptides spanning
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Iy q n a m s g g a p y y f a a e l p p r n l p e p a p f
Figure 7.8: Selection of an immunogenic region of PTPR-K/m minigenes suitable as a replica 
sequence for the design of peptides. The amino acid sequences o f minigene M2 and M3 is shown. The 
mutated base R (in read), is located at position 677 of the PTPR-K/m protein and the two internal ATG 
codons at position 649 and 662 are indicated. As shown in Figure 7.7 T cell recognition was markedly 
reduced for M2, but fully lost for M3. This showed that the truncated region NLPEPAPF (marked by a 
double line) at the COOH end of M2 (shown in Figure 7.7) was important for recognition and indicated 
that the immunogenic epitope should extend further towards the NHj end of the minigenes. Based on 
these data, a region of 28 amino acid was chosen as a replica sequence for the design o f peptides. The 
arrow indicated the position of the mutated amino acid.
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the mutated R of the PTPR-K/m gene were designed from the selected region shown in 
Figure 7.9. These peptides were pulsed at different concentrations onto autologous LCL 
and evaluated for the ability to stimulate the clone TB515.
The best stimulation was achieved by Peptide 2, i.e. PYYFAAELPPRNLPEP (mutation in 
bold), PTPR-K/m667-682, that showed a dose response curve (Figure 7.9) and, in addition, 
induced IFN-y release at a concentration of only 10 nM. As all the 4 tested peptides were 
well recognised, no conclusion could be made regarding the precise peptide COOH and 
NH2 ends. However, peptides overlap with an 11-mer core sequence, located between the 
second Y669 (position 669) at the NH2 end and the L679 at the COOH end, which contains 
the G->R point mutation at amino acid 677. Thus, these results indicated that the epitope 
of the PTPR-K/m gene should be located within this core sequence. Moreover, the 
significance of the point mutation (residue R) in immune induction was clearly 
demonstrated in a pulsing experiment where Peptide 5, corresponding to the wild type 
sequence, was unable to stimulate IFN-y release form clone TB515 (Figure 7.10A), while 
Peptide 2, carrying the mutation, induced a strong T cell recognition.
Peptide 2 was used as a model sequence also in the assessment of the putative binding 
anchors for the NH2 and COOH ends. First, the crucial role of the ¥ 5 0 9  as a residue for the 
NH2 end of the peptide was demonstrated by the abolished capability of modified peptides 
to induce IFN-y release (Figure 7.1 OB). More precisely. Peptide 6, ending at the F residue 
and Peptide 7, having the ¥ 5 6 9  substituted with a neutral G, were not recognised by TB515 
when pulsed onto LCL cells. Second, a marked impairment in the stimulatory capacity was 
observed when the L was removed from the COOH end, as observed after pulsing with 
Peptide 9 (Figure 7.IOC). Removal of the Nô78 residue also abrogated the recognition. 
Taken together, these results indicate that the minimal PTPR-K/m epitope is represented by
Î8 Ï












Peptide 1 : YFAAELPPRNU
Peptide 2: PY YFAAELPPRNU
Peptide 3 : GAPY YFAAELPPRNL 





FIGURE 7.9: The definition of the immunogenic core region of the PTPR-K/m gene. Autologous 
LCL 15392 cells (5000 cells/well) were pulsed with increasing concentrations of overlapping 16-mer 
peptides for 2h and then incubated overnight with 1x1 O'* cells/well of the CD4+ clone TB515. The 
supernatants were evaluated for their IFN-y content by ELISA. Boxed amino acids indicate the herein 
defined core sequence. Data are representative of the mean ± S.D. of 3 individual experiments performed 
in duplicates.
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the TB515 clone corresponds to 11-mer core sequence YFAAELPPRNL669-679, while 
Peptide 2 constitutes the best recognised epitope. Finally, given the previously observed 
polyclonal T cell response against Clone #11 (Figure 7.6) and minigenes M l and M2 
(Figure 7.7), experiments were set up in order to estimate the individual responses of the T 
cell clones TB515, TB39 and TB48 against the mutated (Peptide 2) and wild type (Peptide 
5) peptides. All three clones showed a specific recognition of Peptide 2, with clones TB39 
and TB48 showing similar response curves (Figure 7.11).
7.4 D is c u s s io n
Ptl5392 showed a favourable clinical course and was therefore selected and assessed for 
the presence of an anti-tumour immune response at a cellular (as described in Chapter 3 
and 4) and molecular level (described in this chapter).
7.4.1 Characteristics of the PTPR-ic/m gene
The subcloning of the positive pool defined in Chapter 6 led to the identification of a 
immunogenic cDNA insert of 667 bp (Clone #11). The insert of Clone #11 was 99% 
identical to the human PTPR-k  gene and corresponded to a region located between amino 
acid 622 to 844 of the membrane spanning region with a G (Gly) to R (Arg) point mutation 
at position 677, i.e. in the extra-cellular part of the protein (Figure 7.4). These data 
demonstrate the identification of PTPR-K/m as a novel TAA, though sequence and protein 
structure of the wild type protein were already known (Yang et a l,  1997).
The PTPR-k  gene encodes an open reading firame of 4322 bp, which becomes translated 
into a mature protein of 1440 amino acids. This protein is expressed in several normal 
tissues such as brain, thymus, testis, colon, liver, pancreas, stomach, kidney, and placenta 
and also in mammary carcinoma (Yang et a l, 1997). The PTPR-k  belongs to the
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large enzyme family of protein tyrosine phosphatases (PTPases). This protein family can 
be ftirther subdivided into receptor like or non-receptor like PTPases. The PTPR-k  gene 
relates to the former group together with four other sub-members: PTPR-p,-p, -X and -n 
(Cheng et al., 1997; Crossland et al., 1996; McAndrew et aL, 1998).
The PTPR-k protein is composed of an extracellular portion (753 amino acids), a 
transmembrane domain (22 amino acids) and a cytoplastic region (665 amino acids) (Yang 
et a l, 1997), as illustrated in Figure 7.4. The cytoplasmatic portion of PTPR-k gene, with 
two protein tyrosine phosphatase domains arranged in tandem, is classic for members of 
the PTPases and defines P T P R - g e n e  as a member of this group (Sap et a l, 1994; 
Zhang et a l, 1998). Moreover, the PTPR-k  gene share structural similarities with cell 
adhesion molecules, owing to the presence of an extracellular region encoding an Ig-like 
domain, a meprin-A5 antigen-PTP p (MAM) domain and four fibronectin type III repeats 
(Figure 7.4).
7.4.2 No need for the invariant chain
The fusion of the li to selected gene sequences is a molecular way to assure a specific 
delivery of library inserts to endocytic compartments. However, it does not address the 
question of whether the guidance by the li is required also for T cell recognition in the 
physiological context. My experiments show that transfection of the cDNA #11 without li, 
resulted in a CD4+ T cell recognition comparable to that induced when delivered as a 
fusion protein. Thus, in this applied system the identified protein, although endogenously 
produced, is per se able to gain access to HLA-class II processing compartments (Figure 
7.5).
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However, in contrast to the results presented herein, it has recently been documented that 
the li is a molecular prerequisite for recognition of HLA class II restricted antigens, as 
reported for the fusion protein BCR-ABL b2a2 (ten Bosch et a l, 1999). This recombinant 
protein was immunogenic only in combination with the li. However, the mechanism of 
action of li in determining the immunogenic potential of endogenous protein mainly relies 
on its ability to guide protein to distinct cellular compartments where they would otherwise 
not be present. Data supporting this conclusion have been provided in the case of the CDC- 
27 antigen (Wang et a l, 1999a).
The reasons for these opposing requirements for the li are not known. However, the 
observation that the CD4+ T cell recognition of the PTPR-K/m epitope is independent from 
the li guidance opens several questions about antigen processing and presentation. One 
enigma is where the loading of the PTPR-K/m epitope takes place in the recipient cells; the 
engineered 293 cells should be considered a closed cellular system with an optimal 
expression of both the internal and supplied genes involved in the class II HLA machinery, 
due to the up regulatory capacity of CIITA (Chang and Flavell, 1995). In the absence of 
the supplied li, the 293 cells will continue to express their internal li, while the synthesised 
PTPR-K/m antigen will not be artificially chaperoned into the endocytic peptide loading 
compartments. Instead the PTPR-K/m protein is forced to enter the endocytic route from a 
cytoplasmic location which involves entrance into the endoplasmatic reticulum, transfer to 
the Golgi network and endosome transport to the cell surface.
One alternative for this would be that the PTPR-K/m protein follows the same pathways as 
cytoplasmatic proteins which take advantage from sorting sequences for entrance into 
endocytic trafficking. For example, the Tyr-Gln-Thr-Ile signal in the cytoplasmic tail of the 
lysosomal protein LAMP-1, enabled expression of a chimeric gene guiding the E7 model
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TAA of the human papilloma virus to the endosomal/lysosomal compartments (Wu et a l, 
1995). Likewise, a di-leucin motif contained in the melanosomal transport signal (MTS) 
has been reported to assist TAAs like tyrosinase, gplOO and Trp-2 to this route (Wang et 
a l, 1999c). However, as the PTPR-K/m protein lacks such known signal sequences this 
scenario should not be possible in this instance.
A second alternative would be that the cytosolic PTPR-K/m protein uses the li independent 
pathway for HLA class II antigen processing; i.e. recycling of membrane receptors 
(reviewed in (Geuze, 1998; Hiltbold et a l, 1998)) and HLA-DR molecules (Pinet et a l, 
1995; Pinet and Long, 1998). This endogenic route is probably applied by another defined 
TAA: the EhA3 membrane receptor (Chiari et a l, 2000). It is thus possible that the PTPR- 
K/m receptor become recycled to endosomal/lysosomal system directly firom the membrane 
and then re-routed as an antigenic peptide cargo loaded onto HLA molecules guided by a 
leucin motif in their p-chain (Pinet et a l, 1995).
In addition, indications of a third alternative pathway comes fi'om studies with immature 
DCs which demonstrate that extracellular peptide loading may occur (Santambrogio et a l, 
1999a; Santambrogio et a l, 1999b) and that the li maybe dispensable for MHC expression 
(Villadangos et a l, 2001). Collectively, these findings may argue for proteolysis of the 
PTPR-K/m receptor in an extracellular milieu with loading to empty HLA class II 
molecules for recycling (Santambrogio et a l, 1999b).
It is known that endogenous proteins can enter to the HLA class II pathway (Sanderson et 
a l, 1995), but a dichotomy for intracellular trafficking has been described for HLA-DR 
restricted CD4+ T cell epitopes. Indeed, MAGE-3, an antigen of cytosolic origin, encodes 
epitopes which either can reach the cell surface (Manici et a l, 1999; Schultz et a l,  2000)
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or not (Chaux et a l, 1999b). Taken together, these findings reveal the complexity of the 
intracellular trafficking pathways for class II HLA restricted antigens (reviewed in 
(Robinson and Delvig, 2002)). Thus, the loading compartment for CD4+ T cell antigens 
which, like PTPR-K/m, are independent firom chaperon help of the li, remains to be 
defined. However, such “li independent epitopes” may be important for inducing CD4+ T 
cell responses against tumours in physiological situations, e.g. when as tumour cells cannot 
fimction as professional APCs and therefore, may have inadequate HLA class II 
machinery.
7.4.3 The definition of the epitope
The HLA-DR locus has been frequently described as a restriction element for CD4+ T cell 
defined TAAs, but PTPR-ic/m is the first antigen with an epitope restricted to the HLA- 
DRpi* 10011, as this allele has not previously been reported as an restriction element for 
tumour antigens. The results of the library screening (Chapter 6) anticipated the presence 
of such a novel antigenic epitope restricted by the HLA-DRP 1*10011 allele. The results 
presented herein describe the PYYFAAELPPRNLPEP, PTPR-K/m667-682, as the 
immunogenic epitope of the PTPR-K/m gene. Substitution of the mutated base (R) 
completely abrogated the T cell recognition (Figure 7.10A) and underscored the essential 
role for the G-> A point mutation in providing immune recognition.
Moreover, HLA-DRp 1*10011 is an allele with an unknown distribution (reported at 
http//:www.ashi.hla.org under Resources/allele frequencies) and although the development 
of new assay systems has facilitated the definition of binding motifs for HLA class II 
molecules (Southwood et a l, 1998), no definitive binding anchors have yet been defined 
for HLA-DRp 1*10011. However, another study proposed the presence of a Y residue as a 
putative binding anchor in position 2 or 3 of the HLA-DRpi*10011 allele (Hickling et a l,
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1990). These data are in accordance with the observation that further truncation of our 
PTPR-K/m peptide YFAAELPPRNL defined core sequence, results in loss of recognition. 
This implied that the Ygeg at the NH2 end and the L679 at the COOH end may represent 
amino acids residues with putative binding anchors for the interaction between this peptide 
and the TCR.
The position of the mutated amino acid is located in the extracellular region between the 
IV fibronectin III domain and the transmembrane region (Figure 7.4); fiiture work should 
be aimed at exploring whether this mutation may affect the function of the PTPR-k 
protein.
7.4.4 Conclusions
Upon screening of an li-cDNA fusion library, constructed firom RNA purified fi'om a 
metastatic melanoma, we succeeded in identifying PTPR-K/m as a novel TAA. The results 
presented in this chapter show the crucial role of the point mutation for the recognition of 
autologous anti-tumour specific CD4+ T cells.
Taken together these data allow us to add the PTPR-K/m gene to the increasingly growing 
list of identified TAAs recognised by T cells. The point mutation makes PTPR-k a unique 
antigen, probably with a high immunogenicity. In fact a strong polyclonal CD4+ anti­
tumour response could be detected in vitro against the PTPR-K/m667-682 epitope. This has 
probably contributed to the favourable clinical course of the melanoma patient whose 
tumour bears this particular mutation. Whether the mutation, in addition to determining the 
immunogenicity of this protein, is also affecting its physiological functions remain to be 
determined.
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Chapter 8
DISCUSSION AND FUTURE PERSPECTIVES
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8.1 D isc u ssio n
8.1.1 Background
Cutaneous malignant melanoma is a neoplasm of multi-genetic origin, whose progression 
to an aggressive phenotype involves a step-wise accumulation of mutations in genes 
critical for cell proliferation, differentiation and death. Although a genetic model for 
melanoma transformation does not exist, several genes have been characterised that confer 
susceptibility to melanoma. For example cyclin-dependent kinase 4 {CDK4) is a gene 
involved in regulation of the cell cycle progression, while the melancortin- 1  receptor 
{MCIR) conférés susceptibility, and p53 and N-ras are connected to defects in cell 
signalling (reviewed in (Castellano and Parmiani, 1999)). Other genes that activate 
transforming activity of melanom are the apoptotic protease activating factor - 1 (APAF-1) 
(Soengas et a l, 2001), BRAF (Davies et a l, 2002) and WNT5A (Weeraratna et a l,  2002). 
Of note the observation that BRAF appears to be mutated in approximately 60% of 
melanomas.
It is also known that melanoma expresses genes that encode antigens that can be 
recognised by T cells and activate the immune system against the tumour (reviewed in 
(Renkvist et a l, 2001; Van den Eynde and Van der Bruggen, 2001)). The molecular 
identification of such T cell-defined TAAs has opened new avenues for an immunological 
based treatment of cancer patients. However, vaccination strategies that use antigenic 
peptides have met with limited success, with only 10-30% of patients demonstrating 
tumour regression (reviewed in (Parmiani et a l, 2002a)). This may be due to the many 
mechanisms of tumour escape (reviewed in (Perez-Diez and Marincola, 2002)), suboptimal 
activation of the immune system (Gervois et a l, 1996), low peptide affinity, T cell 
unresponsiveness or to TCR signal impairment (reviewed in (Whiteside, 1999)).
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Nevertheless, the few patients achieving clinical response demonstrate that (i) it is possible 
to break self tolerance against TAAs deriving from normal proteins, (ii) tumour cells can 
be immunogenic in vivo and (iii) under certain conditions such immune response translates 
into clinically effective tumour rejection. However, the knowledge of the precise 
mechanisms mediating tumour eradication is still inadequate. Therefore, immunological 
monitoring in those patients responding to treatments or spontaneously experiencing 
tumour regression may be crucial for dissecting the in vivo immunological mechanisms 
potentially leading to clinical responses (review (Parmiani et a l, 2002a)).
8.1.2 Choice of patient
The overall study of this thesis has been focused on the functional characterisation of the 
antigen-specific response that may have accompanied the positive clinical evolution 
observed in a patient (Ptl5392) who is still disease-free 12 years after surgical resection of 
a lymph node metastatic melanoma.
This patient was selected for several reasons. First, she showed a long disease-free period 
without therapeutic interventions except the early lymph node resection. Thus, patients 
with a favourable clinical evolution might represent examples of activation and 
maintenance of strong anti-tumour responses. Secondly, Ptl5392 displayed a T cell 
mediated immunity directed against class I HLA-restricted epitopes derived from the TRP- 
2 and gplOO proteins (Castelli et a l, 1999). Therefore, it was interesting to explore 
whether (i) this CD8 + T cell-mediated response was also associated to the presence a 
CD4+ T cell response and (ii) such a CD4+ T cell response could be directly involved in 
the establishment of an anti-tumour systemic immunity, eventually (Castelli et a l,  1999) 
contributing the positive clinical evolution of the disease. Thirdly, initial characterisation 
of various CD4+ T cell clones suggested that, beside gplOO and TRP-2, additional tumour-
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associated proteins could have been immunogenic in this patient. The molecular definition 
of such immunogenic determinants could represent an initial step in clarifying the 
immunological mechanisms eventually involved in the favourable clinical evolution 
experienced by Ptl5392.
8.1.3 Identification of a CD4+ T cell epitope
Several data indicate a pivotal role of CD4+ T cells in anti-tumour responses (Toes et a l, 
1999) and reviewed in (Pardoll and Topalian, 1998; Wang, 2001). However, the diverse 
molecular requirements for the generation of peptides presented by class II HLA have 
hampered the identification of CD4+ T cell epitopes. Recently, an implementation of the 
molecular approach used for the identification of class I HLA-restricted TAAs has been 
modified and adapted to identify HLA-class II presented epitopes (Wang et a l, 1999a). 
The use of a similar method included the construction of a chimeric Ii - cDNA library in 
which tumour-derived cDNAs were fused to the first 80 amino acids of the Ii forcing the 
presentation of the encoded protein into the HLA-class II processing pathways. I used this 
method for antigen screening that resulted in the molecular identification of the TAA 
expressed by Mel 5392 and recognised by autologous HLA-DR-restricted T cell clones. A 
mutated form of the PTPR-k was identified as a melanoma-specific antigen. In fact, the 
cDNA cloned firom Mel 5392 cells was homologous to the PTPR-k sequence (Accession 
number NM-002844.2) with the exception of a g->a point mutation at nucleotide position 
2249. This mutation led to an amino acid change in the PTPR-k protein and the mutated 
nucleotide changed a neutral glycin (G) to a positively charged arginine (R). The PTPR-k 
mutated gene was shown to be responsible for the generation of an immunogenic epitope 
classifying this protein as a novel TAA.
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The mutation in PTPR-k /m gene generated an antigenic epitope presented by the HLA- 
DRpi*10011 allele to the CD4+ T cells clones isolated from tumour infiltrated lymph 
nodes. The best recognised peptide corresponded to the PTPR-K/m667-682 epitope, 
PYYFAAELPPRNLPEP (mutation in bold), as T cell recognition was lost or strongly 
impaired by further delimitation of the NH2 or COOH ends. The mutated R is crucial in 
determining the immunogenicity of the peptide since the corresponding wild type peptide 
did not stimulate any of the CD4+ T cells evaluated in this thesis.
8.1.4 The role of the mutation in the transformation process
The main DNA damage linked to carcinogenesis of the skin occurs in cyclobutan 
pyrimidines (Bykov et a l, 1999) and is caused by ultraviolet radiation (UVR), known to be 
a high risk factor for melanoma. As the point mutation in the PTPR-ic/m gene occurred in 
the guanine base, a pyrimidine, it may be possible that this mutation had a role in the 
transformation process, though recent data demonstrated that the repair kinetics of UVR 
induced DNA lesions in patients with cutaneous melanoma was not reduced compared to 
healthy controls (Xu et a l, 2000).
8.1.5 CD4+ T cell defined antigens belong to the category of unique tumour antigens
Among the four defined groups of TAAs (reviewed in (Renkvist et a l, 2001; Van den 
Eynde and Van der Bruggen, 2001)) (shared , differentiation, widely expressed and unique 
antigens), the presence of a mutation crucial for T cell recognition qualifies PTPR-ic/m as a 
melanoma-specific unique TAA. Although several unique antigens have been described for 
cytotoxic T cells, hitherto only three of them, CDC27 (Wang et a l, 1999a) and TPI/m 
(Pieper et a l, 1999) from melanoma, and HPV-E7 (Hohn et a l, 1999) from cervic 
carcinoma, have been derived from mutated proteins recognised by CD4+ T cells.
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Unfortunately, given the present technology, unique TAAs are not suitable for large scale 
vaccination programs, because their expression is restricted by and large to individual 
patients. However, in mouse models, unique antigens have been shown to be more 
immunogenic than shared antigens (Dudley and Roopenian, 1996) and shown to function 
as tumour-rejection antigens (Prehn and Main, 1957).
Nevertheless, PTPR-ic/m extends the group of class II HLA-restricted unique TAAs and 
though not promising for vaccine development and clinical approaches in other subjects, 
its nature as a protein tyrosine phosphatase may contribute to increase our knowledge of 
tumour biology. Indeed, in addition to their structural diversity, the complexity of PTPases, 
as cellular enzymes, as membrane receptors and regulators of kinases, indicate the PTPR- 
K/m as an interesting antigen for biological studies.
8.1.6 PTPR-K/m: association with tumour suppression
The PTPases include several structural groups. The PTPR-k protein belongs to a receptor­
like group, which has a domain topology composed of one meprin/A5/p antigen (MAM) 
domain, one Ig-like domain and four fibronectin III repeats in the extracellular region and 
a cytoplasmic region encoding two tandemly repeated tyrosine phosphatase domains 
(reviewed in (Brady-Kalnay and Tonks, 1995; Hickling et a l, 1990; Li and Dixon, 2000)). 
Moreover, while the functions of most TAAs are unknown, PTPR-K/m belongs to a large 
family of PTPase associated with signal transduction, cell adhesion and neoplastic 
transformation (reviewed in (Fischer et a l, 1991)). Although the knowledge about PTPases 
is limited (reviewed in (Petrone and Sap, 2000)), several findings suggest a role for PTPR- 
K/m as a potential tumour suppressor gene.
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Firstly, a 20% down regulation of the PTPR-k and PTPR-tc phosphatase submembers has 
been observed in primary and metastatic melanoma cell lines (McArdle et a l, 2001), an 
observation compatible with a role for PTPR-k in tumour suppression. Secondly, the 
PTPR-k gene has been physically mapped to a putative tumour suppressor region, 6q22.2- 
22.3 (Zhang et a l, 1998). Thirdly, as a membrane receptor protein with tyrosinase 
phosphatase activity, PTPR-k has been implied in signalling (reviewed in (Zondag and 
Moolenaar, 1997)). Fourthly, the PTPR-k protein has a complex structure with several 
extracellular domains (Figure 7.4 and 8.1) of which particularly the meprin/A5/p (MAM) 
domain has been associated with cell-cell interactions (Sap et a l,  1994; Zondag et a l, 
1995). Moreover, it has been shown that PTPR-k is dependent on cell density and that it 
becomes upregulated by signals induced by cell-cell interaction (Fuchs et a l, 1996). Since 
loss of cellular connections via cell adhesion is a typical feature contributing to neoplastic 
phenotype (reviewed in (Johnson, 1999; Ruoslahti, 1996)), these data strongly associate 
PTPR-K/m with tumourigenesis.
Another special feature of PTPR-k is represented by post-transcriptional modification 
(Jiang et a l, 1993). More precisely, a furin-like endoprotease cleaves a signal sequence 
located between amino acid 640-643 in the fourth fibronectin type III domain, after which 
the halves of the domain become non-covalently connected (Figure 8.1). The protein then 
appears as an interrupted structure on the cell surface. This extracellular region of PTPR-k 
has a pronounced role in homophilic cell-cell interaction, i.e. interaction between the same 
type of surface molecules on two opposing cell membranes (Sap et a l, 1994; Zondag et 
a l, 1995).
Taken together, these data point towards a role of the PTPR-K/m protein as a possible 
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(mutations) of this gene may have a role in neoplastic transformation. In fact, the mutation 
could hinder the negative regulatory role of this tyrosine phosphatase and, therefore, 
contribute to malignant transformation by placing a cellular oncogene, target for the 
negative regulation by PTPR-K/m, under a constant activation state.
Thus, the results presented in this thesis may contribute also to a new view of the PTPR- 
K protein (Figure 8.2). In fact, previously, PTPR-K/m was known as a membrane receptor 
( 1), whose dimerization via homophilic interactions induced downstream signalling events 
(reviewed in (Zondag and Moolenaar, 1997)) possibly linked to malignant transformation 
(Sap et a l, 1994) (2). My data described herein depict PTPR-K/m as a novel tumour 
specific antigen (3). However, few examples exist of TAAs being directly involved in 
neoplastic transformation and progression, and the T cell epitopes derived firom murine 
oncogenic proteins such as p53 (Noguchi et a l, 1994) and ras (Abrams et a l,  1996; Peace 
et a l, 1994; Skipper and Stauss, 1993) bave been defined by reverse immunology 
approaches. Mutated fibronectin is the only TAA, identified by using a genetic approach 
and recognized by TILs, for which the point mutation generating the immunogenic peptide 
was also proved to be associated with the malignant phenotype (Wang et a l,  2002). In fact, 
the mutation described by Wang and co-workers (Wang et a l, 2002) was shown to directly 
interfere with the formation of extracellular matrix and disrupt cellular connections. There 
is no such evidence for the mutation in PTPR-k, but it is nevertheless intriguing that such 
mutation occurred in a protein with phosphatase activity and with defined roles in 
important cellular processes like signalling and cell cycle regulation.
PTPR-K/m is the first phosphatase described as a TAA, although previous publications 
have reported mutated epitopes deriving from proteins with kinase activity (Chiari et a l, 
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having a role in dephosphorylation and phosporylation of proteins and involved in the 
regulation and balance of internal cellular events, as potential targets for an immune- 
mediated recognition and as source of unique as well as shared TAAs. This set of proteins 
may therefore constitute an unexplored reservoir for novel undefined tumour-specific 
antigens.
8.1.7 Immunogenicity of unique tumour-antigen
PTPR-K/m has been identified as a unique TAA in a melanoma patient who is still disease 
free 1 2  years after surgery that removed a lymph node metastasis and was not followed by 
therapeutic interventions. Given that also other unique TAAs, like CDK-4 (Wolfel et a l, 
1995), MUM-1 (Coulie et a l, 1995), MUM-2 (Chiari et a l, 1999) and MUM-3 (Baurain et 
a l,  2 0 0 0 ), have been identified in long term surviving melanoma patients, it is possible 
that immune responses against mutated TAAs are strong enough to eliminate or to keep at 
bay tumour cells (reviewed in (Parmiani et a l, 2002b)) (Table 8.1). Therefore, such TAAs 
may constitute the best TAAs for therapeutic interventions despite their restriction to 
individual patients (reviewed in (Gilboa, 1999a)). Indeed, although never observed for CT 
antigens, spontaneous regression for melanoma has been reported as determined by T cell 
reaction against a TAA encoded by a mutated myosin gene (Zorn and Hercend, 1999b). 
Thus, PTPR-K/m may represent a TAA with a strong immunogenic potential associated 
with its point mutation.
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Table 8.1. TAAs with a putative role in neoplastic transformation. Possible strategies for tumour cells to 
take command of the cellular regulation and facilitate neoplastic transformation. EMC = extracellular matrix.
ANTIGEN IMPLIED FUNCTION REFERENCE
SART-2 Signal transduction of 
cellular proliferation
Nakao et al., 2000
CDK4/m Cell cycle regulation Wolfel era/., 1995
Hsp70-2M Cell cycle regulation Gaudine^a/., 1999
^^P-catenin Cell adhesion Robbins et al., 1996
CASP- 8 Apoptosis signalling pathways Mandruzzato et al., 1997
^^Fibronectin ECM formation Wang et al., 2002
Lck Anchorage independent growth Harashima et al., 2001
^PTPR-K/m Tumour suppression, 
cell-cell adhesion
Novellino et al. 2002 
(submitted)
1) Also implied in cell-cell contact.
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8.1.8 CD4*f T cell response in Ptl5392
Indeed PTPR-K/m was able to induce in Pt15392 a strong immune response in the 
surgically removed, infiltrated lymph node. In fact, several CD4+ T cell clones obtained 
from such lymph nodes were found to be reactive against the autologous melanoma and 
recognised the PTPR-K/m peptide.
The T cell mediated anti-tumour response occurring in the tumour-infiltrated lymph nodes 
of this patient was analysed at clonal level and CD4+ T cell clones were established from 
metastatic lymph nodes and then characterized in vitro for their functional activities.
The cloning procedure of the established TALs resulted in the isolation of several CD4+ T 
cell clones that have been assigned to 5 different groups on the basis of composition of 
their TCR. Library screening led to the identification of the PTPR-K/m667-682 as the epitope 
for the CD4+ T cells of three of these groups. Interestingly, a predominant expression of 
TCRVA3, TCRVA13 and TCRVB21 was observed in the clones recognizing the PTPR- 
K/m667-682 cpitope. Unfortunately, T cells belonging to the two other groups were not 
available for the final epitope screening, but the composition of their TCR, also including 
TCRVB21 or TCRAV13, strongly suggests that they too were directed against this same 
epitope.
All the CD4+ T cell clones demonstrated the characteristics of full T cell activation; i.e. 
IL-2 secretion, antigen specific proliferation (data not shown) and lysis of the antigen 
positive tumour cells. Sensitization of these clones with the PYYFAAELPPRNLPEP 
peptide at a concentration as low as 10 nM demonstrated a T cell activation fulfilling all 
the above parameters. The half maximum release of IFN-y was achieved at approximately 
100 nM, suggesting that these CD4+ clones expressed TCRs with a high affinity/avidity
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against this epitope. As shown for class I HLA-restricted epitopes (Loftus et a l, 1998), 
mutated peptides may be able to induce T cells that, bearing high affinity TCRs, are more 
efficient in the recognition of their nominal MHC/peptide complexes expressed at the cell 
surface of tumour cells.
Cytokines released from activated CD4+ T cells help to shape the direction of an immune 
response. Therefore, attention was focused on the estimation of the exact cytokine profile 
of the CD4+ T cell clones shown to participate in the response to the autologous tumour. 
Remarkably, an atypical cytokine pattern was observed, since the anti-melanoma CD4+ T 
cell response directed against the unique PTPR-K/m antigen had been accompanied by a 
Thl dominating, but high IL-10 releasing cytokine profile. This finding is compatible with 
recent reports which suggest a less dogmatic view of the Thl/Th2 fimction and define an 
important role for CD4+ T cells with new cytokine profiles in tumour responses (Brady et 
a l, 2000; Segal et a l,  2002; Shimizu et a l, 1999).
However, the possible contribution of this previously un-described cytokine profile to the 
favourable clinical outcome in Pt5392 remains elusive. Though IL-10 is known to be 
immunosuppressive (as reviewed in (Wakkach et a l, 2000)), these ILlO-secreting CD4+ T 
cells did not display inhibitory effects on the in vitro generation of an anti-tumour T cell 
mediated response in Ptl5392. Moreover, the findings reported in this thesis are also 
consistent with previous data showing that IL-10 may have a stimulatory activity on CD8 + 
T cells that are already tumour-specific (Fujii et a l, 2001). CD4+ T cells releasing IL-10 at 
tumour site may therefore serve to potentiate a local CD8 + mediated response and be 
directly involved in anti-tumour protection (Segal et a l, 2002).
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8.1.9 Conclusions
The functional evaluation of anti-tumour immunity in P t15392 has demonstrated the 
simultaneous presence of tumour-specific classes I and II HLA-restricted T cells directed 
against different TAA determinants derived from gplOO, TRP-2 and mutated PTPR-k 
protein. It is not clear whether these responses have been activated simultaneously and may 
have had a synergistic effect on each other. Future studies need to be performed to answer 
the question as to whether the CD4+ T cell repertoire may have been involved in 
orchestrating the previously described CD8 + T cell mediated systemic immune response 
(Castelli et a l, 1999).
Moreover, the results presented herein suggest that both CD8 + and CD4+ immune 
responses have contributed to the favourable clinical outcome in Ptl5392. Taking 
advantage of the availability of the immunogenic epitope defined in the present thesis and 
of the ELISPOT technique, further immunological monitoring aimed at evaluating the 
systemic immunity during the subsequent follow up period of Ptl5392 will be possible.
The functional characterisation of the T cell response in Ptl5392 has contributed to a better 
understanding of a positive immune response, indicating a possible co-operating CD8 + and 
CD4+ T cell activity. The current knowledge about CD4+ T cell responses is limited and 
together with the data presented herein, additional studies of other patients with favourable 
outcomes may contribute to an increased knowledge about the role of CD4+ T cells in 
cancer control and allow the application of new strategies for immunotherapy.
In conclusion, the results presented in this thesis demonstrate that CD4+ T cell defined 
TAAs can be cloned by a novel molecular method and provide evidence for the presence 
of tumour reactive CD8 + and CD4+ T cells derived from the metastatic lymph node of a 
melanoma patient with a positive clinical evolution after therapeutic interventions. This
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response was accompanied by an unknown cytokine profile whose role in the tumour 
regression is elusive. Moreover, the data suggest that protein tyrosine phosphatases may 
constitute a novel group of proteins whose mutation can result in T cell targets. Therefore, 
a continuous endeavour should be done to identify class II HLA restricted TAAs and 
characterise CD4+ T cell mediated anti-tumour responses, as such data may provide new 
insights on in vivo T cell/tumour cell interactions situation of cancer patients and hopefully 
result in new therapeutic strategies.
8.2 Fu t u r e  pla n s
The identification of PTPR-K/m as a TAA opened several questions regarding its nature 
and possible roles in the anti-tumour response in Ptl5392. The sections below outline 
future experiments that may be designed to address these issues.
8.2.1 Definition of the shortest epitope/binding motifs for the COOH end
The putative binding anchors at the carboxyl end of the PTPR-K/m epitope have only been 
partially defined. In order to more closely characterise the involvement of the N 6?8 and Lô79 
in the binding between the TCR and the peptide, peptides should be designed where these 
positions have been replaced with glycine.
8.2.2 Tissue expression of PTPR-K/m
Although defined as a somatic point mutation and, therefore, considered to be restricted to 
the melanoma cells of Ptl5392, the presence of the PTPR-K/m gene in additional 
melanoma samples should be evaluated in order to exclude a wider tumour distribution and 
role of this particular mutation.
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8.2.3 Cloning of the full length PTPR-K/m gene
The insert of Clone #11, i.e. cDNA #11, corresponded to a 667 bp long region of the 4322 
base pair full length PTPR-k  gene (Yang et a l, 1997). Therefore, to analyse if the PTPR- 
K/m gene may have a truncated expression in tumour cells and if  this may be relevant to a 
malignant phenotype, the cloning of the full length PTPR-K/m gene could be performed. 
PCR using genomic DNA extracted from frozen tumour samples will confirm the presence 
of the identified mutation in vivo.
8.2.4 Analysis of the in vivo expressed PTPR-k protein
As revealed by sequence analysis, the PTPR-K/m protein may be translated from either or 
both of two internal ATG codons. Thus, to assess whether both or only one o f these 
proteins (791 or 778 amino acids respectively) are expressed in vivo. Western blot can be 
performed providing specific antibodies are available that can distinguish between the two 
proteins.
8.2.5 Potential transformation activity
One additional point that remains to be elucidated is the role, if  any, of the mutation in 
modifying the physiological functions of PTPR-k. In particular the question of whether the 
mutated gene has acquired transformation capacities still reamins to be addressed. 
Transfection experiments performed in NH3T3 fibroblasts using the mutated and the wild 
type gene will represent initial steps for clarifying this issue.
8.2.6 Systemic immune response directed against PTPR-K/m
The specific T cell response directed against the PTPR-K/m was detected in the tumour 
infiltrated lymph nodes. Whether the PTPR-K/m was also able to induce a systemic 
response remains to be addressed. To this purpose, the specific response directed against
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the mutated or non mutated peptide will be evaluated by ELISPOT in the PBMCs of 
Ptl5392 obtained during the follow up period.
208
B ib lio g r a ph y
9  BIBLIOGRAPHY
Aamoudse, C. A., van den Doel, P. B., Heemskerk, B., and Schrier, P. I. 
(1999). Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, 
an unexpected translation product of LAGE-1. I n t J  C a n c e r  82: 442-8.
Abrams, S. I., Stanziale, S. F., Lunin, S. D., Zaremba, S., and Schlom, J.
(1996). Identification of overlapping epitopes in mutant ras oncogene peptides 
that activate CD4+ and CD8+ T cell responses. E u r J I m m u n o l  26: 435-43.
Adris, S., Klein, S., Jasnis, M., Chuluyan, E., Ledda, M., Bravo, A., Carbone, 
C., Chemajovsky, Y., and Podhajcer, O. (1999). IL-10 expression by CT26 
colon carcinoma cells inhibits their malignant phenotype and induces a T cell- 
mediated tumor rejection in the context of a systemic Th2 response. G e n e  
T h e r 6 :  1705-12.
Albert, M. L., Sauter, B., and Bhardwaj, N. (1998). Dendritic cells acquire 
antigen from apoptotic cells and induce class I-restricted CTLs. N a t u r e  392: 
86-9.
Andersson, G. (1998). Evolution of the human HLA-DR region. F r o n t  B i o s c i  
3: D739-45.
Anichini, A., Maccalli, C., Mortarini, R., Salvi, S., Mazzocchi, A., Squarcina, 
P., Herlyn, M., and Parmiani, G. (1993). Melanoma cells and normal 
melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell 
clones from melanoma patients. J  E x p  M e d  177: 989-98.
Anichini, A., Molla, A., Mortarini, R., Tragni, G., Bersani, L, Di Nicola, M., 
Gianni, A. M., Pilotti, S., Dunbar, R., Cerundolo, V., and Parmiani, G. 
(1999). An expanded peripheral T cell population to a cytotoxic T lymphocyte 
(CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients 
impacts on generation of peptide-specific CTLs but does not overcome tumor 
escape fi*om immune surveillance in metastatic lesions. J  E x p  M e d  190: 651- 
67.
Anichini, A., Mortarini, R., Maccalli, C., Squarcina, P., Fleischhauer, K., 
Mascheroni, L., and Parmiani, G. (1996). Cytotoxic T cells directed to tumor 
antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted 
immune repertoire to melanoma. J  I m m u n o l  156: 208-17.
Bakke, O., and Dobberstein, B. (1990). MHC class Il-associated invariant 
chain contains a sorting signal for endosomal compartments. C e l l  63: 707-16.
209
B ib lio g r a ph y
Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. 
A., Adema, G. J., and Figdor, C. G. (1994). Melanocyte lineage-specific 
antigen gplOO is recognized by melanoma-derived tumor-infiltrating 
lymphocytQS. J  E x p  M e d  179: 1005-9.
Balkwill, F., and Mantovani, A. (2001). Inflammation and cancer: back to 
Virchow? L a n c e t  357: 539-45.
Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of 
immunity. N a tu r e  3 9 2 :  245-52.
Barth, R. J., Coppola, M. A., and Green, W. R. (1996). In vivo effects of 
locally secreted IL-10 on the murine antitumor immune response. A n n  S u r g  
O n c o l  3: 381-6.
Basombrio, M. A. (1970). Search for common antigenicities among twenty- 
five sarcomas induced by methylcholanthrene. C a n c e r  R e s  30: 2458-62.
Bastuji-Garin, S., and Diepgen, T. L. (2002). Cutaneous malignant melanoma, 
sun exposure, and sunscreen use: epidemiological evidence. B r  J  D e r m a to l  
146 Suppl 61: 24-30.
Baurain, J. F., Colau, D., van Baren, N., Landry, C., Martelange, V., Vikkula, 
M., Boon, T., and Coulie, P. G. (2000). High frequency of autologous anti­
melanoma CTL directed against an antigen generated by a point mutation in a 
new helicase gene. J  I m m u n o l  164: 6057-66.
Baxevanis, C. N., Voutsas, I. F., Tsitsilonis, O. E., Gritzapis, A. D., 
Sotiriadou, R., and Papamichail, M. (2000). Tumor-specific CD4+ T 
lymphocytes fi*om cancer patients are required for optimal induction of 
cytotoxic T cells against the autologous tumor. J  I m m u n o l  164: 3902-12.
Beatty, G., and Paterson, Y. (2001). IFN-gamma-dependent inhibition o f  
tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor 
responsiveness to IFN-gamma. J  I m m u n o l  166: 2276-82.
Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F., and 
Heath, W. R. (1998). Help for cytotoxic-T-cell responses is mediated by 
CD40 signalling. N a tu r e  393: 478-80.
Bennett, S. R., Carbone, F. R., Karamalis, F., Miller, J. F., and Heath, W. R.
(1997). Induction of a CD8+ cytotoxic T lymphocyte response by cross­
priming requires cognate CD4+ T cell help. J  E x p  M e d  186: 65-70.
Berman, R. M., Suzuki, T., Tahara, H., Robbins, P. D., Narula, S. K., and 
Lotze, M. T. (1996). Systemic administration of cellular IL-10 induces an
210
B ib lio g r a ph y
effective, specific, and long-lived immune response against established 
tumors in mice. J  I m m u n o l  157: 231-8.
Bimboim, H. C., and Doly, J. (1979). A rapid alkaline extraction procedure 
for screening recombinant plasmid DNA. N u c le ic  A c i d s  R e s  7: 1513-23.
Boel, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J. C., Coulie, P., 
Boon, T., and van der Bruggen, P. (1995). BAGE: a new gene encoding an 
antigen recognized on human melanomas by cytolytic T lymphocytes. 
I m m u n i t y  2: 167-75.
Boon, T. (1993). Teaching the immune system to fight cancer. S c i  A m  268: 
82-9.
Boon, T., Szikora, J. P., De Plaen, E., Wolfel, C., and Van Pel, A. (1989). 
Cloning and characterisation of genes coding for tum- transplantation 
antigens. J  A u to im m u n i ty  2  (Supplement): 109-14.
Boon, T., and van der Bruggen, P. (1996). Human tumor antigens recognized 
by T lymphocytes. J  E x p  M e d  183: 725-9.
Brady, M. S., Eckels, D. D., Lee, P., Ree, S. Y., and Lee, J. S. (1999). 
Cytokine production by CD4+ T-cells responding to antigen presentation by 
melanoma cells. M e la n o m a  R e s  9: 173-80.
Brady, M. S., Lee, F., Petrie, H., Eckels, D. D., and Lee, J. S. (2000). CD4(+) 
T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide 
in vitro. C a n c e r  I m m u n o l  I m m u n o th e r  4 S : 621-6.
Brady-Kalnay, S. M., and Tonks, N. K. (1995). Protein tyrosine phosphatases 
as adhesion receptors. C u r r  O p in  C e l l  B i o l  7: 650-7.
Brasseur, F., Rimoldi, D., Lienard, D., Lethe, B., Carrel, S., Arienti, F., Suter, 
L., Vanwijck, R., Bourlond, A., Humblet, Y., and et al. (1995). Expression of 
MAGE genes in primary and metastatic cutaneous melanoma. I n t  J  C a n c e r  
63: 375-80.
Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., 
Coulie, P., and Boon, T. (1993). The tyrosinase gene codes for an antigen 
recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J  
E x p  M e d  178: 489-95.
Brichard, V. G., Herman, J., Van Pel, A., Wildmann, C., Gaugler, B., Wolfel, 
T., Boon, T., and Lethe, B. (1996). A tyrosinase nonapeptide presented by 
HLA-B44 is recognized on a human melanoma by autologous cytolytic T 
lymphocytes. E u r  J  I m m u n o l  26: 224-30.
211
B ib lio g r a ph y
Brosterhus, H., Brings, S., Leyendeckers, H., Manz, R. A., Miltenyi, S., 
Radbruch, A., Assenmacher, M., and Schmitz, J. (1999). Enrichment and 
detection of live antigen-specific CD4(+) and CD8(+) T cells based on 
cytokine secretion. E u r  J  I m m u n o l  29: 4053-9.
Burnet, F. M. (1970). The concept of immunological surveillance. P r o g  E x p  
T u m o r  R e s  13: 1-27.
Bykov, V. J., Sheehan, J. M., Hemminki, K., and Young, A. R. (1999). In situ 
repair of cyclobutane pyrimidine dimers and 6-4 photoproducts in human skin 
exposed to solar simulating radiation. J  I n v e s t  D e r m a to l  112: 326-31.
Carbone, F. R., Kurts, C., Bennett, S. R., Miller, J. F., and Heath, W. R.
(1998). Cross-presentation: a general mechanism for CTL immunity and 
tolerance. I m m u n o l  T o d a y  19: 368-73.
Cartwright, N., Demaine, A., Jahromi, M., Sanders, H., and Kaminski, E. R.
(1999). A study of cytokine protein secretion, frequencies o f cytokine 
expressing cells and IFN-G gene polymorphisms in normal individuals. 
T r a n s p la n ta t io n  68: 1546-52.
Castellano, M., and Parmiani, G. (1999). Genes involved in melanoma: an 
overview of INK4a and other loci. M e la n o m a  R e s  9: 421-32.
Castelli, C., Mazzocchi, A., Rini, F., Tarsini, P., Rivoltini, L., Maio, M., 
Gallino, G., Belli, F., and Parmiani, G. (1998). Immunogenicity of the 
ALLAVGATK (gplOO[ 17-25]) peptide in HLA-A3.1 melanoma patients. E u r  
J  I m m u n o l  2%\ 1143-54.
Castelli, C., Tarsini, P., Mazzocchi, A., Rini, F., Rivoltini, L., Ravagnani, F., 
Gallino, F., Belli, F., and Parmiani, G. (1999). Novel HLA-Cw8-restricted T 
cell epitopes derived from tyrosinase-related protein-2 and gplOO melanoma 
antigens.//mmwwo/162: 1739-48.
Caux, C., Massacrier, C., Vanbervliet, B., Barthélémy, C., Liu, Y. J., and 
Banchereau, J. (1994). Interleukin 10 inhibits T cell alloreaction induced by 
human dendritic cells. I n t  I m m u n o l  6: 1177-85.
Chai, J. G., Bartok, L, Chandler, P., Vendetti, S., Antoniou, A., Dyson, J., and 
Lechler, R. (1999). Anergic T cells act as suppressor cells in vitro and in vivo. 
E u r  J  I m m u n o l  29: 686-92.
Chang, C. H., and Flavell, R. A. (1995). Class II transactivator regulates the 
expression of multiple genes involved in antigen presentation. J  E x p  M e d  181 : 
765-7.
212
B ib lio g r a ph y
Chaux, P., Lethe, B., Van Snick, L, Corthals, J., Schultz, E. S., Cambiaso, C. 
L., Boon, T., and van der Bruggen, P. (2001). A MAGE-1 peptide recognized 
on HLA-DR 15 by CD4(+) T cells. E u r  J  I m m u n o l  3 1 : 1910-6.
Chaux, P., Luiten, R., Demotte, N., Vantomme, V., Stroobant, V., Traversari, 
C., Russo, V., Schultz, E., Cornells, G. R., Boon, T., and van der Bruggen, P. 
(1999a). Identification of five MAGE-A1 epitopes recognized by cytolytic T 
lymphocytes obtained by in vitro stimulation with dendritic cells transduced 
with y i K G E - A \ . J  I m m u n o l  163: 2928-36.
Chaux, P., Vantomme, V., Coulie, P., Boon, T., and van der Bruggen, P.
(1998). Estimation of the frequencies of anti-MAGE-3 cytolytic T- 
lymphocyte precursors in blood from individuals without cancer. I n t  J  C a n c e r  
77: 538-42.
Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, 
R., Eggermont, A. M., Boon, T., and van der Bruggen, P. (1999b). 
Identification of MAGE-3 epitopes presented by HLA-DR molecules to 
CD4(+) T lymphocytes [see comments]. J E x p  M e d  189: 767-78.
Chen, Q., Daniel, V., Maher, D. W., and Hersey, P. (1994a). Production of 
IL-10 by melanoma cells: examination of its role in immunosuppression 
mediated by melanoma. I n t  J  C a n c e r  56: 755-60.
Chen, W. F., and Zlotnik, A. (1991). IL-10: a novel cytotoxic T cell 
differentiation factor. J  I m m u n o l  147: 528-34.
Chen, Y., Kuchroo, V. K., Inobe, J., Hafier, D. A., and Weiner, H. L. (1994b). 
Regulatory T cell clones induced by oral tolerance: suppression of 
autoimmune encephalomyelitis. S c ie n c e  265: 1237-40.
Cheng, J., Wu, K., Armanini, M., O’Rourke, N., Dowbenko, D., and Lasky, L. 
A. (1997). A novel protein-tyrosine phosphatase related to the homotypically 
adhering kappa and mu receptors. J B i o l  C h e m  272: 7264-77.
Cher, D. J., and Mosmann, T. R. (1987). Two types of murine helper T cell 
clone. II. Delayed-type hypersensitivity is mediated by THl clones. J  
I m m u n o l  138: 3688-94.
Chervonsky, A. V., Gordon, L., and Sant, A. J. (1994). A segment of the 
MHC class II beta chain plays a critical role in targeting class II molecules to 
the endocytic pathway. I n t  I m m u n o l  6: 973-82.
Cherwinski, H. M., Schumacher, J. H., Brown, K. D., and Mosmann, T. R. 
(1987). Two types of mouse helper T cell clone. III. Further differences in 
lymphokine synthesis between Thl and Th2 clones revealed by RNA
213
B ib lio g r a ph y
hybridization, functionally monospecific bioassays, and monoclonal 
antibodies. MeJ 166: 1229-44.
Chiari, R., Foury, F., De Plaen, E., Baurain, J. F., Thonnard, J., and Coulie, P. 
G. (1999). Two antigens recognized by autologous cytolytic T lymphocytes 
on a melanoma result fi*om a single point mutation in an essential 
housekeeping gene. C a n c e r  R e s  59: 5785-92.
Chiari, R., Hames, G., Stroobant, V., Texier, C., Maillere, B., Boon, T., and 
Coulie, P. G. (2000). Identification of a tumor-specific shared antigen derived 
from an Eph receptor and presented to CD4 T cells on HLA class II 
molecules. C a n c e r  R e s  60: 4855-63.
Chômez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T., and Lucas, 
S. (2001). An overview of the MAGE gene family with the identification of 
all human members of the family. C a n c e r  R e s  61 : 5544-51.
Conrad, C. T., Ernst, N. R., Dummer, W., Brocker, E. B., and Becker, J. C.
(1999). Differential expression of transforming growth factor beta 1 and 
interleukin 10 in progressing and regressing areas of primary melanoma. J  
E x p  C lin  C a n c e r  R e s  18: 225-32.
Constant, S. L., and Bottomly, K. (1997). Induction of Thl and Th2 CD4+ T 
cell responses: the alternative approaches. A n n u  R e v  I m m u n o l  15: 297-322.
Corinti, S., Albanesi, C., la Sala, A., Pastore, S., and Girolomoni, G. (2001). 
Regulatory activity of autocrine IL-10 on dendritic cell functions. J  I m m u n o l  
166: 4312-8.
Corman, J. M., Sercarz, E. E., and Nanda, N. K. (1998). Recognition of 
prostate-specific antigenic peptide determinants by human CD4 and CD8 T 
cells. C lin  E x p  I m m u n o l  114: 166-72.
Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., 
Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. (1997). Enhancement 
of cellular immunity in melanoma patients immunized with a peptide from 
MART -1 /Melan A. C a n c e r  J  S c i  A m  3:37-44.
Cotran, R. S., Kumar, V., and Collins, T. (1999). Robbins Pathologic Basis of 
Disease. 6th ed. W B  S a u n d e r s  c o m p a n y , P h i la d e lp h ia .
Coulie, P. G. (1997). Human tumour antigens recognized by T cells: new 
perspectives for anti-cancer vaccines? M o l  M e d  T o d a y  3: 261-8.
Coulie, P. G., Hanagiri, T., and Takenoyama, M. (2001). From tumor antigens 
to immunotherapy. I n t  J  C lin  O n c o l  6: 163-70.
214
B ib lio g r a ph y
Coulie, P. G., Lehmann, P., Lethe, B., Herman, J., Lurquin, C., Andrawiss, 
M., and Boon, T. (1995). A mutated intron sequence codes for an antigenic 
peptide recognized by cytolytic T lymphocytes on a human melanoma. P r o c  
N a t l  A c a d  S c i  U S  A 9 2 :  7976-80.
Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Harrow, T. L., 
Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. 
(1994). Identification of a peptide recognized by five melanoma-specific 
human cytotoxic T cell lines. S c ie n c e  264: 716-9.
Cresswell, P. (1994). Assembly, transport, and function of MHC class II 
molecules, R e v  I m m u n o l  12: 259-93.
Cresswell, P. (1996). Invariant chain structure and MHC class II function. 
C e l l  84: 505-7.
Crossland, S., Smith, P. D., and Crompton, M. R. (1996). Molecular cloning 
and characterization of PTP pi, a novel receptor-like protein-tyrosine 
phosphatase. B io c h e m  /  319: 249-54.
Dalerba, P., Ricci, A., Russo, V., Rigatti, D., Nicotra, M. R., Mottolese, M., 
Bordignon, C., Natali, P. G., and Traversari, C. (1998). High homogeneity of 
MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART -1 gene expression in 
clusters o f multiple simultaneous métastasés of human melanoma: 
implications for protocol design of therapeutic antigen-specific vaccination 
strategies. I n t  J  C a n c e r  77: 200-4.
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., 
Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks,
E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., 
Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., 
Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, 
J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., 
Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., 
Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H.
F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., 
Stratton, M. R., and Futreal, P. A. (2002). Mutations of the BRAF gene in 
human cancer. N a tu r e  417: 949-54.
De Plaen, E., Arden, K., Traversari, C., Gaforio, J. J., Szikora, J. P., De Smet, 
C., Brasseur, F., van der Bruggen, P., Lethe, B., Lurquin, C., Brasseur, R., 
Chômez, P., De Backer, O., Cavenee, W., and Boon, T. (1994). Structure, 
chromosomal localization, and expression of 12 genes o f the MAGE family. 
I m m u n o g e n e t ic s  40: 360-9.
215
B ib lio g r a ph y
De Plaen, E., Lurquin, C., Lethe, B., van der Bruggen, P., Brichard, V., 
Renauld, J. C., Coulie, P., Van Pel, A., and Boon, T. (1997). Identification of 
genes coding for tumor antigens recognized by cytolytic T lymphocytes. 
M e th o d s  12: 125-42.
De Plaen, E., Lurquin, C., Van Pel, A., Madame, B., Szikora, J. P., Wolfel, 
T., Sibille, C., Chômez, P., and Boon, T. (1988). Immunogenic (tum-) 
variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and 
identification of the tum- mutation. P r o c  N a t l  A c a d  S c i  U S  A  8 5 : 2274-8.
De Smedt, T., Van Mechelen, M., De Becker, G., Urbain, J., Leo, O., and 
Moser, M. (1997). Effect of interleukin-10 on dendritic cell maturation and 
f a n c t io n .  E u r  J  I m m u n o l  2 1 : 1229-35.
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., and de Vries, J. 
E. (1991a). Interleukin 10(IL-10) inhibits cytokine synthesis by human 
monocytes: an autoregulatory role of IL-10 produced by monocytes. J  E x p  
M e d  174: 1209-20.
de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., 
Figdor, C., Johnson, K., Kastelein, R., Yssel, H., and de Vries, J. E. (1991b). 
Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human 
T cell proliferation by diminishing the antigen-presenting capacity of 
monocytes via downregulation of class II major histocompatibility complex 
expression. J E x p  M e d  174: 915-24.
DeJfrance, T., Vanbervliet, B., Briere, F., Durand, I., Rousset, F., and 
Banchereau, J. (1992). Interleukin 10 and transforming growth factor beta 
cooperate to induce anti-CD40-activated naive human B cells to secrete 
immunoglobulin A. J E x p  M e d  175: 671 -82.
Del Prete, G., De Carli, M., Almerigogna, F., Giudizi, M. G., Biagiotti, R., 
and Romagnani, S. (1993). Human IL-10 is produced by both type 1 helper 
(Thl) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific 
proliferation and cytokine production. J  I m m u n o l  150: 353-60.
Del Prete, G. F., De Carli, M., Mastromauro, C., Biagiotti, R., Macchia, D., 
Falagiani, P., Ricci, M., and Romagnani, S. (1991). Purified protein derivative 
of Mycobacterium tuberculosis and excretory-secretory antigen(s) of 
Toxocara canis expand in vitro human T cells with stable and opposite (type 1 
T helper or type 2 T helper) profile of cytokine production. J  C l in  I n v e s t  88: 
346-50.
Dieckmann, D., Plottner, H., Berchtold, S., Berger, T., and Schuler, G.
(2001). Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with 
regulatory properties firom human blood. J E x p  M e d  \9 3 :  1303-10.
216
B ib lio g r a ph y
Diepgen, T. L., and Mahler, V. (2002). The epidemiology o f skin cancer. B r J  
146 Suppl 61: 1-6.
Ding, L., and Shevach, E. M. (1992). IL-10 inhibits mitogen-induced T cell 
proliferation by selectively inhibiting macrophage costimulatory function. J  
I m m u n o l  148: 3133-9.
Ding, Y., Qin, L., Kotenko, S. V., Pestka, S., and Bromberg, J. S. (2000). A  
single amino acid determines the immunostimulatory activity of interleukin 
\ { ) , J E x p M e d \ 9 \ : 2 \ ? > - 2 A .
Dobrzanski, M. J., Reome, J. B., and Dutton, R. W. (2000). Type 1 and type 2 
CD8+ effector T cell subpopulations promote long-term tumor immunity and 
protection to progressively growing tumor. J  I m m u n o l  164: 916-25.
D’Orazio, T. J., and Niederkom, J. Y. (1998). A novel role for TGF-beta and 
IL-10 in the induction of immune privilege. J  I m m u n o l  160: 2089-98.
Dorsey, R., Kundu, N., Yang, Q., Tannenbaum, C. S., Sun, H., Hamilton, T. 
A., and Fulton, A. M. (2002). Immunotherapy with interleukin-10 depends on 
the CXC chemokines inducible protein-10 and monokine induced by IFN- 
gamma. C a n c e r  R e s  62: 2606-10.
D'Souza, S., Rimoldi, D., Lienard, D., Lejeune, F., Cerottini, J. C., and 
Romero, P. (1998). Circulating Melan-A/Mart-1 specific cytolytic T 
lymphocyte precursors in HLA-A2+ melanoma patients have a memory 
phenotype. I n t J  C a n c e r  78:699-706.
Dudley, M. E., and Roopenian, D. C. (1996). Loss of a unique tumor antigen 
by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene- 
induced mouse sarcoma reveals secondary unique and shared antigens. J  E x p  
184: 441-7.
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., 
Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, 
A. M., Robinson, M. R., Raffeld, M., Duray, P., Seipp, C. A., Rogers-Freezer, 
L., Morton, K. E., Mavroukakis, S. A., V^ite, D. E., and Rosenberg, S. A. 
(2002). Cancer regression and autoimmunity in patients after clonal 
repopulation with antitumor lymphocytes. S c ie n c e  298: 850-4.
Dummer, R., Yue, F. Y., Pavlovic, J., Geertsen, R., Dohring, C., Moelling, 
K., and Burg, G. (1998). Immune stimulatory potential o f B7.1 and B7.2 
retrovirally transduced melanoma cells: suppression by interleukin 10. B r  J  
C a n c e r  1 1 \ 1413-9.
217
B ib lio g r a ph y
Dummer, W., Bastian, B. C., Ernst, N., Schanzle, C., Schwaaf, A., and 
Brocker, E. B. (1996). Interleukin-10 production in malignant melanoma: 
preferential detection of IL-lO-secreting tumor cells in metastatic lesions. I n t  
J  C a n c e r  6 6 \ 607-10.
Dummer, W., Becker, J. C., Schwaaf, A., Leverkus, M., Moll, T., and 
Brocker, E. B. (1995). Elevated serum levels of interleukin-10 in patients with 
metastatic malignant melanoma. M e la n o m a  R e s  5: 67-8.
Dunbar, P. R., Chen, J. L., Chao, D., Rust, N., Teisserenc, H., Ogg, G. S., 
Romero, P., Weynants, P., and Cerundolo, V. (1999). Cutting edge: rapid 
cloning of tumor-specific CTL suitable for adoptive immunotherapy of  
melanoma. J  I m m u n o l  162: 6959-62.
Enk, A. H., Jonuleit, H., Saloga, J., and Knop, J. (1997). Dendritic cells as 
mediators o f tumor-induced tolerance in metastatic melanoma. I n t  J  C a n c e r  
73: 309-16.
Eskdale, J., and Gallagher, G. (1995). A polymorphic dinucleotide repeat in 
the human IL-10 promoter. I m m u n o g e n e t ic s  42: 444-5.
Eskdale, J., Gallagher, G., Verweij, C. L., Keijsers, V., Westendorp, R. G., 
and Huizinga, T. W. (1998). Interleukin 10 secretion in relation to human IL- 
10 locus haplotypes. P r o c  N a t l  A c a d  S c i  U S A 9 5 :  9465-70.
Eskdale, J., Kube, D., and Gallagher, G. (1996). A second polymorphic 
dinucleotide repeat in the 5’ flanking region of the human ILIO gene. 
I m m u n o g e n e t ic s  4 5 : 82-3.
Eskdale, J., Kube, D., Tesch, H., and Gallagher, G. (1997a). Mapping of the 
human ILIO gene and further characterization of the 5’ flanking sequence. 
I m m u n o g e n e t ic s  46: 120-8.
Eskdale, J., Wordsworth, P., Bowman, S., Field, M., and Gallagher, G. 
(1997b). Association between polymorphisms at the human IL-10 locus and 
systemic lupus erythematosus. T is s u e  A n t ig e n s  49: 635-9.
Faiola, B., Doyle, C., Gilboa, E., and Nair, S. (2002). Influence o f CD4 T 
cells and the source of major histocompatibility complex class Il-restricted 
peptides on cytotoxic T-cell priming by dendritic cells. I m m u n o l o g y  105: 47- 
55.
Ferrone, S., and Marincola, F. M. (1995). Loss of HLA class I antigens by 
melanoma cells: molecular mechanisms, functional significance and clinical 
relevance. I m m u n o l  T o d a y  16: 487-94.
218
B ib lio g r a ph y
Fineschi, B., and Miller, J. (1997). Endosomal proteases and antigen 
processing. T r e n d s  B io c h e m  S c i  22: 377-82.
Fiorentino, D. F., Bond, M. W., and Mosmann, T. R. (1989). Two types of 
mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine 
production by Thl clones. J E x p  M e d  170: 2081-95.
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., and O'Garra, A. 
(1991a). IL-10 inhibits cytokine production by activated macrophages. J  
I m m u n o l  147: 3815-22.
Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., 
Moore, K. W., and O'Garra, A. (1991b). IL-10 acts on the antigen-presenting 
cell to inhibit cytokine production by Thl cells. J  I m m u n o l  146: 3444-51.
Fischer, E. H., Charbonneau, H., and Tonks, N. K. (1991). Protein tyrosine 
phosphatases: a diverse family of intracellular and transmembrane enzymes. 
S c ie n c e  253: 401-6.
Fischer, W. H., thor Straten, P., Terheyden, P., and Becker, J. C. (1999). 
Function and dysfunction of CD4(+) T cells in the immune response to 
melanoma. C a n c e r  I m m u n o l  I m m u n o th e r  4 ^ :  363-70.
Fleischhauer, K., Zino, E., Mazzi, B., Severini, G. M., Benazzi, E., and 
Bordignon, C. (1996). HLA-A*02 subtype distribution in Caucasians from 
northern Italy: identification of A*0220. T is s u e  A n t ig e n s  48: 673-9.
Fortis, C., Foppoli, M., Gianotti, L., Galli, L., Citterio, G., Consogno, G., 
Gentilini, O., and Braga, M. (1996). Increased interleukin-10 serum levels in 
patients with solid tumours. C a n c e r  L e t t  104: 1-5.
Fuchs, M., Muller, T., Lerch, M. M., and Ullrich, A. (1996). Association of  
human protein-tyrosine phosphatase kappa with members o f the armadillo 
family. J  B i o l  C h e m  271: 16712-9.
Fujii, S., Shimizu, K., Shimizu, T., and Lotze, M. T. (2001). Interleukin-10 
promotes the maintenance of antitumor CD8(+) T-cell effector function in 
situ. B l o o d  98: 2143-51.
Fukaura, H., Kent, S. C., Pietrusewicz, M. J., Khoury, S. J., Weiner, H. L., 
and Hafler, D. A. (1996). Induction of circulating myelin basic protein and 
proteolipid protein-specific transforming growth factor-betal-secreting Th3 T 
cells by oral administration of myelin in multiple sclerosis patients. J  C l in  
I n v e s t  98: 70-7.
219
B ib lio g r a ph y
Garbe, C., and Krasagakis, K. (1993). Effects of interferons and cytokines on 
melanoma cells. J  I n v e s t  D e r m a to l  100: 239S-44S.
Garcia-Hemandez, M. L., Hemandez-Pando, R., Gariglio, P., and Berumen, J.
(2002). Interleukin-10 promotes B 16-melanoma growth by inhibition of 
macrophage functions and induction of tumour and vascular cell proliferation, 
/mmwwo/ogy 105: 231-43.
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J. J., Lopez-Botet, M., 
Duggan-Keen, M., and Stem, P. L. (1997). Implications for 
immunosurveillance o f altered HLA class I phenotypes in human tumours. 
I m m u n o l  T o d a y  18: 89-95.
Genevee, C., Diu, A., Nierat, J., Caignard, A., Dietrich, P. Y., Ferradini, L., 
Roman-Roman, S., Triebel, F., and Hercend, T. (1992). An experimentally 
validated panel of subfamily-specific oligonucleotide primers (V alpha 1- 
w29W beta l-w24) for the study of human T cell receptor variable V gene 
segment usage by polymerase chain reaction. E u r  J  I m m u n o l  22: 1261-9.
Gervois, N., Guilloux, Y., Diez, E., and Jotereau, F. (1996). Suboptimal 
activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of  
TCR/MHC-tumor peptide interactions. J E x p  M e d  183: 2403-7.
Geuze, H. J. (1998). The role of endosomes and lysosomes in MHC class II 
functioning. I m m u n o l  T o d a y  19: 282-7.
Gilboa, E. (1999a). How tumors escape immune destmction and what we can 
do about it. C a n c e r  I m m u n o l  I m m u n o th e r  48: 382-5.
Gilboa, E. (1999b). The makings of a tumor rejection antigen. I m m u n i t y  11: 
263-70.
Glimcher, L. H., and Murphy, K. M. (2000). Lineage commitment in the 
immune system: the T helper lymphocyte grows up. G e n e s  D e v  14: 1693-711.
Go, N. F., Castle, B. E., Barrett, R., Kastelein, R., Dang, W., Mosmann, T. R., 
Moore, K. W., and Howard, M. (1990). Interleukin 10, a novel B cell 
stimulatory factor: unresponsiveness of X chromosome-linked
immunodeficiency B cells. J E x p  M e d  172: 1625-31.
Goedegebuure, P. S., Lee, K. Y., Matory, Y. L., Peoples, G. E., Yoshino, I., 
and Eberlein, T. J. (1994). Classification of CD4+ T helper cell clones in 
human melanoma. C e l l  I m m u n o l  156: 170-9.
Greten, T. F., and Jaffee, E. M. (1999). Cancer vaccines. J  C l in  O n c o l  17: 
1047-60.
220
B ib lio g r a ph y
Griffiths, G. M. (1995). The cell biology of CTL killing. C u r r  O p in  I m m u n o l  
7: 343-8.
Groux, H., Bigler, M., de Vries, J. E., and Roncarolo, M. G. (1998). 
Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J  
I m m u n o l  160: 3188-93.
Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J.
E., and Roncarolo, M. G. (1997). A CD4+ T-cell subset inhibits antigen- 
specific T-cell responses and prevents colitis. N a tu r e  389: 737-42.
Gure, A. O., Stockert, E., Arden, K. C., Boyer, A. D., Viars, C. S., Scanlan, 
M. J., Old, L. J., and Chen, Y. T. (2000). CTIO: a new cancer-testis (CT) 
antigen homologous to CT7 and the MAGE family, identified by 
representational-difference analysis. I n t  J  C a n c e r  85: 726-32.
Hammond, S. A., Bollinger, R. C., Tobery, T. W., and Silliciano, R. F. 
(1993). Transporter-independent processing o f HIV-1 envelope protein for 
recognition by CD8+ T cells. N a tu r e  364: 158-61.
Harashima, N., Tanaka, K., Sasatomi, T., Shimizu, K., Miyagi, Y., Yamada,
A., Tamura, M., Yamana, H., Itoh, K., and Shichijo, S. (2001). Recognition of 
the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of 
cancer patients with distant métastasés. E u r  J  I m m u n o l  3 1 : 323-32.
Henkart, P. A. (1994). Lymphocyte-mediated cytotoxicity: two pathways and 
multiple effector molecules. I m m u n i ty  1: 343-6.
Hewitt, H. B., Blake, E. R., and Walder, A. S. (1976). A critique o f the 
evidence for active host defence against cancer, based on personal studies of 
27 murine tumours of spontaneous origin. B r J  C a n c e r  33: 241-59.
Hickling, J. K., Fenton, C. M., Howland, K., Marsh, S. G., and Rothbard, J.
B. (1990). Peptides recognized by class I restricted T cells also bind to MHC 
class II molecules. I n t  I m m u n o l  2: 435-41.
Hiltbold, E. M., Ciborowski, P., and Finn, O. J. (1998). Naturally processed 
class II epitope from the tumor antigen MUCl primes human CD4+ T cells. 
C a n c e r  R e s  58: 5066-70.
Ho, A. S., Liu, Y., Khan, T. A., Hsu, D. H., Bazan, J. F., and Moore, K. W. 
(1993). A receptor for interleukin 10 is related to interferon receptors. P r o c  
N a t l  A c a d  S c i  U S A  90: 11267-71.
Hohn, H., Pilch, H., Gunzel, S., Neukirch, C., Hilmes, C., Kaufmann, A., 
Seliger, B., and Maeurer, M. J. (1999). CD4+ tumor-infiltrating lymphocytes
221
B ib lio g r a ph y
in cervical cancer recognize HLA-DR-restricted peptides provided by human 
papillomavirus-E7. 163: 5715-22.
Hoover, D. M., Schalk-Hihi, C., Chou, C. C., Menon, S., Wlodawer, A., and 
Zdanov, A. (1999). Purification of receptor complexes o f interleukin-10 
stoichiometry and the importance of deglycosylation in their crystallization. 
E u r  J  B io c h e m  2 6 2 :  134-41.
Howell, W. M., Turner, S. J., Bateman, A. C., and Theaker, J. M. (2001). IL­
IO promoter polymorphisms influence tumour development in cutaneous 
malignant melanoma. G e n e s  I m m u n  2: 25-31.
Hu, X., Chakraborty, N. G., Spom, J. R., Kurtzman, S. H., Ergin, M. T., and 
Mukheiji, B. (1996). Enhancement of cytolytic T lymphocyte precursor 
frequency in melanoma patients following immunization with the MAGE-1 
peptide loaded antigen presenting cell-based vaccine. C a n c e r  R e s  56: 2479- 
83.
Huang, H., Li, F., Gordon, J. R., and Xiang, J. (2002). Synergistic 
enhancement of antitumor immunity with adoptively transferred tumor- 
specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene 
expression. C a n c e r  R e s  62 : 2043-51.
Huang, M., Wang, J., Lee, P., Sharma, S., Mao, J. T., Meissner, H., Uyemura, 
K., Modlin, R., Wollman, J., and Dubinett, S. M. (1995). Human non-small 
cell lung cancer cells express a type 2 cytokine pattern. C a n c e r  R e s  55: 3847- 
53.
Huang, S., Ullrich, S. E., and Bar-Eli, M. (1999). Regulation of tumor growth 
and metastasis by interleukin-10: the melanoma experience. J  I n te r fe r o n  
C y to k in e  R e s  19: 697-703.
Huang, S., Xie, K., Bucana, C. D., Ullrich, S. E., and Bar-Eli, M. (1996). 
Interleukin 10 suppresses tumor growth and metastasis o f human melanoma 
cells: potential inhibition of angiogenesis. C lin  C a n c e r  R e s  2: 1969-79.
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., and 
Levitsky, H. (1998). The central role of CD4(+) T cells in the antitumor 
immune response. J E x p  M e d  188: 2357-68.
Hurme, M., Lahdenpohja, N., and Santtila, S. (1998). Gene polymorphisms of  
interleukins 1 and 10 in infectious and autoimmune diseases. A n n  M e d  30: 
469-73.
222
B iblio g ra ph y
Ikeda, H., Old, L. J., and Schreiber, R. D. (2002). The roles o f IFN gamma in 
protection against tumor development and cancer immunoediting. C y to k in e  
G r o w th  F a c to r  R e v  13: 95-109.
Inobe, J., Slavin, A. J., Komagata, Y., Chen, Y., Liu, L., and Weiner, H. L. 
(1998). IL-4 is a differentiation factor for transforming growth factor-beta 
secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in 
experimental allergic encephalomyelitis. E u r  J  I m m u n o l  28: 2780-90.
Itoh, K., and Hirohata, S. (1995). The role of IL-10 in human B cell 
activation, proliferation, and differentiation. J  I m m u n o l  154: 4341-50.
Jager, E., Chen, Y. T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., 
Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L. J., and Knuth, A. 
(1998). Simultaneous humoral and cellular immune response against cancer- 
testis antigen NY-ESO-1: definition of human histocompatibility leukocyte 
antigen (HLA)-A2-binding peptide epitopes. J E x p  M e d  187: 265-70.
Jager, E., Gnjatic, S., Nagata, Y., Stockert, E., Jager, D., Karbach, J., 
Neumann, A., Rieckenberg, J., Chen, Y. T., Ritter, G., Hoffman, E., Arand, 
M., Old, L. J., and Knuth, A. (2000a). Induction o f primary NY-ESO-1 
immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated 
patients with NY-ESO-1 + cancers [In Process Citation]. P r o c  N a t l  A c a d  S c i  
U S A  97: 12198-203.
Jager, E., Jager, D., Karbach, J., Chen, Y. T., Ritter, G., Nagata, Y., Gnjatic,
S., Stockert, E., Arand, M., Old, L. J., and Knuth, A. (2000b). Identification 
of NY-ESO-1 epitopes presented by human histocompatibility antigen 
(HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of 
patients with NY-ESO-1-expressing melanoma. J E x p  M e d  191: 625-30.
Jager, E., Ringhoffer, M., Arand, M., Karbach, J., Jager, D., Ilsemann, C., 
Hagedom, M., Oesch, F., and Knuth, A. (1996a). Cytolytic T cell reactivity 
against melanoma-associated differentiation antigens in peripheral blood of 
melanoma patients and healthy individuals. M e la n o m a  R e s  6: 419-25.
Jager, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., Jager, D., 
Ilsemann, C., Hagedom, M., Oesch, F., and Knuth, A. (1996b). Granulocyte- 
macrophage-colony-stimulating factor enhances immune responses to 
melanoma-associated peptides in vivo. I n t  J  C a n c e r  67: 54-62.
Jassim, A., Oilier, W., Payne, A., Biro, A., Oliver, R. T., and Festenstein, H. 
(1989). Analysis o f HLA antigens on germ cells in human semen. E u r  J  
I m m u n o l  19: 1215-20.
223
B ib lio g r a ph y
Jiang, Y. P., Wang, H., D’Eustachio, P., Musacchio, J. M., Schlessinger, J., 
and Sap, J. (1993). Cloning and characterization of R-PTP-kappa, a new 
member o f the receptor protein tyrosine phosphatase family with a 
proteolytically cleaved cellular adhesion molecule-like extracellular region. 
M o l  C e l l  B i o l  \ 3 \ 2 9 4 2 - 5 \ .
Johnson, J. P. (1999). Cell adhesion molecules in the development and 
progression of malignant melanoma. C a n c e r  M e ta s ta s i s  R e v  18: 345-57.
Jonuleit, H., Schmitt, E., Steinbrink, K., and Enk, A. H. (2001). Dendritic 
cells as a tool to induce anergic and regulatory T cells. T r e n d s  I m m u n o l  22: 
394-400.
Kageshita, T., Wang, Z., Calorini, L., Yoshii, A., Kimura, T., Ono, T., 
Gattoni-Celli, S., and Ferrone, S. (1993). Selective loss o f human leukocyte 
class I allospecificities and staining of melanoma cells by monoclonal 
antibodies recognizing monomorphic determinants o f class I human leukocyte 
antigens. C a n c e r  R e s  53: 3349-54.
Kammula, U. S., Lee, K. H., Riker, A. L, Wang, E., Ohnmacht, G. A., 
Rosenberg, S. A., and Marincola, F. M. (1999). Functional analysis of  
antigen-specific T lymphocytes by serial measurement of gene expression in 
peripheral blood mononuclear cells and tumor specimens. J  I m m u n o l  163: 
6867-75.
Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van 
der Eb, A. J., and Melief, C. J. (1989). Eradication of adenovirus El-induced 
tumors by El A-specific cytotoxic T lymphocytes. C e l l  59: 603-14.
Kawakami, Y., Dang, N., Wang, X., Tupesis, J., Robbins, P. F., Wang, R. F., 
Wunderlich, J. R., Yannelli, J. R., and Rosenberg, S. A. (2000). Recognition 
of shared melanoma antigens in association with major HLA-A alleles by 
tumor infiltrating T lymphocytes from 123 patients with melanoma. J  
I m m u n o th e r  2 3 \ 17-27.
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., 
Topalian, S. L., Miki, T., and Rosenberg, S. A. (1994a). Cloning of the gene 
coding for a shared human melanoma antigen recognized by autologous T 
cells infiltrating into tumor. P r o c  N a t l  A c a d  S c i  U S  A  9 \  \ 3 5 1 5 - 9 .
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., 
Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. 
(1994b). Identification of a human melanoma antigen recognized by tumor- 
infiltrating lymphocytes associated with in vivo tumor rejection. P r o c  N a t l  
A c a d  S c i  U S  A 9 \ :  6458-62.
224
B ib lio g r a ph y
Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., 
Southwood, S., Robbins, P. P., Sette, A., Appella, E., and Rosenberg, S. A.
(1995). Recognition of multiple epitopes in the human melanoma antigen 
gplOO by tumor-infiltrating T lymphocytes associated with in vivo tumor 
regression. J  I m m u n o l  154: 3961-8.
Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., 
Yannelli, J. R., Appella, E., and Rosenberg, S. A. (1994c). Identification of 
the immunodominant peptides of the MART-1 human melanoma antigen 
recognized by the majority of HLA-A2-restricted tumor infiltrating 
lymphocytes. J E x p  M e d  180: 347-52.
Kawakami, Y., Robbins, P. F., Wang, R. F., Parkhurst, M., Kang, X., and 
Rosenberg, S. A. (1998). The use of melanosomal proteins in the 
immunotherapy of melanoma. J  I m m u n o th e r  21: 237-46.
Kawakami, Y., and Rosenberg, S. A. (1996). T-cell recognition o f self 
peptides as tumor rejection antigens. I m m u n o l  R e s  15: 179-90.
Kawakami, Y., and Rosenberg, S. A. (1997). Human tumor antigens 
recognized by T-cells. I m m u n o l  R e s  16: 313-39.
Kelso, A. (1995). Thl and Th2 subsets: paradigms lost? I m m u n o l  T o d a y  16: 
374-9.
Kern, I., Steimle, V., Siegrist, C. A., and Mach, B. (1995). The two novel 
MHC class II transactivators RFX5 and CIITA both control expression of 
HLA-DM genes. I n t  I m m u n o l  7: 1295-9.
Kim, J. M., Brannan, C. I., Copeland, N. G., Jenkins, N. A., Khan, T. A., and 
Moore, K. W. (1992). Structure of the mouse IL-10 gene and chromosomal 
localization of the mouse and human genes. J  I m m u n o l  148: 3618-23.
Klein, J., and Sato, A. (2000). The HLA system. First o f two parts. N  E n g l  J  
M e d  3 4 3 : 1 0 2 - 9 ,
Klenerman, P., Cerundolo, V., and Dunbar, P. R. (2002). Tracking T cells 
with tetramers: new tales from new tools. N a tu r e  R e v  I m m u n o l  2 : 263-72.
Kobayashi, H., Kokubo, T., Sato, K., Kimura, S., Asano, K., Takahashi, H., 
lizuka, H., Miyokawa, N., and Katagiri, M. (1998a). CD4+ T cells from 
peripheral blood of a melanoma patient recognize peptides derived from 
nonmutated tyrosinase. C a n c e r  R e s  58: 296-301.
Kobayashi, H., Kokubo, T., Takahashi, M., Sato, K., Miyokawa, N., Kimura,
S., Kinouchi, R., and Katagiri, M. (1998b). Tyrosinase epitope recognized by
225
B ib lio g r a ph y
an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease 
patient. I m m u n o g e n e t ic s  47: 398-403.
Kobayashi, H., Lu, J., and Celis, E. (2001). Identification of Helper T-Cell 
Epitopes That Encompass or Lie Proximal to Cytotoxic T-Cell Epitopes in the 
gplOO Melanoma Tumor Antigen. C a n c e r  R e s  61: 7577-84.
Kobayashi, H., Wood, M., Song, Y., Appella, E., and Celis, E. (2000). 
Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu 
tumor antigen. C a n c e r  R e s  60: 5228-36.
Koppelman, B., Neefjes, J. J., de Vries, J. E., and de Waal Malefyt, R. (1997). 
Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at 
the plasma membrane of monocytes by affecting arrival and recycling. 
I m m u n i t y  1: 861-71.
Krausa, P., Brywka, M., 3rd, Savage, D., Hui, K. M., Bunce, M., Ngai, J. L., 
Teo, D. L., Ong, Y. W., Barouch, D., Allsop, C. E., and et al. (1995). Genetic 
polymorphism within HLA-A*02: significant allelic variation revealed in 
different populations. T is s u e  A n t ig e n s  45: 223-31.
Kropshofer, H., Vogt, A. B., Thery, C., Armandola, E. A., Li, B. C., 
Moldenhauer, G., Amigorena, S., and Hammerling, G. J. (1998). A role for 
HLA-DO as a co-chaperone of HLA-DM in peptide loading o f MHC class II 
molecules. E m b o  J 11: 2 9 1 1-81.
Kruger-Krasagakes, S., Krasagakis, K., Garbe, C., and Diamantstein, T.
(1995). Production of cytokines by human melanoma cells and melanocytes. 
R e c e n t  R e s u l t s  C a n c e r  R e s  139: 155-68.
Kube, D., Platzer, C., von Knethen, A., Straub, H., Bohlen, H., Hafher, M., 
and Tesch, H. (1995). Isolation of the human interleukin 10 promoter. 
Characterization of the promoter activity in Burkitt's lymphoma cell lines. 
C y to k in e  1: 1-7.
Kuby, J. (1997). Immunology. 3rd ed. W H  F r e e m a n  a n d  C o m p n a y ,  N e w  
Y o rk .
Kundu, N., and Fulton, A. M. (1997). Interleukin-10 inhibits tumor 
metastasis, downregulates MHC class I, and enhances NK lysis. C e l l  I m m u n o l  
180: 55-61.
Lalani, I., Bhol, K., and Ahmed, A. R. (1997). Interleukin-10: biology, role in 
inflammation and autoimmunity. A n n  A l l e r g y  A s th m a  I m m u n o l  1 9 : 469-83.
226
B ib lio g r a ph y
Lanzavecchia, A. (1996). Mechanisms of antigen uptake for presentation. 
C u r r  O p in  I m m u n o l  8: 348-54.
Lee, K. H., Wang, E., Nielsen, M. B., Wunderlich, J., Migueles, S., Connors, 
M., Steinberg, S. M., Rosenberg, S. A., and Marincola, F. M. (1999a). 
Increased vaccine-specific T cell frequency after peptide-based vaccination 
correlates with increased susceptibility to in vitro stimulation but does not 
lead to tumor regression. J  I m m u n o l  163: 6292-300.
Lee, K. Y., Goedegebuure, P. S., Linehan, D. C., and Eberlein, T. J. (1995). 
Immunoregulatory effects of CD4+ T helper subsets in human melanoma. 
S u r g e r y  W l \  3 6 5 - 1 2 .
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., 
Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., and 
Davis, M. M. (1999b). Characterization of circulating T cells specific for 
tumor-associated antigens in melanoma patients. N a t  M e d  5: 677-85.
Lelievre, E., Sarrouilhe, D., Morel, F., Preud'Homme, J. L., Wijdenes, J., and 
Lecron, J. C. (1998). Preincubation of human resting T cell clones with 
interleukin 10 strongly enhances their ability to produce cytokines after 
stimulation. C y to k in e  10: 831-40.
Lethe, B., Lucas, S., Michaux, L., De Smet, C., Godelaine, D., Serrano, A., 
De Plaen, E., and Boon, T. (1998). LAGE-1, a new gene with tumor 
specificity. I n t  J  C a n c e r  1 6 : 903-8.
Li, K., Adibzadeh, M., Haider, T., Kalbacher, H., Heinzel, S., Muller, C., 
Zeuthen, J., and Pawelec, G. (1998). Tumour-specific MHC-class-II-restricted 
responses after in vitro sensitization to synthetic peptides corresponding to 
gplOO and Annexin II eluted from melanoma cells. C a n c e r  I m m u n o l  
I m m u n o th e r  4 1 : 3 2 - ^ .
Li, L., and Dixon, J. E. (2000). Form, function, and regulation o f protein 
tyrosine phosphatases and their involvement in human diseases. S e m in  
I m m u n o l  12: 75-84.
Liu, A., Takahashi, M., Toba, K., Zheng, Z., Hashimoto, S., Nikkuni, K., 
Furukawa, T., Koike, T., and Aizawa, Y. (1999). Regulation o f the expression 
of MHC class I and II by class II transactivator (CIITA) in hematopoietic 
cells. H e m a to l  O n c o l  17: 149-60.
Liu, C. C., Walsh, C. M., and Young, J. D. (1995). Perforin: structure and 
function. I m m u n o l  T o d a y  16: 194-201.
227
B ib lio g r a ph y
Liu, y ., Wei, S. H., Ho, A. S., de Waal Malefyt, R., and Moore, K. W. (1994). 
Expression cloning and characterization of a human IL-10 receptor. J  
I m m u n o l  152: 1821-9.
Loftus, D. J., Squarcina, P., Nielsen, M. B., Geisler, C., Castelli, C., Odum, 
N., Appella, E., Parmiani, G., and Rivoltini, L. (1998). Peptides derived from 
self-proteins as partial agonists and antagonists of human CD8+ T-cell clones 
reactive to melanoma/melanocyte epitope MARTI(27-35). C a n c e r  R e s  58: 
2433-9.
Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J. (1994). Cytolytic T-cell 
cytotoxicity is mediated through perforin and Fas lytic pathways. N a t u r e  370: 
650-2.
Lu, J., and Celis, E. (2000). Use of two predictive algorithms of the world 
wide web for the identification of tumor-reactive T-cell epitopes. C a n c e r  R e s  
60: 5223-7.
Lucas, S., Brasseur, F., and Boon, T. (1999). A new MAGE gene with 
ubiquitous expression does not code for known MAGE antigens recognized 
by T cells. C a n c e r  R e s  59: 4100-3.
Lucas, S., De Plaen, E., and Boon, T. (2000). MAGE-B5, MAGE-B6, 
MAGE-C2, and MAGE-C3: four new members of the MAGE family with 
tumor-specific expression. I n t  J  C a n c e r  87: 55-60.
Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, G., Anichini, A., 
Bordignon, C., Sensi, M., Parmiani, G., and Traversari, C. (1998). Translation 
of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a 
new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma 
antigen not expressed in normal cells of the melanocytic lineage. J  E x p  M e d  
188: 1005-16.
Lurquin, C., Van Pel, A., Mariame, B., De Plaen, E., Szikora, J. P., Janssens, 
C., Reddehase, M. J., Lejeune, J., and Boon, T. (1989). Structure o f the gene 
of tum- transplantation antigen P91A: the mutated exon encodes a peptide 
recognized with Ld by cytolytic T cells. C e l l  58: 293-303.
Macatonia, S. E., Doherty, T. M., Knight, S. C., and O'Garra, A. (1993). 
Differential effect of IL-10 on dendritic cell-induced T cell proliferation and 
IFN-gamma production. 150: 3755-65.
Maccalli, C., Mortarini, R., Parmiani, G., and Anichini, A. (1994). Multiple 
sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous 
human melanoma identified by cytokine profiles. I n t  J  C a n c e r  57: 56-62.
228
B ib lio g r a ph y
Maeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., 
Robbins, P., Parmiani, G., Storkus, W. J., and Lotze, M. T. (1996). Tumor 
escape from immune recognition: lethal recurrent melanoma in a patient 
associated with downregulation of the peptide transporter protein TAP-1 and 
loss o f expression of the immunodominant MART -1 /Melan-A antigen. J  C lin  
I n v e s t  9^^: 1633-41.
Maier, R., Falk, K., Rotzschke, O., Maier, B., Gnau, V., Stevanovic, S., Jung, 
G., Rammensee, H. G., and Meyerhans, A. (1994). Peptide motifs of HLA- 
A3, -A24, and -B7 molecules as determined by pool sequencing. 
I m m u n o g e n e t ic s  40: 306-8.
Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., and 
Eisenbach, L. (1994). CTL induction by a tumour-associated antigen 
octapeptide derived from a murine lung carcinoma. N a t u r e  369: 67-71.
Mandelboim, O., Vadai, E., Fridkin, M., Katz-Hillel, A., Feldman, M., Berke,
G., and Eisenbach, L. (1995). Regression of established murine carcinoma 
métastasés following vaccination with tumour-associated antigen peptides. 
N a t  M e d  1179-83.
Mandruzzato, S., Brasseur, F., Andry, G., Boon, T., and van der Bruggen, P.
(1997). A CASP-8 mutation recognized by cytolytic T lymphocytes on a 
human head and neck carcinoma. J E x p  M e d  186: 785-93.
Manici, S., Stumiolo, T., Imro, M. A., Hammer, J., Sinigaglia, F., Noppen, C., 
Spagnoli, G., Mazzi, B., Bellone, M., Dellabona, P., and Protti, M. P. (1999). 
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in 
association with histocompatibility leukocyte antigen D R ll [see comments]. 
J E x p  M e d  189: 871-6.
Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., 
Cascinelli, N., Bourlond, A., Vanwijck, R., Humblet, Y., and et al. (1995). 
Tumor regression responses in melanoma patients treated with a peptide 
encoded by gene MAGE-3. I n t  J  C a n c e r  63: 883-5.
Marincola, F. M., Hijazi, Y. M., Fetsch, P., Salgaller, M. L., Rivoltini, L., 
Cormier, J., Simonis, T. B., Duray, P. H., Herlyn, M., Kawakami, Y., and 
Rosenberg, S. A. (1996a). Analysis of expression of the melanoma-associated 
antigens MART-1 and gplOO in metastatic melanoma cell lines and in in situ 
lesions. J  I m m u n o th e r  E m p h a s i s  T u m o r  I m m u n o l  19: 192-205.
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., and Ferrone, S. (2000). Escape 
of human solid tumors from T-cell recognition: molecular mechanisms and 
functional significance. A d v  I m m u n o l  74: 181-273.
229
B iblio g ra ph y
Marincola, F. M., Rivoltini, L., Salgaller, M. L., Player, M., and Rosenberg, 
S. A. (1996b). Differential anti-MART-1 /MelanA CTL activity in peripheral 
blood of HLA-A2 melanoma patients in comparison to healthy donors: 
evidence of in vivo priming by tumor cells. J  I m m u n o th e r  E m p h a s i s  T u m o r  
I m m u n o l  19: 266-77.
Markus, N. R., Rosenberg, S. A., and Topalian, S. L. (1995). Analysis o f  
cytokine secretion by melanoma-specific CD4+ T lymphocytes. J  I n te r fe r o n  
C y to k in e  R e s  1 5 : 1 3 9 - 4 6 .
Martelange, V., De Smet, C., De Plaen, E., Lurquin, C., and Boon, T. (2000). 
Identification on a human sarcoma of two new genes with tumor-specific 
expression. C a n c e r  R e s  60: 3848-55.
Marzo, A. L., Kinnear, B. F., Lake, R. A., Frelinger, J. J., Collins, E. J., 
Robinson, B. W., and Scott, B. (2000). Tumor-specific CD4+ T cells have a 
major &quot;post-licensing&quot; role in CTL mediated anti-tumor 
immunity. J  I m m u n o l  165: 6047-55.
Matsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., 
Zhang, Q. J., Masucci, M. G., and Kiessling, R. (1994). Interleukin 10 
pretreatment protects target cells from tumor- and allo-specific cytotoxic T 
cells and downregulates HLA class I expression. J E x p  M e d  180: 2371-6.
Mazzocchi, A., Storkus, W. J., Traversari, C., Tarsini, P., Maeurer, M. J., 
Rivoltini, L., Vegetti, C., Belli, F., Anichini, A., Parmiani, G., and Castelli, C.
(1996). Multiple melanoma-associated epitopes recognized by HLA-A3- 
restricted CTLs and shared by melanomas but not melanocytes. J  I m m u n o l  
157: 3030-8.
McAndrew, P. E., Frostholm, A., White, R. A., Rotter, A., and Burghes, A. H.
(1998). Identification and characterization of RPTP rho, a novel RPTP 
mu/kappa-like receptor protein tyrosine phosphatase whose expression is 
restricted to the central nervous system. B r a in  R e s  M o l  B r a in  R e s  5 6 : 9-21.
McArdle, L., Rafferty, M., Maelandsmo, G. M., Bergin, O., Farr, C. J., 
Dervan, P. A., O'Loughlin, S., Herlyn, M., and Easty, D. J. (2001). Protein 
tyrosine phosphatase genes downregulated in melanoma. J  I n v e s t  D e r m a t o l  
117: 1255-60.
Melief, C. J., and Kast, W. M. (1995). T-cell immunotherapy o f tumors by 
adoptive transfer of cytotoxic T lymphocytes and by vaccination with 
minimal essential epitopes. I m m u n o l  R e v  145: 167-77.
Melief, C. J., Offringa, R., Toes, R. E., and Kast, W. M. (1996). Peptide- 
based cancer vaccines. C u r r  O p in  I m m u n o l  8: 651-7.
230
B ib lio g r a ph y
Mocellin, S., Wang, E., and Marincola, F. M. (2001). Cytokines and immune 
response in the tumor microenvironment. J  I m m u n o th e r  24: 392-407.
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., and O’Garra, A. (2001). 
Interleukin-10 and the interleukin-10 receptor. A n n u  R e v  I m m u n o l  19: 683- 
765.
Moore, K. W., Vieira, P., Fiorentino, D. F., Trounstine, M. L., Khan, T. A., 
and Mosmann, T. R. (1990). Homology of cytokine synthesis inhibitory factor 
(IL-10) to the Epstein-Barr virus gene BCRFI. S c ie n c e  248: 1230-4.
Morse, H. R., Olomolaiye, O. O., Wood, N. A., Keen, L. J., and Bidwell, J. L.
(1999). Induced heteroduplex genotyping of TNF-alpha, IL-lbeta, IL-6 and 
IL-10 polymorphisms associated with transcriptional regulation. C y to k in e  11: 
789-95.
Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., and Coffinan, 
R. L. (1986). Two types of murine helper T cell clone. I. Definition according 
to profiles of lymphokine activities and secreted proteins. J  I m m u n o l  136: 
2348-57.
Mosmann, T. R., and Sad, S. (1996). The expanding universe o f T-cell 
subsets: Thl, Th2 and more. I m m u n o l  T o d a y  17: 138-46.
Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., 
Schreiber, R. D., and Schreiber, H. (1999). CD4(+) T cells eliminate MHC 
class Il-negative cancer cells in vivo by indirect effects o f IFN-gamma. P r o c  
N a t l  A c a d  S c i  U S A  96: 8633-8.
Nakagomi, H., Pisa, P., Pisa, E. K., Yamamoto, Y., Halapi, E., Backlin, K., 
Juhlin, C., and Kiessling, R. (1995). Lack of interleukin-2 (IL-2) expression 
and selective expression of IL-10 mRNA in human renal cell carcinoma. I n t J  
C a n c e r  63: 366-71.
Natali, P. G., Nicotra, M. R., Bigotti, A., Venturo, L, Marcenaro, L., 
Giacomini, P., and Russo, C. (1989). Selective changes in expression o f HLA 
class I polymorphic determinants in human solid tumors. P r o c  N a t l  A c a d  S c i  
U S A  86: 6719-23.
N eeles, J. J., Momburg, F., and Hammerling, G. J. (1993). Selective and 
ATP-dependent translocation of peptides by the MHC-encoded transporter. 
S c ie n c e  261: 769-71.
Nepom, G. T., Buckner, J. H., Novak, E. J., Reichstetter, S., Reijonen, H., 
Gebe, J., Wang, R., Swanson, E., and Kwok, W. W. (2002). HLA class II
231
B ib lio g r a ph y
tetramers: tools for direct analysis of antigen-specific CD4+ T cells. A r t h r i t i s  
R h e u m  46: 5-12.
Nielsen, M. B., and Marincola, F. M. (2000). Melanoma vaccines: the 
paradox of T cell activation without clinical response. C a n c e r  C h e m o th e r  
P h a r m a c o l  46: S62-6.
Noguchi, Y., Chen, Y. T., and Old, L. J. (1994). A mouse mutant p53 product 
recognized by CD4+ and CD8+ T cells. P r o c  N a t l  A c a d  S c i  U  S  A 9 \ :  3 1 1  \ - 5 .
Odorizzi, C. G., Trowbridge, I. S., Xue, L., Hopkins, C. R., Davis, C. D., and 
Collawn, J. F. (1994). Sorting signals in the MHC class II invariant chain 
cytoplasmic tail and transmembrane region determine trafficking to an 
endocytic processing compartment. /  Ce// B i o l  126: 317-30.
Oertli, D., Marti, W. R., Zajac, P., Noppen, C., Kocher, T., Padovan, E., 
Adamina, M., Schumacher, R., Harder, F., Heberer, M., and Spagnoli, G. C. 
(2002). Rapid induction of specific cytotoxic T lymphocytes against 
melanoma-associated antigens by a recombinant vaccinia virus vector 
expressing multiple immunodominant epitopes and costimulatory molecules 
in vivo. H u m  G e n e  T h e r  13: 569-75.
Ossendorp, F., Mengede, E., Camps, M., Filius, R., and Melief, C. J. (1998). 
Specific T helper cell requirement for optimal induction of cytotoxic T 
lymphocytes against major histocompatibility complex class II negative 
tumors. J & p  187: 693-702.
Pardoll, D. M. (1998). Cancer vaccines. N a t  M e d  4: 525-31.
Pardoll, D. M., and Topalian, S. L. (1998). The role o f CD4+ T cell responses 
in antitumor immunity. C u r r  O p in  I m m u n o l  10: 588-94.
Parmiani, G. (1993). Tumor immunity as autoimmunity: tumor antigens 
include normal self proteins which stimulate anergic peripheral T cells. 
I m m u n o l  T o d a y  14: 536-8.
Parmiani, G., Carbone, G., and Lembo, R. (1973). Immunogenic strength of 
sarcomas induced by methylcholanthrene in millipore filter diffusion 
chambers. C a n c e r  R e s  33: 750-4.
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola,
F. M., and Anichini, A. (2002a). Cancer immunotherapy with peptide-based 
vaccines: what have we achieved? Where are we going? J  N a t l  C a n c e r  I n s t  
94: 805-18.
232
B ib lio g r a ph y
Parmiani, G., Sensi, M., Castelli, C., Rivoltini, L., and Anichini, A. (2002b). 
T-cell response to unique and shared antigens and vaccination of cancer 
patients. C a n c e r  I m m u n i ty  [ s e r ia l  o n l in e ]  2:6.
Pass, H. A., Schwarz, S. L., Wunderlich, J. R., and Rosenberg, S. A. (1998). 
Immunization of patients with melanoma peptide vaccines: immunologic 
assessment using the ELISPOT assay. C a n c e r  J  S c i  A m  4: 316-23.
Peace, D. J., Smith, J. W., Chen, W., You, S. G., Cosand, W. L., Blake, J., 
and Cheever, M. A. (1994). Lysis of ras oncogene-transformed cells by 
specific cytotoxic T lymphocytes elicited by primary in vitro immunization 
with mutated ras peptide. J E x p  M e d  179: 473-9.
Perez, S. A., Sotiropoulou, P. A., Sotiriadou, N. N., Mamalaki, A., Gritzapis, 
A. D., Echner, H., Voelter, W., Pawelec, G., Papamichail, M., and Baxevanis, 
C. N. (2002). HER-2/neu-derived peptide 884-899 is expressed by human 
breast, colorectal and pancreatic adenocarcinomas and is recognized by in- 
vitro-induced specific CD4(+) T cell clones. C a n c e r  I m m u n o l  I m m u n o th e r  
50: 615-24.
Perez-Diez, A., and Marincola, F. M. (2002). Immunotherapy against 
antigenic tumors: a game with a lot of players. C e l l  M o l  L i f e  S c i  59: 230-40.
Perrey, C., Pravica, V., Sinnott, P. J., and Hutchinson, I. V. (1998). 
Genotyping for polymorphisms in interferon-gamma, interleukin-10, 
transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a 
technical report. T r a n s p l  I m m u n o l  6: 193-7.
Petrone, A., and Sap, J. (2000). Emerging issues in receptor protein tyrosine 
phosphatase function: lifting fog or simply shifting? /  C e l l  S c i  113 ( Pt 13): 
2345-54.
Pieper, R., Christian, R. E., Gonzales, M. I., Nishimura, M. I., Gupta, G., 
Settlage, R. E., Shabanowitz, J., Rosenberg, S. A., Hunt, D. F., and Topalian, 
S. L. (1999). Biochemical identification of a mutated human melanoma 
antigen recognized by CD4(+) T cells [see comments]. J  E x p  M e d  189: 757- 
66.
Pieters, J. (2000). MHC class Il-restricted antigen processing and 
presentation. A d v  I m m u n o l  75: 159-208.
Pieters, J., Bakke, O., and Dobberstein, B. (1993). The MHC class II- 
associated invariant chain contains two endosomal targeting signals within its 
cytoplasmic XdiX. J  C e l l  S c i  106: 831-46.
233
B ib lio g r a ph y
Pinet, V., Vergelli, M., Martin, R., Bakke, O., and Long, E. O. (1995). 
Antigen presentation mediated by recycling of surface HLA-DR molecules. 
N a tu r e  375: 603-6.
Pinet, V. M., and Long, E. O. (1998). Peptide loading onto recycling HLA- 
DR molecules occurs in early endosomes. E u r  J  I m m u n o l  28: 799-804.
Pisa, P., Halapi, E., Pisa, E. K., Gerdin, E., Hising, C., Bucht, A., Gerdin, B., 
and Kiessling, R. (1992). Selective expression o f interleukin 10, interferon 
gamma, and granulocyte-macrophage colony-stimulating factor in ovarian 
cancer biopsies. P r o c  N a t l  A c a d  S c i  U S A  89: 7708-12.
Prehn, R. T., and Main, J. M. (1957). Immunity to methylcholanthrene- 
induced sarcomas. J  N a t  C a n c e r  I n s t  U S A  18: 759-78.
Qin, Z., and Blankenstein, T. (2000). CD4+ T cell—mediated tumor rejection 
involves inhibition of angiogenesis that is dependent on IFN gamma receptor 
expression by nonhematopoietic cells. I m m u n i ty  12: 677-86.
Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., and 
Stevanovic, S. (1999). SYFPEITHI: database for MHC ligands and peptide 
motifs. I m m u n o g e n e t ic s  50: 213-9.
Renkvist, N., Castelli, C., Robbins, P. F., and Parmiani, G. (2001). A listing 
of human tumor antigens recognized by T cells. C a n c e r  I m m u n o l  I m m u n o t h e r  
50: 3-15.
Ressing, M. E., Offringa, R., Toes, R. E., Ossendorp, F., de Jong, J. H., 
Brandt, R. M., Kast, W. M., and Melief, C. J. (1996). Immunotherapy of 
cancer by peptide-based vaccines for the induction of tumor-specific T cell 
immunity. I m m u n o te c h n o lo g y  2: 241-51.
Ridge, J. P., Di Rosa, F., and Matzinger, P. (1998). A conditioned dendritic 
cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. 
N a tu r e  393: 474-8.
Rivoltini, L., Barracchini, K. C., Viggiano, V., Kawakami, Y., Smith, A., 
Mixon, A., Restifo, N. P., Topalian, S. L., Simonis, T. B., Rosenberg, S. A., 
and et al. (1995a). Quantitative correlation between HLA class I allele 
expression and recognition of melanoma cells by antigen-specific cytotoxic T 
lymphocytes. C a n c e r  R e s  55: 3149-57.
Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., 
Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E., 
and et al. (1995b). Induction of tumor-reactive CTL from peripheral blood 
and tumor-infiltrating lymphocytes of melanoma patients by in vitro
234
B ib lio g r a ph y
Stimulation with an immunodominant peptide of the human melanoma 
antigen MART-1. J  I m m u n o l  154: 2257-65.
Rivoltini, L., Radrizzani, M., Accomero, P., Squarcina, P., Chiodoni, C., 
Mazzocchi, A., Castelli, C., Tarsini, P., Viggiano, V., Belli, P., Colombo, M. 
P., and Parmiani, G. (1998). Human melanoma-reactive CD4+ and CD8+ 
CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand- 
independent mechanisms for tumor killing. J  I m m u n o l  161: 1220-30.
Robbins, P. F., el-Gamil, M., Kawakami, Y., Stevens, E., Yannelli, J. R., and 
Rosenberg, S. A. (1994). Recognition of tyrosinase by tumor-infiltrating 
lymphocytes from a patient responding to immunotherapy. C a n c e r  R e s  54: 
3124-6.
Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella,
E., and Rosenberg, S. A. (1996). A mutated beta-catenin gene encodes a 
melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J  
E x p M e d n 3 \  m 5 - 9 2 .
Robbins, P. F., and Kawakami, Y. (1996). Human tumor antigens recognized 
by T cells. C u r r  O p in  I m m u n o l  8: 628-36.
Robinson, J. H., and Delvig, A. A. (2002). Diversity in MHC class II antigen 
p r e s e n t a t i o n . 105: 252-62.
Roche, P. A., Teletski, C. L., Stang, E., Bakke, O., and Long, E. O. (1993). 
Cell surface HLA-DR-invariant chain complexes are targeted to endosomes 
by rapid internalization. P r o c  N a t l  A c a d  iS'cz f / 5'^ 90: 8581-5.
Romero, P., Cerottini, J. C., and Waanders, G. A. (1998). Novel methods to 
monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. 
M o l  M e d  T o d a y  A\ 3 0 5 -1 2 .
Roncarolo, M. G., and Levings, M. K. (2000). The role of different subsets of 
T regulatory cells in controlling autoimmunity. C u r r  O p in  I m m u n o l  12: 676- 
83.
Ronsin, C., Chung-Scott, V., Poullion, L, Aknouche, N., Gaudin, C., and 
Triebel, F. (1999). A non-AUG-defined alternative open reading frame of the 
intestinal carboxyl esterase mRNA generates an epitope recognized by renal 
cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J  I m m u n o l  
163: 483-90.
Rosenberg, S. A. (1997). Cancer vaccines based on the identification of genes 
encoding cancer regression antigens. I m m u n o l  T o d a y  18: 175-82.
235
B ib lio g r a ph y
Rosenberg, S. A. (2001). Progress in human tumour immunology and 
immunotherapy. N a tu r e  411: 380-4.
Rosenberg, S. A., and White, D. E. (1996). Vitiligo in patients with 
melanoma: normal tissue antigens can be targets for cancer immunotherapy. J  
I m m u n o th e r  E m p h a s i s  T u m o r  I m m u n o l  19:81-4.
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. 
M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. 
J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhom, 
J. H., and White, D. E. (1998). Immunologic and therapeutic evaluation of a 
synthetic peptide vaccine for the treatment of patients with metastatic 
melanoma. N a t  M e d  4: 321-7.
Rousset, F., Garcia, E., Defiance, T., Peronne, C., Vezzio, N., Hsu, D. H., 
Kastelein, R., Moore, K. W., and Banchereau, J. (1992). Interleukin 10 is a 
potent growth and differentiation factor for activated human B lymphocytes. 
P r o c  N a t l  A c a d  S c i  U S A S 9 :  1890-3.
Ruoslahti, E. (1996). How cancer spreads. S c i  A m  275: 62-70.
Sad, S., Marcotte, R., and Mosmann, T. R. (1995). Cytokine-induced 
differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells 
secreting Thl or Th2 cytokines. I m m u n i ty  2: 271-9.
Sahin, U., Tureci, O., and Pfieundschuh, M. (1997). Serological identification 
of human tumor antigens. C u r r  O p in  I m m u n o l  9: 709-16.
Sakaguchi, S. (2000). Regulatory T cells: key controllers o f immunologic 
self-tolerance. C e//101: 455-8.
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M. (1995). 
Immunologic self-tolerance maintained by activated T cells expressing IL-2 
receptor alpha-chains (CD25). Breakdown of a single mechanism o f self­
tolerance causes various autoimmune diseases. J  I m m u n o l  155: 1151-64.
Salazar-Onfiay, F. (1999). Interleukin-10: a cytokine used by tumors to 
escape immunosurveillance. M e d  O n c o l  16: 86-94.
Salgaller, M. L., Afshar, A., Marincola, F. M., Rivoltini, L., Kawakami, Y., 
and Rosenberg, S. A. (1995). Recognition of multiple epitopes in the human 
melanoma antigen gplOO by peripheral blood lymphocytes stimulated in vitro 
with synthetic peptides. C a n c e r  R e s  55: 4972-9.
Sallusto, F., Celia, M., Danieli, C., and Lanzavecchia, A. (1995). Dendritic 
cells use macropinocytosis and the mannose receptor to concentrate
236
B ib lio g r a ph y
macromolecules in the major histocompatibility complex class II 
compartment: downregulation by cytokines and bacterial products. J E x p  M e d  
182: 389-400.
Salmeron, M. A., Morita, T., Seki, H., Platsoucas, C. D., and Itoh, K. (1992). 
Lymphokine production by human melanoma tumor-infiltrating lymphocytes. 
C a n c e r  I m m u n o l  I m m u n o th e r  35:211-7.
Sanderson, S., Frauwirth, K., and Shastri, N. (1995). Expression of 
endogenous peptide-major histocompatibility complex class II complexes 
derived from invariant chain-antigen fusion proteins. P r o c  N a t l  A c a d  S c i  U  S  
^92:7217-21.
Santambrogio, L., Sato, A. K., Carven, G. J., Belyanskaya, S. L., Strominger, 
J. L., and Stem, L. J. (1999a). Extracellular antigen processing and 
presentation by immature dendritic cells. P r o c  N a t l  A c a d  S c i  U  S  A  96 :  
15056-61.
Santambrogio, L., Sato, A. K., Fischer, F. R., Dorf, M. E., and Stem, L. J. 
(1999b). Abundant empty class II MHC molecules on the surface of immature 
dendritic cells. P r o c  N a t l  A c a d  S c i  U S A 9 6 :  15050-5.
Santin, A. D., Hermonat, P. L., Ravaggi, A., Bellone, S., Pecorelli, S., 
Roman, J. J., Parham, G. P., and Cannon, M. J. (2000). Interleukin-10 
increases Thl cytokine production and cytotoxic potential in human 
papillomavims-specific CD8(+) cytotoxic T lymphocytes. J  V ir o l  74: 4729- 
37.
Sap, J., Jiang, Y. P., Friedlander, D., Gmmet, M., and Schlessinger, J. (1994). 
Receptor tyrosine phosphatase R-PTP-kappa mediates homophilic binding. 
M o l  C e l l  B io l  \A : 1-9.
Sasaki, M., Nakahira, K., Kawano, Y., Katakura, H., Yoshimine, T., Shimizu, 
K., Kim, S. U., and Ikenaka, K. (2001). MAGE-El, a new member of the 
melanoma-associated antigen gene family and its expression in human 
glioma. C a n c e r  R e s  61: 4809-14.
Sato, T., McCue, P., Masuoka, K., Salwen, S., Lattime, E. C., Mastrangelo, 
M. J., and Berd, D. (1996). Interleukin 10 production by human melanoma. 
C lin  C a n c e r  R e s  2: 1383-90.
Scanlan, M. J., Altorki, N. K., Gure, A. O., Williamson, B., Jungbluth, A., 
Chen, Y. T., and Old, L. J. (2000). Expression of cancer-testis antigens in 
lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new 
CT gene, CT9. C a n c e r  L e t t  150: 155-64.
237
B ib lio g r a ph y
Schneider, J., Brichard, V., Boon, T., Meyer zum Buschenfelde, K. H., and 
Wolfel, T. (1998). Overlapping peptides of melanocyte differentiation antigen 
Melan-A/MART -1 recognized by autologous cytolytic T lymphocytes in 
association with HLA-B45.1 and Y i h A - A l A .  I n t  J  C a n c e r  75: 451-8.
Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R., and 
Melief, C. J. (1998). T-cell help for cytotoxic T lymphocytes is mediated by 
CD40-CD40L interactions. 393: 480-3.
Schultz, E. S., Lethe, B., Cambiaso, C. L., Van Snick, J., Chaux, P., Corthals, 
J., Heirman, C., Thielemans, K., Boon, T., and van der Bruggen, P. (2000). A 
MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by 
CD4+ cytolytic T lymphocytes. C a n c e r  R e s  60: 6272-5.
Schultze, J. L., and Vonderheide, R. H. (2001). From cancer genomics to 
cancer immunotherapy: toward second-generation tumor antigens. T r e n d s  
I m m u n o l 2 2 : 5 X 6 -2 3 .
Segal, B. M., Glass, D. D., and Shevach, E. M. (2002). Cutting Edge: IL-10- 
producing CD4+ T cells mediate tumor rejection. J  I m m u n o l  168: 1-4.
Shevach, E. M., McHugh, R. S., Piccirillo, C. A., and Thornton, A. M. 
(2001). Control of T-cell activation by CD4+ CD25+ suppressor T cells. 
I m m u n o l  R e v  182: 58-67.
Shimizu, J., Yamazaki, S., and Sakaguchi, S. (1999). Induction o f tumor 
immunity by removing CD25+CD4+ T cells: a common basis between tumor 
immunity and autoimmunity. J  I m m u n o l  163: 5211-8.
Skipper, J., and Stauss, H. J. (1993). Identification of two cytotoxic T 
lymphocyte-recognized epitopes in the Ras protein. J E x p  M e d  177: 1493-8.
Smyth, M. J., and Trapani, J. A. (1995). Granzymes: exogenous proteinases 
that induce target cell apoptosis. I m m u n o l  T o d a y  16: 202-6.
Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, 
X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., Cordon- 
Cardo, C., and Lowe, S. W. (2001). Inactivation o f the apoptosis effector 
Apaf-1 in malignant melanoma. N a tu r e  409: 207-11.
Southwood, S., Sidney, J., Kondo, A., del Guercio, M. F., Appella, E., 
Hoffinan, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., and Sette, A. (1998). 
Several common HLA-DR types share largely overlapping peptide binding 
repertoires. J  I m m u n o l  160: 3363-73.
238
B ib lio g r a ph y
Steinbrink, K., Graulich, E., Kubsch, S., Knop, J., and Enk, A. H. (2002). 
CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human 
dendritic cells display antigen-specific suppressor activity. B l o o d  99: 2468- 
76.
Surman, D. R., Dudley, M. E., Overwijk, W. W., and Restifo, N. P. (2000). 
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor 
antigen. J  I m m u n o l  164: 562-5.
Suzuki, T., Tahara, H., Narula, S., Moore, K. W., Robbins, P. D., and Lotze, 
M. T. (1995). Viral interleukin 10 (IL-10), the human herpes virus 4 cellular 
IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J  
E x p  M e d  m :  477-86.
Taams, L. S., van Rensen, A. J., Poelen, M. C., van Els, C. A., Besseling, A.
C., Wagenaar, J. P., van Eden, W., and Wauben, M. H. (1998). Anergic T 
cells actively suppress T cell responses via the antigen-presenting cell. E u r  J  
I m m u n o l  28: 2902-12.
Tan, J. C., Braun, S., Rong, H., DiGiacomo, R., Dolphin, E., Baldwin, S., 
Narula, S. K., Zavodny, P. J., and Chou, C. C. (1995). Characterization of 
recombinant extracellular domain of human interleukin-10 receptor. J  B i o l  
C h e m l l O :  \2906-n.
Tan, L. J., Ceman, S., Chervonsky, A., Rodriguez-Paris, J., Steck, T. L., and 
Sant, A. J. (1997). Late events in the intracellular sorting o f major 
histocompatibility complex class II molecules are regulated by the 80-82 
segment o f the class II beta chain. E u r  J  I m m u n o l  27: 1479-88.
Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, 
J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. 
W., and Storkus, W. J. (2002). Disease-associated bias in T helper type 1 
(Thl)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401 (+) 
patients with renal cell carcinoma or melanoma. J E x p  M e d  196: 619-28.
ten Bosch, G. J., Kessler, J. H., Joosten, A. M., Bres-Vloemans, A. A., Geluk, 
A., Godthelp, B. C., van Bergen, J., Melief, C. J., and Leeksma, O. C. (1999). 
A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by 
HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR 
matched cells transfected with an Ii(b2a2) construct. B l o o d  94: 1038-45.
Teyton, L., O'Sullivan, D., Dickson, P. W., Lotteau, V., Sette, A., Fink, P., 
and Peterson, P. A. (1990). Invariant chain distinguishes between the 
exogenous and endogenous antigen presentation pathways. N a t u r e  348: 39- 
44.
239
B ib lio g r a ph y
Thomas, W. D., and Hersey, P. (1998a). CD4 T cells kill melanoma cells by 
mechanisms that are independent of Fas (CD95). I n t  J  C a n c e r  75: 384-90.
Thomas, W. D., and Hersey, P. (1998b). TNF-related apoptosis-inducing 
ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and 
mediates CD4 T cell killing of target cells. J  I m m u n o l  161: 2195-200.
Thompson-Snipes, L., Dhar, V., Bond, M. W., Mosmann, T. R., Moore, K. 
W., and Rennick, D. M. (1991). Interleukin 10: a novel stimulatory factor for 
mast cells and their progenitors. J E x p  M e d  173: 507-10.
Thomson, S. A., Sherritt, M. A., Medveczky, J., Elliott, S. L., Moss, D. J., 
Fernando, G. J., Brown, L. E., and Suhrbier, A. (1998). Delivery o f multiple 
CD8 cytotoxic T cell epitopes by DNA vaccination. J  I m m u n o l  160: 1717-23.
Thomssen, H., Kahan, M., and Londei, M. (1995). Differential effects of 
interleukin-10 on the expression of HLA class II and GDI molecules induced 
by granulocyte/macrophage colony-stimulating factor/interleukin-4. E u r  J  
I m m u n o l  25: 2465-70.
Thornton, A. M., and Shevach, E. M. (1998). CD4+CD25+
immunoregulatory T cells suppress polyclonal T cell activation in vitro by 
inhibiting interleukin 2 production. J E x p  M e d  188: 287-96.
Thornton, A. M., and Shevach, E. M. (2000). Suppressor effector function of  
CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J  I m m u n o l  
164: 183-90.
Toes, R. E., Ossendorp, F., Offringa, R., and Melief, C. J. (1999). CD4 T cells 
and their role in antitumor immune responses. J E x p  M e d  189: 753-6.
Topalian, S. L., Gonzales, M. I., Parkhurst, M., Li, Y. F., Southwood, S., 
Sette, A., Rosenberg, S. A., and Robbins, P. F. (1996). Melanoma-specific 
CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. 
J E x p M e d \ % 3 \  1965-71.
Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., 
Kawakami, Y., and Rosenberg, S. A. (1994). Human CD4+ T cells 
specifically recognize a shared melanoma-associated antigen encoded by the 
tyrosinase gene. P r o c  N a t l  A c a d  S c i  U  S A 9 \ :  9461-5.
Townsend, A. R., Gotch, F. M., and Davey, J. (1985). Cytotoxic T cells 
recognize fragments of the influenza nucleoprotein. C e l l  42: 457-67.
Townsend, A. R., Rothbard, J., Gotch, F. M., Bahadur, G., Wraith, D., and 
McMichael, A. J. (1986). The epitopes of influenza nucleoprotein recognized
240
B ib lio g r a ph y
by cytotoxic T lymphocytes can be defined with short synthetic peptides. C e l l  
44: 959-68.
Townsend, S. E., and Allison, J. P. (1993). Tumor rejection after direct 
costimulation of CD8+ T cells by B7-transfected melanoma cells. S c ie n c e  
2 5 9 :  368-70.
Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chômez, P., 
Van Pel, A., De Plaen, E., Amar-Costesec, A., and Boon, T. (1992). A 
nonapeptide encoded by human gene MAGE-1 is recognized on HLA-Al by 
cytolytic T lymphocytes directed against tumor antigen MZ2-E. J  E x p  M e d  
176: 1453-7.
Tureci, O., Sahin, U., and Pffeundschuh, M. (1997). Serological analysis of 
human tumor antigens: molecular definition and implications. M o l  M e d  T o d a y  
3: 342-9.
Turner, D. M., Williams, D. M., Sankaran, D., Lazarus, M., Sinnott, P. J., and 
Hutchinson, I. V. (1997). An investigation of polymorphism in the 
interleukin-10 gene promoter. E u r  J I m m u n o g e n e t  24: 1-8.
Valmori, D., Lienard, D., Waanders, G., Rimoldi, D., Cerottini, J. C., and 
Romero, P. (1997). Analysis of MAGE-3-specific cytolytic T lymphocytes in 
human leukocyte antigen-A2 melanoma patients. C a n c e r  R e s  57: 735-41.
Van den Eynde, B., Hainaut, P., Herin, M., Knuth, A., Lemoine, C., 
Weynants, P., van der Bruggen, P., Fauchet, R., and Boon, T. (1989). 
Presence on a human melanoma of multiple antigens recognized by 
autologous CTL. I n t  J  C a n c e r  44: 634-40.
Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., and 
Boon, T. (1995). A new family of genes coding for an antigen recognized by 
autologous cytolytic T lymphocytes on a human melanoma. J  E x p  M e d  182: 
689-98.
Van den Eynde, B., and Van der Bruggen, P. (2001). Peptide database o f T 
cell defined tumour antigens. C a n c e r  I m m u n i ty .
Van den Eynde, B. J., and Boon, T. (1997). Tumor antigens recognized by T 
lymphocytes. I n t  J  C lin  L a b  R e s  27: 81 -6.
Van Den Eynde, B. J., Gaugler, B., Probst-Kepper, M., Michaux, L., Devuyst, 
O., Lorge, F., Weynants, P., and Boon, T. (1999). A new antigen recognized 
by cytolytic T lymphocytes on a human kidney tumor results from reverse 
strand transcription [see comments]. J E x p  M e d  190: 1793-800.
241
B ib lio g r a ph y
Van den Eynde, B. J., and van der Bruggen, P. (1997). T cell defined tumor 
antigens. C u r r  O p in  I m m u n o l  9: 684-93.
van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boel, P., De 
Smet, C., Traversai!, C., Townsend, A., and Boon, T. (1994). A peptide 
encoded by human gene MAGE-3 and presented by HLA-A2 induces 
cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. E u r  
J  I m m u n o l  2 4 : 3 0 3 S -4 3 .
van der Bruggen, P., Traversari, C., Chômez, P., Lurquin, C., De Plaen, E., 
Van den Eynde, B., Knuth, A., and Boon, T. (1991). A gene encoding an 
antigen recognized by cytolytic T lymphocytes on a human melanoma. 
S c ie n c e  2 5 4 :  1 6 4 3 -7 .
Venetsanakos, E., Beckman, I., Bradley, J., and Skinner, J. M. (1997). High 
incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in 
human breast tumours. B r  J  C a n c e r  75: 1826-30.
Vieira, P., de Waal-Malefyt, R., Dang, M. N., Johnson, K. E., Kastelein, R., 
Fiorentino, D. F., deVries, J. E., Roncarolo, M. G., Mosmann, T. R., and 
Moore, K. W. (1991). Isolation and expression of human cytokine synthesis 
inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading 
frame BCRFI. P r o c  N a t l  A c a d  S e t  U S  A  88: 1 172-6.
Villadangos, J. A., Cardoso, M., Steptoe, R. J., van Berkel, D., Pooley, J., 
Carbone, F. R., and Shortman, K. (2001). MHC class II expression is 
regulated in dendritic cells independently of invariant chain degradation. 
I m m u n i t y  14: 739-49.
Vogelstein, B., and Gillespie, D. (1979). Preparative and analytical 
purification of DNA from agarose. P r o c  N a t l  A c a d  S c i  U  S A 1 6 :  615-9.
Volk, H., Asadullah, K., Gallagher, G., Sabat, R., and Grutz, G. (2001). IL-10 
and its homologs: important immune mediators and emerging
immunotherapeutic targets. T r e n d s  I m m u n o l  2 2 : 414-7.
Vukmanovic-Stejic, M., Vyas, B., Gorak-Stolinska, P., Noble, A., and 
Kemeny, D. M. (2000). Human Tel and Tc2/Tc0 CD8 T-cell clones display 
distinct cell surface and functional phenotypes. B l o o d  95: 231-40.
Wakkach, A., Cottrez, F., and Groux, H. (2000). Can interleukin-10 be used 
as a true immunoregulatory cytokine? E u r  C y to k in e  N e t w  11: 153-60.
Wang, H. Y., Zhou, J., Zhu, K., Riker, A. I., Marincola, F. M., and Wang, R.
F. (2002). Identification of a mutated fibronectin as a tumor antigen
242
B ib lio g r a ph y
recognized by CD4+ T cells: its role in extracellular matrix formation and 
tumor metastasis. J  E x p  M e d  195: 1397-406.
Wang, R. F. (1999). Human tumor antigens: implications for cancer vaccine 
development. J  M o l  M e d  77: 640-55.
Wang, R. F. (2001). The role of MHC class Il-restricted tumor antigens and 
CD4+ T cells in antitumor immunity. T r e n d s  I m m u n o l  22: 269-76.
Wang, R. F., Appella, E., Kawakami, Y., Kang, X., and Rosenberg, S. A.
(1996). Identification of TRP-2 as a human tumor antigen recognized by 
cytotoxic T lymphocytes. J  E x p  M e d  184: 2207-16.
Wang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q., and Rosenberg, S.
A. (1995). Identification of a gene encoding a melanoma tumor antigen 
recognized by HLA-A31 -restricted tumor-infiltrating lymphocytes. J  E x p  
Mec/181: 799-804.
Wang, R. F., and Rosenberg, S. A. (1999). Human tumor antigens for cancer 
vaccine development. I m m u n o l  R e v  170: 85-100.
Wang, R. F., Wang, X., Atwood, A. C., Topalian, S. L., and Rosenberg, S. A. 
(1999a). Cloning genes encoding MHC class Il-restricted antigens: mutated 
CDC27 as a tumor antigen. S c ie n c e  284: 1351-4.
Wang, R. F., Wang, X., and Rosenberg, S. A. (1999b). Identification of a 
novel major histocompatibility complex class Il-restricted tumor antigen 
resulting fi*om a chromosomal rearrangement recognized by CD4(+) T cells. J  
E x p M e d \ 8 9 :  1659-68.
Wang, S., Bartido, S., Yang, G., Qin, J., Moroi, Y., Panageas, K. S., Lewis, J. 
J., and Houghton, A. N. (1999c). A role for a melanosome transport signal in 
accessing the MHC class II presentation pathway and in eliciting CD4+ T cell 
responses.//mmwwo/163: 5820-6.
Weeraratna, A. T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, 
M., and Trent, J. M. (2002). Wnt5a signaling directly affects cell motility and 
invasion of metastatic melanoma. C a n c e r  C e l l  1: 279-88.
Whiteside, T. L. (1999). Signaling defects in T lymphocytes o f patients with 
malignancy. C a n c e r  I m m u n o l  I m m u n o th e r  48: 346-52.
Whiteside, T. L. (2000). Monitoring of antigen-specific cytolytic T 
lymphocytes in cancer patients receiving immunotherapy. C lin  D i a g n  L a b  
I m m u n o l  7: 3 2 7 -3 2 .
243
B ib lio g r a ph y
Williams, N. S., and Engelhard, V. H. (1996). Identification of a population of 
CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent 
cytotoxic mechanism. 156: 153-9.
Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann- 
Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Buschenfelde, K. H., and 
Beach, D. (1995). A pl6INK4a-insensitive CDK4 mutant targeted by 
cytolytic T lymphocytes in a human melanoma. S c ie n c e  2 6 9 :  1281-4.
Wolfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum 
Buschenfelde, K. H., and Boon, T. (1994). Two tyrosinase nonapeptides 
recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. 
E u r  J  I m m u n o l  24: 759-64.
Wright, K. L., Chin, K. C., Linhoff, M., Skinner, C., Brown, J. A., Boss, J. 
M., Stark, G. R., and Ting, J. P. (1998). CIITA stimulation of transcription 
factor binding to major histocompatibility complex class II and associated 
promoters in vivo. P r o c  N a t l  A c a d  S c i  U  S A 9 5 :  6267-72.
Wu, T. C., Guamieri, F. G., Staveley-O’Carroll, K. F., Viscidi, R. P., 
Levitsky, H. I., Hedrick, L., Cho, K. R., August, J. T., and Pardoll, D. M. 
(1995). Engineering an intracellular pathway for major histocompatibility 
complex class II presentation of antigens. P r o c  N a t l  A c a d  S c i  U  S A  92:  
11671-5.
Xu, G., Snellman, E., Bykov, V. J., Jansen, C. T., and Hemminki, K. (2000). 
Cutaneous melanoma patients have normal repair kinetics o f ultraviolet- 
induced DNA repair in skin in situ. J  I n v e s t  D e r m a to l  114: 628-31.
Yang, Y., Gil, M. C., Choi, E. Y., Park, S. H., P^^n, K. H., and Ha, H. (1997). 
Molecular cloning and chromosomal localization o f a human gene 
homologous to the murine R-PTP-kappa, a receptor-type protein tyrosine 
phosphatase. G e n e  186: 77-82.
Yee, C., Thompson, J. A., Roche, P., Byrd, D. R., Lee, P. P., Piepkom, M., 
Kenyon, K., Davis, M. M., Riddell, S. R., and Greenberg, P. D. (2000). 
Melanocyte destruction after antigen-specific immunotherapy o f melanoma: 
direct evidence of t cell-mediated vitiligo. J  E x p  M e d  192: 1637-44.
York, I. A., and Rock, K. L. (1996). Antigen processing and presentation by 
the class I major histocompatibility complex. A n n u  R e v  I m m u n o l  14: 369-96.
Yssel, H., De Waal Malefyt, R., Roncarolo, M. G., Abrams, J. S., Lahesmaa, 
R., Spits, H., and de Vries, J. E. (1992). IL-10 is produced by subsets of 
human CD4+ T cell clones and peripheral blood T cells. J  I m m u n o l  149: 
2378-84.
244
B ib lio g r a ph y
Yue, F. Y., Dummer, R., Geertsen, R., Hofbauer, G., Laine, E., Manolio, S., 
and Burg, G. (1997). Interleukin-10 is a growth factor for human melanoma 
cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. 
I n t  J  C a n c e r  1 1: 630-7.
Zarour, H. M., Kirkwood, J. M., Kierstead, L. S., Herr, W., Brusic, V., 
Slingluff, C. L., Jr., Sidney, J., Sette, A., and Storkus, W. J. (2000). Melan- 
A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope 
recognized by melanoma-reactive CD4(+) T cells. P r o c  N a t l  A c a d  S c i  U S A  
97: 400-5.
Zeng, G., Touloukian, C. E., Wang, X., Restifo, N. P., Rosenberg, S. A., and 
Wang, R. F. (2000). Identification of CD4+ T cell epitopes from NY-ESO-1 
presented by HLA-DR molecules. J  I m m u n o l  165: 1153-9.
Zhang, Y., Siebert, R., Matthiesen, P., Yang, Y., Ha, H., and Schlegelberger,
B. (1998). Cytogenetical assignment and physical mapping of the human R- 
PTP-kappa gene (PTPRK) to the putative tumor suppressor gene region 
6q22.2-q22.3. G e n o m ic s  51: 309-11.
Zheng, L. M., Ojcius, D. M., Garaud, F., Roth, C., Maxwell, E., Li, Z., Rong,
H., Chen, J., Wang, X. Y., Catino, J. J., and King, I. (1996). Interleukin-10 
inhibits tumor metastasis through an NK cell-dependent mechanism. J  E x p  
184: 579-84.
Zhong, G., Romagnoli, P., and Germain, R. N. (1997). Related leucine-based 
cytoplasmic targeting signals in invariant chain and major histocompatibility 
complex class II molecules control endocytic presentation of distinct 
determinants in a single protein. J  E x p  M e d  185: 429-38.
Zinkemagel, R. M., and Doherty, P. C. (1997). The discovery of MHC 
restriction. I m m u n o l  T o d a y  18: 14-7.
Zondag, G. C., Koningstein, G. M., Jiang, Y. P., Sap, J., Moolenaar, W. H., 
and Gebbink, M. F. (1995). Homophilic interactions mediated by receptor 
tyrosine phosphatases mu and kappa. A critical role for the novel extracellular 
MAM domain. J  B i o l  C h e m  270: 14247-50.
Zondag, G. C., and Moolenaar, W. H. (1997). Receptor protein tyrosine 
phosphatases: involvement in cell-cell interaction and signaling. B io c h im ie  
79: 477-83.
Zorn, E., and Hercend, T. (1999a). A MAGE-6-encoded peptide is recognized 
by expanded lymphocytes infiltrating a spontaneously regressing human 
primary melanoma lesion. E u r  J  I m m u n o l  29: 602-7.
245
B ib lio g r a ph y
Zom, E., and Hercend, T. (1999b). A natural cytotoxic T cell response in a 
spontaneously regressing human melanoma targets a neoantigen resulting 




*Novellino N., *Renkvist N., Rini F., Mazzocchi A., Rivoltini L., Greco A., Deho P., 
Tarsini P., Boss J.M., Robbins P., Parmiani P. and Castelli C. Identiflcation o f  a mutated 
receptor-like tyrosine phosphatase kappa as a novel class II  -  MHC restricted melanoma 
antigen associated with an in vivo long lasting immunity. * Joint first author. (Submitted to 
Cancer Research)
Carrabba M., Castelli C., Maeurer M.J., Squarcina P., Cova A., Pilla L., Renkvist N., 
Parmiani G. and Rivoltini L. Suboptimal activation o f  CD8+ T cells by melanoma derived 
altered peptide ligands: Role o f  Melan-A/MART-1 optimised analogues. (Accepted for 
publication in Cancer Research)
Renkvist N., Castelli C., Robbinas P.P. and Parmiani G. A listing o f  human tumor antigens 
recognized by T cells. Cancer Immunology and Immunotherapy. 50:3-15. 2001
(Web sites: http://www.lstitutotumori.mi.it; http://www.cancerimmunity.org)
Castelli C., Rivoltini L., Andreola G., Carrabba M., Renkvist N. and Parmiani G. T cell 
recognition o f  melanoma-associated antigens. Journal of Cellular Physiology. 182:323- 
331.2001
247
Reproduced with permission of copyright owner. Further reproduction prohibited without permission.
